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The	   emergence	   of	   multi-­‐drug	   resistant	   organisms	   and	   their	   rapid	   global	   spread	   has	   transformed	  
resistance	  from	  a	  challenge	  of	  an	  effective	  prescription	  to	  an	  important	  global	  public	  health	  threat	  
with	  a	  substantial	  impact	  on	  patient	  outcomes	  such	  as	  duration	  of	  hospitalization,	  mortality,	  as	  well	  
as	  on	  healthcare	  costs.	  
The	   European	   Antimicrobial	   Resistance	   Surveillance	   Network	   (EARS-­‐Net)	   system	   has	   reported	   a	  
dangerous	   rise	   in	   both	  Gram-­‐positive	   and	  Gram-­‐negative	  multidrug	   resistance	   bacteria	   in	   the	   last	  
years	   showing	   that	   some	   countries	   such	   as	   Italy	   and	   Greece	   are	   strongly	   contributing	   to	   this	  
worrisome	  increase.	  
In	  the	  US,	  each	  year	  at	  least	  2	  million	  people	  become	  infected	  with	  multi-­‐drug	  resistant	  bacteria	  and	  
at	   least	   12,000	   die	   as	   a	   direct	   result	   of	   these	   infections.	   In	   the	   EU	   the	   infections	   result	   in	   an	  
estimated	  25,000	  deaths	   in	  29	  countries	   (5.1	  per	  100	  000	   inhabitants).	  Nevertheless,	  adverse	  drug	  
events	  and	  excessive	  costs	  of	  treatment	  are	  also	  reasons	  for	  concern.	  
Antimicrobials	  are	  the	  most	  common	  prescribed	  drugs	  in	  the	  community	  and	  in	  hospitals,	  especially	  
in	  the	  pediatric	  age.	  Unfortunately	  at	  the	  current	  time	  antibiotics	  are	  often	  unnecessarily	  prescribed	  
both	   in	   the	   community,	   where	   too	   many	   people	   and	   especially	   children	   are	   receiving	   broad-­‐
spectrum	   antibiotics	   for	   viral	   infections,	   and	   in	   the	   hospital,	   where	   unnecessary	   long	   courses	   of	  
broad-­‐spectrum	  antibiotics	  drive	  antimicrobial	  resistance.	  	  
Although	  prudent	  antibiotic	  prescribing	  has	  been	  a	  high	  priority	  in	  the	  EU,	  there	  has	  not	  been	  a	  true	  
focus	  on	  prescription	  patterns	  in	  the	  pediatric	  population.	  
For	   these	   reasons,	   in	   order	   to	   maintain	   efficacy	   of	   currently	   available	   drugs,	   initiatives	   such	   as	  
antimicrobial	  stewardship	  programs	  have	  become	  increasingly	  vital.	  
Antimicrobial	   stewardship	   encompasses	   a	   heterogeneous	   set	   of	   interventions.	   Antimicrobial	  
stewardship	  practices	  frequently	  focus	  on	  antimicrobial	  agent	  selection,	  dose,	  frequency	  and	  route.	  	  
Each	  antimicrobial	  stewardship	  programs	  utilizes	  any	  number	  of	  these	  interventions	  based	  on	  local	  
practices,	   resistance	   trends,	   and	   available	   resources.	   Guidelines	   for	   stewardship	   identify	   several	  
potential	  strategies	  including:	  disease-­‐specific	  clinical	  pathways,	  audit	  with	  feedback	  and	  formulary	  
restriction	  with	   preauthorization	   of	   select	   agents.	   Each	   intervention	   has	   demonstrated	   decreased	  
unnecessary	  antimicrobial	  exposure,	  reduced	  costs,	  and	  improved	  patient	  outcomes	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A	   recent	   evaluation	   of	   various	   interventions	   concluded	   that	   active	   clinician	   education	   targeting	  
multiple	   conditions	   is	   most	   likely	   to	   impact	   community	   antibiotic	   use.	   Clinical	   pathways	   are	   an	  
effective	   means	   to	   change	   antibiotic	   prescribing	   behavior.	   Their	   purpose	   is	   to	   standardize	   care	  
without	  adversely	  affecting	  patient	  safety	  or	  outcomes.	  	  
According	   to	   the	   most	   recent	   evidences,	   I've	   developed	   and	   implemented	   pediatric	   in-­‐hospital	  
antimicrobial	   stewardship	   policy	   through	   pediatric	   clinical	   pathways	   with	   the	   aim	   of	   creating	   a	  
feasible,	  efficient,	   sharable	  and	  sustainable	   tool	   that	  can	  effectively	   influence	  prescribing	  practices	  
without	  compromising	  clinical	  outcomes.	  	  
My	  PhD	  research	  protocol	  was	  articulated	  to	  study	  antimicrobial	  use	  and	  the	  way	  to	  optimize	  it	  from	  
different	  perspectives.	  The	  first	  part	  of	  my	  work	  focused	  on	  epidemiological	  studies	  to	  evaluate	  the	  
antibiotic	  prescription	  pattern	   in	  different	  settings.	  The	  overall	  pattern	  of	  antimicrobial	  use	   in	   Italy	  	  
was	  studied	  (1)	  and	  then	  more	  specially	  the	  management	  of	  community-­‐acquired	  pneumonia	  (5).	  	  
I	   then	   focused	  more	   specifically	  on	  Antimicrobial	   Stewardship.	  A	   systematic	   review	   in	  all	   different	  
settings	  (2)	  and	  in	  the	  Neonatal	  Intensive	  Care	  unit	  (3)	  provided	  the	  background	  to	  implement	  some	  
specific	  strategies	  such	  as	  Clinical	  Pathways,	  in	  the	  Pediatric	  Emergency	  Department,	  which	  has	  been	  
evaluated	  for	  acute	  otitis	  media,	  pharyngitis	  	  (4,7)	  and	  community-­‐acquired	  pneumonia	  (6,7),	  and	  in	  
the	  Surgical	  Pediatric	  Department	  for	  the	  perioperative	  antibiotic	  prophylaxis	  (8).	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Abstract	  
Background	  
Antimicrobials	   are	   the	   most	   commonly	   prescribed	   drugs.	   Many	   studies	   have	   evaluated	  
antibiotic	   prescriptions	   in	   the	   paediatric	   outpatient	   but	   few	   studies	   describing	   the	   real	  
antibiotic	  consumption	  in	  Italian	  children’s	  hospitals	  have	  been	  published.	  Point-­‐prevalence	  
survey	  (PPS)	  has	  been	  shown	  to	  be	  a	  simple,	  feasible	  and	  reliable	  standardized	  method	  for	  
antimicrobials	  surveillance	  in	  children	  and	  neonates	  admitted	  to	  the	  hospital.	  In	  this	  paper,	  
we	  presented	  data	   from	  a	  PPS	  on	  antimicrobial	  prescriptions	  carried	  out	   in	  7	   large	   Italian	  
paediatric	  institutions.	  
Methods	  
A	  1-­‐day	  PPS	  on	  antibiotic	  use	  in	  hospitalized	  neonates	  and	  children	  was	  performed	  in	  Italy	  
between	  October	  and	  December	  2012	  as	  part	  of	  the	  Antibiotic	  Resistance	  and	  Prescribing	  in	  
European	  Children	  project	  (ARPEC).	  Seven	  institutions	  in	  seven	  Italian	  cities	  were	  involved.	  
The	  survey	   included	  all	  admitted	  patients	   less	  than	  18	  years	  of	  age	  present	   in	  the	  ward	  at	  
8:00	  am	  on	  the	  day	  of	  the	  survey,	  who	  had	  at	  least	  one	  on-­‐going	  antibiotic	  prescription.	  For	  
all	   patients	   data	   about	   age,	   weight,	   underlying	   disease,	   antimicrobial	   agent,	   dose	   and	  
indication	  for	  treatment	  were	  collected.	  
Results	  
The	  PPS	  was	  performed	  in	  61	  wards	  within	  7	  Italian	  institutions.	  A	  total	  of	  899	  patients	  were	  
eligible	   and	   349	   (38.9%)	   had	   an	   on-­‐going	   prescription	   for	   one	   or	   more	   antibiotics,	   with	  
variable	   rates	   among	   the	   hospitals	   (25.7%	   -­‐	   53.8%).	  We	   describe	   antibiotic	   prescriptions	  
separately	   in	   neonates	   (<30	  days	   old)	   and	   children	   (>	   =	   30	   days	   to	   <18	   years	   old).	   In	   the	  
neonatal	   cohort,	   62.8%	   received	   antibiotics	   for	   prophylaxis	   and	   only	   37.2%	   on	   those	   on	  
antibiotics	   were	   treated	   for	   infection.	   Penicillins	   and	   aminoglycosides	   were	   the	   most	  
prescribed	   antibiotic	   classes.	   In	   the	   paediatric	   cohort,	   64.4%	   of	   patients	   were	   receiving	  
antibiotics	   for	   treatment	   of	   infections	   and	   35.5%	   for	   prophylaxis.	   Third	   generation	  
cephalosporins	  and	  penicillin	  plus	   inhibitors	  were	  the	  top	  two	  antibiotic	  classes.	  The	  main	  
reason	   for	  prescribing	  antibiotic	   therapy	   in	   children	  was	   lower	   respiratory	   tract	   infections	  
(LRTI),	  followed	  by	  febrile	  neutropenia/fever	  in	  oncologic	  patients,	  while,	  in	  neonates,	  sepsis	  
was	  the	  most	  common	  indication	  for	  treatment.	  Focusing	  on	  prescriptions	  for	  LRTI,	  43.3%	  of	  
patients	  were	  treated	  with	  3rd	  generation	  cephalosporins,	  followed	  by	  macrolides	  (26.9%),	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quinolones	  (16.4%)	  and	  carbapenems	  (14.9%)	  and	  50.1%	  of	  LRTI	  cases	  were	  receiving	  more	  
than	   one	   antibiotic.	   For	   neutropenic	   fever/fever	   in	   oncologic	   patients,	   the	   preferred	  
antibiotics	   were	   penicillins	   with	   inhibitors	   (47.8%),	   followed	   by	   carbapenems	   (34.8%),	  
aminoglycosides	   (26.1%)	   and	   glycopeptides	   (26.1%).	   Overall,	   the	   60.9%	   of	   patients	   were	  
treated	  with	  a	  combination	  therapy.	  
Conclusions	  
Our	   study	   provides	   insight	   on	   the	   Italian	   situation	   in	   terms	   of	   antibiotic	   prescriptions	   in	  
hospitalized	  neonates	  and	  children.	  An	  over-­‐use	  of	  third	  generation	  cephalosporins	  both	  for	  
prophylaxis	   and	   treatment	   was	   the	   most	   worrisome	   finding.	   A	   misuse	   and	   abuse	   of	  
carbapenems	   and	   quinolones	   was	   also	   noted.	   Antibiotic	   stewardship	   programs	   should	  
immediately	   identify	   feasible	   targets	   to	   monitor	   and	   modify	   the	   prescription	   patterns	   in	  
children’s	   hospital,	   also	   considering	   the	   continuous	   and	   alarming	   emergence	   of	   MDR	  
bacteria.	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Background	  
Antimicrobials	   are	   the	   most	   commonly	   prescribed	   drugs	   in	   the	   community	   and	   hospital	  
setting,	   especially	   among	   paediatric	   patients	   [1].	   However,	   antibiotics	   are	   often	  
unnecessarily	   used	   both	   in	   the	   community,	   where	   too	   many	   children	   receive	   broad-­‐
spectrum	  antibiotics	   for	  viral	   infections,	  and	   in	   the	  hospital,	  where	   long	  courses	  of	  broad-­‐
spectrum	   antibiotics	   are	   frequently	   prescribed	   [2].	   Recent	   studies	   have	   found	   that	   up	   to	  
50%	  of	  antimicrobial	  prescriptions	  are	  inappropriate	  [3,4].	  
The	   emergence	   of	   multi-­‐drug	   resistant	   (MDR)	   pathogens	   and	   their	   rapid	   global	   spread,	  
strictly	  associated	  with	  an	   inappropriate	  use	  of	  antimicrobials,	  are	   important	  global	  public	  
health	  threats	  with	  a	  substantial	  impact	  on	  patient	  outcomes	  such	  as	  hospital	  length	  of	  stay	  
and	  mortality,	  as	  well	  as	  on	  healthcare	  costs	  [5–8].	  The	  European	  Antimicrobial	  Resistance	  
Surveillance	  Network	  (EARS-­‐Net)	  system	  has	  reported	  a	  dangerous	  rise	   in	  MDR	  bacteria	   in	  
the	   last	   years	   showing	   that	   some	   countries	   such	   as	   Italy	   are	   strongly	   contributing	   to	   this	  
worrying	  increase	  [9].	  
Many	  studies	  have	  evaluated	  antibiotic	  prescriptions	  in	  the	  paediatric	  outpatient	  population	  
highlighting	   the	   problem	   that	   Italian	   prescribing	   habits	   that	   differ	   from	   those	   of	   other	  
European	  countries.	  An	  Italian	  child	  is	  more	  likely	  to	  be	  exposed	  to	  antibiotics	  than	  children	  
are	   in	   North	   Europe	   [10]	   and,	   in	   particular,	   the	   prevalence	   of	   antibiotic	   prescriptions	   in	  
childhood	  have	  been	  reported	  to	  be	  4	  times	  higher	  than	  in	  the	  UK	  and	  6	  times	  higher	  than	  in	  
the	   Netherlands	   [11,12].	   Moreover,	   Italy	   reported	   the	   highest	   prescription	   rate	   (1.3	   per	  
infants	  per	  year)	  in	  a	  study	  comparing	  antibiotic	  use	  in	  the	  first	  year	  of	  life	  in	  five	  European	  
countries	   [13].	   In	   fact,	   data	   from	   the	   Gagliotti	   et	   al	   study	   in	   2006	   show	   that	   the	   55%	   of	  
Italian	  infants	  in	  the	  community	  have	  already	  received	  at	  least	  one	  course	  of	  antibiotics	  at	  1	  
year	  of	  age	  and	  84%	  at	  2	  years	  of	  age	  [14].	  
Although	   a	   positive	   correlation	   between	  outpatient	   and	   inpatient	   antibiotic	   use	   has	   been	  
noted	   [15],	   few	   studies	   describing	   the	   real	   antibiotic	   consumption	   in	   Italian	   children’s	  
hospitals	  have	  been	  published.	  A	  single	  centre	  study	  was	  carried	  out	  in	  Rome	  in	  2008	  [16]	  
confirming	   the	  abuse	  of	   antibiotics	  observed	   in	   the	  outpatient	  population.	  A	  more	   recent	  
paper	  evaluating	   the	   trend	  of	  antibiotic	  use	   in	  all	   the	  paediatric	  wards	  of	  Emilia-­‐Romagna	  
Region	  over	  an	  8-­‐year-­‐period	  [17]	  indicated	  a	  slight	  increase	  of	  antibiotic	  consumption	  over	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time,	  an	  inadequate	  tendency	  to	  prefer	  penicillin	  plus	  inhibitors	  to	  plain	  penicillins,	  an	  over-­‐
use	  of	  third	  generation	  cephalosporins	  and	  a	  worrisome	  increase	  in	  linezolid	  prescriptions.	  
In	   this	   paper,	   we	   present	   the	   results	   of	   a	   point-­‐prevalence	   survey	   (PPS)	   on	   antibiotic	  
prescriptions	   carried	  out	   in	   seven	   large	   Italian	  paediatric	   institutions	   in	  2012.	  The	  aims	  of	  
our	  study	  were:	  i)	  to	  describe	  prevalence	  rates	  of	  antibiotic	  prescriptions	  for	  prophylaxis	  and	  
treatment	   of	   infections	   for	   neonatal	   (<30	   days)	   and	   paediatric	   (age	   ≥30	   days)	   patients	   in	  
seven	  Italian	  centres;	  ii)	  to	  evaluate	  antibiotic	  prescriptions,	  indications,	  number	  and	  type	  of	  
antibiotic	  agents	  and	  administration	  route	  in	  the	  same	  age	  sub-­‐groups	  both	  for	  prophylaxis	  
and	   treatment	   of	   infections;	   iii)	   to	   describe	   over-­‐all	   consumption	   and	   off-­‐label	   use	   of	  
particular	  classes	  of	  antibiotics,	  such	  as	  carbapenems	  and	  quinolones,	  in	  our	  cohort;	  and	  iiii)	  
to	  identify	  targets	  for	  improving	  the	  quality	  of	  antimicrobial	  prescribing	  in	  these	  centres.	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Methods	  
This	  research	  has	  been	  conducted	  according	  to	  the	  principles	  expressed	  in	  the	  Declaration	  
of	  Helsinki.	  Ethical	  approval	  has	  been	  obtained	  for	  the	  coordinating	  centre.	  No	  consent	  was	  
given,	   because	   data	   were	   collected	   by	   reviewing	   medical	   charts	   and	   were	   analyzed	  
anonymously.	   Every	   patient	   record	   was	   given	   a	   unique	   non-­‐identifiable	   survey	   number,	  
which	   was	   automatically	   generated	   by	   a	   computer	   program	   specifically	   designed	   for	  
anonymous	  data	  entry.	  
A	   1-­‐day	   PPS	   on	   antibiotic	   use	   in	   hospitalized	   children	   was	   performed	   in	   Italy	   between	  
October	   and	   December	   2012	   as	   part	   of	   the	   Antibiotic	   Resistance	   and	   Prescribing	   in	  
European	  Children	  project	  (ARPEC).	  Seven	  paediatric	  or	  mixed	  adult-­‐paediatric	  hospitals	   in	  
seven	   Italian	   cities	   were	   involved	   (Genoa,	   Milan,	   Padua,	   Florence,	   Viareggio,	   Rome	   and	  
Naples).	  The	  survey	  included	  all	  admitted	  patients	  less	  than	  18	  years	  of	  age	  present	  in	  the	  
ward	   at	   8:00	   am	   on	   the	   day	   of	   the	   survey	   who	   had	   at	   least	   one	   on-­‐going	   antibiotic	  
prescription.	  The	  wards	  of	  admission	  were:	  medical	  (general	  neonatal	  and	  maternal	  wards,	  
and	   general	   paediatric	  wards),	   special	  medical	   (cardiology,	   nephrology,	   onco-­‐hematology,	  
neuromuscolary,	   neurology,	   bronchopneumology,	   infectious	   diseases	   unit),	   neonatal	   and	  
paediatric	   intensive	  care	   (NICUs	  and	  PICUs),	   surgical	   (neonatal	   surgery,	  paediatric	  surgery,	  
orthopedics,	   neurosurgery).	   For	   feasibility	   reasons,	   one	   hospital	   provided	   data	   from	  
randomly	   selected	   wards,	   maintaining	   the	   patient	   distribution	   among	   medical,	   special	  
medical,	   surgical	  and	   intensive	  care	  units,	   in	  agreement	  with	   the	  coordinating	  centre.	  Full	  
details	  of	  the	  ARPEC	  methodology	  are	  described	  elsewhere	  [18].	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Results	  
The	  PPS	  was	  performed	  in	  61	  wards	  within	  seven	  Italian	  institutions.	  Characteristics	  of	  the	  
centres	  involved	  are	  shown	  in	  Table	  1.	  A	  total	  of	  899	  patients	  was	  present	  in	  the	  hospitals	  at	  
8:00	  am	  on	  the	  day	  of	  the	  survey	  and	  349	  (38.9%)	  of	  these	  had	  an	  on-­‐going	  prescription	  for	  
one	  or	  more	  antibiotics.	  However,	  this	  rate	  was	  variable	  among	  the	  hospitals	  ranging	  from	  
25.7%	  to	  53.8%	  (Table	  1).	  Combination	  therapies	  were	  variably	  used	  among	  the	  institutions	  
(21.7–60.3%)	  with	   a	   ratio	   between	   number	   of	   prescribed	   antibiotics	   and	   treated	   patients	  




Table	  1.	  Characteristics	  of	  the	  7	  Italian	  institutions	  involved	  in	  the	  ARPEC	  project.	  
	  
A	   wide	   variability	   also	   existed	   in	   the	   proportions	   of	   patients	   treated	   with	   at	   least	   one	   antibiotic	  
stratified	  by	  ward	  type.	   In	  particular,	   special	  medical	  wards	  and	   intensive	  care	  units	  accounted	  for	  
higher	  proportions	  of	  patients	  receiving	  antibiotics	  compared	  to	  surgical	  and	  medical	  wards	  (Fig.	  1).	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Figure	  1.	  	  Proportion	  of	  paediatric	  patients	  treated	  with	  at	  least	  one	  antibiotic	  by	  ward	  type.	  
	  
Characteristics	   of	   all	   patients	   enrolled	   are	   summarized	   in	   Table	   2.	   Median	   patient	   age	   was	   24	  
months	   and	   12.3%	   were	   less	   than	   30	   days	   old.	   Overall,	   24.6%	   of	   patients	   were	   affected	   by	   a	  
medical/surgical	  underlying	  condition	  and	  the	  most	  frequent	  was	  an	  oncologic/hematologic	  disease.	  
Noteworthy	  is	  that	  the	  rate	  of	  oncologic/hematologic	  patients	  admitted	  to	  the	  hospital	  at	  the	  time	  
of	   the	   survey	  was	   5%	   (45/899),	   but	   this	   rate	   increased	   to	   22.3%	   (78/349)	   looking	   at	   the	   group	  of	  
patients	   receiving	   antibiotics.	   These	   data	   reflect	   the	   fact	   that	   oncologic	   and	   hematologic	   patients	  
were	  responsible	  for	  a	  large	  proportion	  of	  antibiotic	  consumption	  in	  our	  survey.	  
	  
	  
Abbreviations:	  IQR=	  interquartile	  range	  
	  
Table	  2.	  Characteristics	  of	  the	  349	  Italian	  patients	  enrolled	  in	  the	  24-­‐hour	  ARPEC	  PPS.	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We	  analyzed	  antibiotic	  prescriptions	  separately	  in	  neonates	  and	  children	  (Table	  3).	  
	  
	  
Table	  3.	  Demographic	  characteristics	  and	  antibiotic	  prescription	  patterns	  of	  the	  neonates	  and	  children	  
enrolled	  in	  the	  study.	  
	  
	  
	   	  
	   15	  
Neonates	  
At	   the	   time	   of	   the	   survey,	   248	   neonates	   were	   admitted	   in	   participating	   hospitals	   and	   43	   were	  
receiving	   antibiotics	   (17.3%).	   As	   shown	   in	  Table	   3,	   neonates	   treated	  with	   antibiotics	  were	  mostly	  
admitted	   in	   the	   NICUs	   (83.7%,	   36/43).	   Moreover,	   62.8%	   (27/43)	   of	   newborns	   were	   receiving	  
antibiotics	   for	   prophylaxis	   and	   only	   37.2%	   (16/43)	   were	   being	   treated	   for	   infection.	   The	   top	   two	  
active	  antibiotic	  prescriptions	  were	  penicillins	   (69.8%,	  30/43)	   and	  aminoglycosides	   (58.1%,	  25/43).	  
Details	   about	   indications	   to	   receive	   antibiotics	   are	   summarized	   in	   Table	   3.	   All	   antibiotic	   classes	  
prescribed	  are	  listed	  in	  Fig	  2.	  
	  
Figure	  2.	  Antibiotic	  prescriptions	  among	  the	  neonates	  and	  children.	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Antibiotic	  prophylaxis	  in	  neonates	  
The	  main	   indication	   to	   prescribe	   antibiotic	   prophylaxis	  was	  medical	   risk	   factors	   (e.g.	   prematurity,	  
maternal	   fever	   during	   labor,	   prolonged	   rupture	   of	   the	   membranes),	   accounting	   for	   55.8%	   of	   all	  
indications	  for	  antibiotic	  therapy	  in	  the	  neonatal	  subset.	  The	  other	  neonatal	  patients	  were	  receiving	  
prophylaxis	   for	   surgical	   reasons.	   Monotherapy	   was	   prescribed	   in	   10	   of	   the	   27	   patients	   on	  
prophylaxis	  (37%),	  and	  penicillin	  was	  the	  most	  prescribed	  antibiotic	  (7/10).	  Combination	  therapies	  in	  
the	   other	   17/27	   patients	   (63%)	  were	   variable:	   penicillins	  were	   combined	  with	   aminoglycosides	   in	  
7/17	  cases,	  while	  glycopeptides	  were	  used	  with	  third	  generation	  cephalosporins	  in	  3	  cases	  and	  with	  
aminoglycosides	   in	   3	   cases.	   The	   last	   4	   patients	   received	   3	   drug	   combination	   therapy,	   including	  
glycopeptides	  plus	  aminoglycosides	  combined	  with	  metronidazole	  (2/4)	  or	  penicillin	  (2/4).	  
	  
Antibiotic	  treatment	  in	  neonates	  
Among	  all	   the	   indications	   for	  antibiotic	   treatment	  of	   infection	   in	  neonates,	   the	  most	  common	  was	  
sepsis	  (30.2%,	  13/43).	  Monotherapy	  was	  used	  just	  in	  two	  cases	  (one	  case	  treated	  with	  ampicillin	  and	  
the	   other	   treated	   with	   meropenem).	   Penicillins	   plus	   aminoglycosides	   was	   by	   far	   the	   preferred	  
combination	   therapy	   (8/11),	  while	   in	   the	   other	   patients	   (3/11)	   glycopeptides	  were	   used	  widely	   in	  
combination	  with	  other	  classes	  of	  antibiotics.	  
	  
Children	  
The	   paediatric	   group	   was	   composed	   of	   651	   patients,	   47%	   (306/651)	   of	   whom	   had	   an	   active	  
antibiotic	   prescription	   at	   the	   time	   of	   the	   PPS.	   In	   the	   group	   of	   patients	   with	   active	   antibiotic	  
prescriptions,	   64.4%	   (197/306)	   were	   being	   treated	   for	   infections	   and	   35.5%	   (109/306)	   for	  
prophylaxis	  (Table	  3).	  Third	  generation	  cephalosporins	  and	  penicillin	  plus	  enzyme	  inhibitors	  were	  the	  
most	   commonly	  used	  antibiotic	   classes.	  More	  details	   about	   indications	   to	   therapy	  are	   reported	   in	  
Table	  3.	  All	  antibiotic	  classes	  prescribed	  are	  listed	  in	  “Fig	  2”.	  
	  
Antibiotic	  prophylaxis	  in	  children	  
Approximately	   half	   of	   the	   children	   on	   antibiotics	   for	   prophylaxis	   received	   antibiotics	   for	   surgical	  
reasons	   (52.3%,	   57/109),	   the	   others	   for	   medical	   problems	   (47.7%,	   52/109).	   The	   most	   prescribed	  
antibiotics	  were	  third	  generation	  cephalosporins	  for	  surgery	  (35.9%,	  20/57),	  used	  as	  monotherapy	  in	  
14/20	  cases	  and	  combined	  most	  often	  with	  metronidazole	  in	  the	  other	  cases	  (3/20).	  Cotrimoxazole	  
was	  the	  most	  commonly	  prescribed	  agent	  for	  the	  medical	  problems	  (67.3%,	  35/52),	  mainly	  used	  as	  
monotherapy	  (30/35).	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Antibiotic	  treatment	  in	  children	  
	  
The	  main	  reason	  for	  prescribing	  antibiotics	  for	  infection	  among	  children	  was	  lower	  respiratory	  tract	  
infections	  (LRTI)	  (34%,	  67/197),	  followed	  by	  febrile	  neutropenia/fever	  in	  oncologic	  patients	  (11.7%,	  
23/197).	   Focusing	   on	   prescriptions	   for	   LRTI,	   43.3%	   (29/67)	   of	   patients	   were	   treated	   with	   third	  
generation	   cephalosporins,	   followed	  by	  macrolides	   (26.9%,	  18/67),	   quinolones	   (16.4%,	  11/67)	   and	  
carbapenems	   (14.9%,	   10/67).	   Cephalosporins	   were	   used	   as	   monotherapy	   in	   13/29	   cases	   and	  
combined	   in	  the	  other	  16	  cases,	  mostly	  with	  macrolides	  (6/16).	  For	  73.1%	  (49/67)	  of	  children	  with	  
LRTI,	  the	  route	  of	  antibiotic	  administration	  was	  parenteral.	  
For	  oncology	  patients	  affected	  by	  neutropenic	  fever/fever,	  the	  preferred	  antibiotics	  were	  penicillins	  
with	   enzyme	   inhibitors	   (47.8%,	   11/23),	   followed	   by	   carbapenems	   (34.8%,	   8/23),	   aminoglycosides	  
(26.1%,	   6/23)	   and	   glycopeptides	   (26.1%,	   6/23).	   Penicillins	   with	   enzyme	   inhibitors	   were	   used	   in	  
monotherapy	   in	   5/11	   cases	   and	   combined	   mostly	   with	   aminoglycosides	   in	   the	   other	   6	   cases.	  
Carbapenem	  monotherapy	  was	  prescribed	  in	  4/8	  cases,	  while	  combination	  therapy	  with	  anti-­‐Gram	  
positive	   agents	   (glycopeptides	   or	   oxazolidinones)	   was	   preferred	   in	   the	   other	   cases.	   The	   route	   of	  
antibiotic	  administration	  was	  parenteral	  in	  the	  95.7%	  of	  cases	  (22/23).	  
	  
Use	  of	  Carbapenems	  
Among	   the	  899	  patients	  admitted	   to	   the	  hospital	   at	   the	   time	  of	   the	   survey,	  32	   (3.6%)	  were	  being	  
treated	  with	  carbapenems.	  Focusing	  on	  the	  group	  of	  349	  patients	  with	  active	  antibiotic	  prescriptions	  
at	  the	  time	  of	  the	  PPS,	  8.9%	  (32/349)	  were	  receiving	  carbapenems	  (in	  particular	  4.6%	  [2/43]	  in	  the	  
neonatal	  group	  and	  9.8%	  [30/306]	  in	  the	  paediatric	  group).	  Considering	  the	  overall	  rates	  of	  therapy	  
by	  department,	   those	  with	   the	  highest	   rates	  of	  carbapenem	  prescription	  were	   the	  special	  medical	  
wards	   (14.2%,	   19/134)	   and	   the	   intensive	   care	   units	   (11.2%,	   9/80),	   compared	   to	   2.6%	   (2/76)	   in	  
medical	  wards	  and	  1.7%	  (1/59)	  in	  surgical	  wards.	  Indications	  for	  prescription	  of	  carbapenems	  were	  
community-­‐acquired	   infections	   in	   53.1%	   of	   cases,	   hospital-­‐acquired	   infections	   in	   37.5%	   and	  
prophylaxis	  in	  9.3%.	  Febrile	  neutropenia	  was	  the	  most	  common	  reason	  for	  carbapenem	  prescription	  
(34.8%,	  8/23).	  Therapy	  was	  empirically	  prescribed	  in	  62.5%	  (20/32)	  of	  patients.	  Carbapenems	  were	  
mostly	   prescribed	   in	   combination	   with	   one	   or	   more	   other	   antibiotics	   (65.6%,	   21/32),	   most	  
commonly	   with	   glycopeptides	   (10/21),	   followed	   by	   quinolones	   (4/21),	   cotrimoxazole	   (4/21)	   and	  
aminoglycosides	   (3/21).	   Meropenem	   was	   the	   most	   prescribed	   carbapenem,	   with	   great	  
heterogeneity	  in	  doses	  and	  number	  of	  administrations	  recorded.	  Daily	  doses	  of	  meropenem	  ranged	  
from	   19	   mg/kg/day	   to	   129	   mg/kg/day,	   while	   the	   mean	   dose	   was	   70	   mg/kg/day.	   Off-­‐label	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prescription	  of	  carbapenems	  (i.e.	  below	  3	  months	  of	  age)	  was	  recorded	  in	  18.7%	  (6/32)	  of	  patients	  
and	  the	  indications	  were	  LRTI,	  sepsis	  and	  surgical	  prophylaxis.	  
	  
Use	  of	  Quinolones	  
In	  the	  entire	  cohort	  of	  patients	  admitted	  to	  the	  hospital,	  3%	  (27/899)	  were	  prescribed	  quinolones.	  
Among	  the	  patients	  with	  active	  antibiotic	  prescriptions,	  this	  rate	  was	  7.7%	  (27/349).	  None	  of	  them	  
were	   neonates,	   but	   37%	   (10/27)	   were	   below	   2	   years	   of	   age.	   Considering	   the	   overall	   rates	   of	  
prescriptions	   into	   the	   departments,	   the	   special	  medical	  wards	   (10.4%,	   14/134)	   and	   intensive	   care	  
units	  (7.5%,	  6/80)	  reported	  the	  highest	  rates	  of	  quinolone	  prescription,	  compared	  to	  6.6%	  (5/76)	  in	  
medical	   wards	   and	   3.4%	   (2/59)	   in	   surgical	   wards.	   Indications	   for	   prescription	   of	   quinolones	  were	  
community-­‐acquired	   infections	   in	   44.4%	   of	   cases,	   hospital-­‐acquired	   infections	   in	   40.7%and	  
prophylaxis	   in	   14.8%.	   Considering	   the	   rates	   of	   antibiotic	   prescription	   by	   indication,	   the	   most	  
common	  indication	  was	  LRTI	  (17.6%,	  12/67).	  Among	  the	  group	  affected	  by	  LRTI,	  41.6%	  (5/12)	  had	  an	  
underlying	   chronic	   lung	   disease	   including	   cystic	   fibrosis	   and	   25%	   (3/12)	   congenital	  
immunodeficiency.	   In	   general,	   quinolone	   therapy	   was	   empirically	   prescribed	   in	   63%	   of	   patients.	  
Quinolones	  were	   prescribed	   as	  monotherapy	   just	   in	   29.6%	   (8/27)	   of	   patients.	   In	   the	   other	   cases,	  
they	  were	  widely	   combined	  with	  other	  antibiotics	   (70.4%,	  19/27),	  especially	  with	   third	  generation	  
cephalosporins	  (5/19).	  The	  mostly	  prescribed	  quinolone	  was	  ciprofloxacin.	  Focusing	  on	  ciprofloxacin,	  
the	  prescribed	  daily	  dose	  ranged	  from	  6	  mg/kg/day	  to	  30	  mg/kg/day,	  while	  the	  mean	  dose	  was	  18	  
mg/kg/day.	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Discussion	  
The	  1-­‐day	  ARPEC	  PPS	  provided	  very	  useful	  data	  on	  hospital	  antibiotic	  prescriptions	  for	  paediatric	  and	  
neonatal	   patients	   in	   Italy.	   According	   to	   data	   collected	   in	   seven	   large	   Italian	   institutions,	   38.9%	   of	  
inpatients	  received	  at	   least	  one	  antibiotic	  prescription	  during	  hospitalization.	  This	  rate	   is	  similar	   to	  
the	  mean	  rate	  reported	  from	  the	  worldwide	  ARPEC	  PPS	  (36.7%)	  [18].	  
To	  better	  analyze	  antibiotic	  prescription	  patterns	  and	  their	  appropriateness,	  we	  assessed	  antibiotic	  
prescriptions	  for	  prophylaxis	  and	  treatment	  of	  infection	  separately.	  
Our	   results	   show	   that	  overall	   39%	  of	  patients	  were	  prescribed	  antibiotics	   for	  prophylaxis	  with	   the	  
highest	   rate	   observed	   in	   the	   neonatal	   population	   (63%	   of	   neonatal	   prescriptions	   were	   for	   this	  
indication).	   The	  main	   indication	   for	  neonatal	  prophylaxis	  was	   the	  presence	  of	  perinatal	   conditions	  
(e.g.	  prematurity,	  maternal	   fever	  during	   labor,	  prolonged	  rupture	  of	  the	  membranes).	  Prophylactic	  
monotherapy	  was	  prescribed	  just	   in	  37%	  of	  neonates	  and	  penicillin	  was	  the	  preferred	  agent,	  while	  
combination	   prophylactic	   therapies	   including	   penicillin	   plus	   aminoglycosides	   or	   glycopeptides	   plus	  
cephalosporins/aminoglycosides	  were	  widely	  used	  in	  neonatal	  patients.	  This	  approach	  is	  not	  in-­‐line	  
with	   the	   international	   literature.	   Although	   neonates	   represent	   a	   high	   risk	   population	   due	   to	   their	  
immature	   immune	   system	   and	   the	   invasive	   procedure	   they	   are	   likely	   to	   undergo	   in	   NICU	   (e.g.	  
indwelling	   catheters,	   invasive	   mechanical	   ventilation),	   recent	   reviews	   reject	   the	   routine	   use	   of	  
antibiotic	   prophylaxis	   due	   to	   lack	   of	   efficacy	   in	   many	   conditions	   [19–22].	   Moreover,	   in	   2010	   the	  
Center	   for	   Disease	   Control	   and	   Prevention	   revised	   their	   guidelines	   regarding	   the	   prevention	   of	  
perinatal	   Group	   B	   streptococcal	   disease	   in	   healthy	   neonates,	   restricting	   the	   need	   for	   prophylaxis	  
only	   to	   well-­‐defined	   subgroups	   of	   patients	   [23].	   Prolonged	   courses	   of	   antibiotics	   have	   also	   been	  
associated	  with	  increased	  risk	  of	  necrotizing	  enterocolitis	  or	  death	  in	  low	  birth	  weight	  infants	  [24].	  
In	   the	   paediatric	   group,	   the	   rate	   of	   antibiotic	   prescriptions	   for	   prophylaxis	   was	   35.5%	   of	   all	   the	  
prescriptions.	   Approximately,	   half	   of	   these	   patients	   were	   receiving	   antibiotics	   for	   surgical	  
prophylaxis	   in	   accordance	   with	   previous	   European	   reports	   in	   which	   the	   proportion	   of	   children	  
receiving	   surgical	   prophylaxis	   ranged	   from	   13	   to	   42%	   [25,	   26].	   Third	   generation	   cephalosporins	  
ranked	  first	  in	  prescription	  frequency	  in	  this	  scenario,	  used	  often	  in	  monotherapy	  but	  combined	  with	  
metronidazole	  in	  some	  cases,	  confirming	  their	  alarming	  overuse	  for	  this	  indication.	  This	  problem	  in	  
fact	  was	  already	  raised	  by	  Ciofi	  et	  al	  in	  2008	  [16],	  but	  a	  recent	  paper	  published	  by	  Buccellato	  et	  al	  in	  
2015	   shows	   that	   a	   limitation	   on	   the	   prescriptions	   of	   these	   drugs	   has	   not	   yet	   been	   reached	   [17].	  
However,	  it	  is	  worth	  noting	  that	  this	  finding	  was	  very	  variable	  among	  the	  seven	  centers,	  since	  some	  
hospitals	   preferred	   the	   first	   generation	   cephalosporins	   for	   surgical	   prophylaxis,	   as	   suggested	   by	  
international	  guidelines	  [27].	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Cotrimoxazole	  was	  the	  most	  prescribed	  antibiotic	  for	  medical	  prophylaxis,	  used	  alone	  in	  most	  cases.	  
As	   explanation,	   most	   of	   the	   treated	   children	   were	   affected	   by	   onco-­‐hematological	   diseases	   and	  
cotrimoxazole	   is	   the	   best	   treatment	   to	   prevent	   Pneumocystis	   jirovecii	   pneumonia	   in	  
immunocompromised	  patients	  [28].	  
Regarding	  the	  prescription	  patterns	  for	  treatment	  of	  infection,	  the	  37.2%	  of	  our	  neonatal	  cohort	  was	  
prescribed	  at	  least	  one	  antibiotic	  for	  treating	  an	  infection,	  the	  main	  reason	  was	  sepsis	  and	  the	  most	  
common	   antibiotic	   class	   was	   penicillins,	   combined	   with	   aminoglycosides	   in	   a	   large	   number	   of	  
patients,	  in	  line	  with	  international	  literature	  [29,	  30].	  It	  is	  hard	  to	  compare	  prescription	  habits	  in	  our	  
centres	  with	  other	  NICUs	  because	  of	  a	  wide	  variability	  of	  the	  rate	  of	  neonates	  prescribed	  antibiotics	  
across	  hospitals,	  as	  shown	  by	  a	  recent	  multicenter	  study	  involving	  127	  NICUs	  in	  the	  US	  [31].	  The	  40-­‐
fold	  variations	  in	  prescription	  frequencies	  noted	  in	  this	  study	  did	  not	  appear	  to	  be	  related	  to	  higher	  
infection	   burden,	   necrotizing	   enterocolitis	   incidence,	   surgical	   volume	   or	   mortality	   rate	   [31].	   They	  
have	  instead	  been	  attributed	  to	  frequent	  inappropriate	  courses	  of	  antibiotics	  in	  inpatient	  neonates,	  
more	   commonly	   owing	   to	   an	   unnecessary	   antibiotic	   continuation	   than	   starting	   of	   a	   non-­‐required	  
therapy	  [32].	  
Focusing	   instead	   on	   the	   paediatric	   group,	   we	   noticed	   an	   excessive	   use	   of	   third	   generation	  
cephalosporins	   for	   treatment	   of	   infection	   similar	   to	   that	   seen	   for	   surgical	   prophylactic	   use,	   as	  
underlined	   before.	   In	   children	  with	   LRTIs,	   ceftriaxone	  was	   the	  most	   prescribed	   antibiotic,	   used	   as	  
monotherapy	   or	   often	   combined	  with	  macrolides,	   with	   a	  wide	   total	   daily	   dose	   variability	   ranging	  
from	  12.1	  mg/kg/day	  to	  153.8	  mg/kg/day.	  The	  frequent	  choice	  of	  ceftriaxone	  as	  first	  line	  therapy	  for	  
treatment	  of	   uncomplicated	   LRTIs	   and,	   in	   some	   cases,	   the	  high	  dosage	  prescribed,	   are	   reasons	  of	  
concern	   because	   they	   are	   not	   supported	   by	   current	   guidelines	   [33].	   In	   fact,	   other	   European	  
countries,	   as	   the	   UK	   and	   France,	   seem	   to	   have	   different	   prescribing	   patterns	   for	   LRTI,	   preferring	  
amoxicillin/clavulanic	  acid	  as	  first	  line	  therapy	  [34].	  
An	  abuse	  of	  parenteral	   cephalosporins	   in	   Italian	  hospitalized	   children	  was	  already	  denounced	   in	  a	  
study	  conducted	  by	  Esposito	  in	  2001	  [35]	  and	  is	  a	  well-­‐known	  problem	  also	  in	  the	  adult	  population	  
[36].	  
Noteworthy	   was	   also	   the	   widespread	   use	   of	   carbapenems	   and	   quinolones.	   Indeed,	   in	   our	   study	  
population,	   among	   the	   349	   patients	   receiving	   antibiotics,	   8.9%	   were	   being	   treated	   with	  
carbapenems,	  whereas	  proportion	  of	  carbapenems	  for	  therapeutic	  use	  reported	  in	  the	  literature	  in	  
European	  paediatric	  units	  is	  4,2%	  [37].	  Though	  carbapenems	  were	  prescribed	  in	  most	  cases	  for	  fever	  
in	   cancer	   patients,	   which	   often	   requires	   aggressive	   antibiotic	   treatment	   considering	   the	   patients’	  
immunological	   status	   and	   predisposition	   to	   severe	   infections,	   we	   are	   concerned	   about	   the	  
increasingly	   popular	   usage	   of	   these	   agents	   for	   community	   acquired-­‐infections,	   empiric	   treatment	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and	  combination	   therapy.	  This	   is	  a	  very	  alarming	   finding,	   considering	   the	  doubling	  of	   carbapenem	  
resistance	  rates	  in	  invasive	  isolates	  of	  Klebsiella	  pneumoniae	  reported	  by	  the	  European	  Antimicrobial	  
Resistance	  Surveillance	  Network	  (EARS-­‐Net)’s	  report	  from	  2010	  to	  2013	  [9]	  for	  Italy.	  We	  also	  found	  
18.7%	   off-­‐label	   use	   in	   patients	   below	   3	   months	   of	   life,	   but	   this	   could	   be	   explained	   by	   the	  
involvement	   of	   many	   of	   our	   centers	   in	   the	   European	   NEOMERO	   study,	   which	   aimed	   to	   evaluate	  
pharmacokinetics,	  safety	  and	  efficacy	  of	  meropenem	  in	  neonatal	  sepsis	  and	  meningitis	  [38].	  
Similar	  problems	  were	  noticed	  also	  for	  quinolone	  prescription.	  Quinolones	  were	  widely	  used	  in	  our	  
cohort,	  even	  if	  the	  license	  for	  the	  use	  of	  this	  antibiotic	  class	  below	  18	  years	  of	  age	  is	  restricted	  to	  few	  
rare	   indications	   such	   as	   cystic	   fibrosis	   with	   pulmonary	   exacerbations,	   complicated	   urinary	   tract	  
infections,	   post	   exposure	   prophylaxis	   against	   inhalational	   anthrax	   and	   severe	   infections	   with	  
allergies	   to	   other	   antibiotics	   [39,40].	   Among	   our	   patients,	   the	  main	   indication	   for	   treatment	  with	  
quinolones	  was	   LRTI.	   In	   this	   group	   of	   patients,	   quinolones	  were	   often	   prescribed	   empirically	   and	  
combined	   with	   other	   drugs,	   though	   current	   guidelines	   do	   not	   suggest	   quinolones	   as	   a	   first-­‐line	  
treatment	   considering	   that	   infections	   caused	   by	   pneumococci	   or	   atypical	   bacteria	   can	   still	   be	  
successfully	   treated	   with	   high	   doses	   of	   β-­‐lactams	   [41].	   Furthermore,	   the	   Scottish	   Antimicrobial	  
Prescribing	  Group	  (SAGP)	  in	  2008	  and	  the	  National	  Institute	  for	  Health	  and	  Care	  Excellence	  (NICE)	  in	  
2015	  [42]	  recommended	  to	  avoid	  the	  use	  of	  quinolones	  as	  first	  line	  agents	  for	  empirical	  treatment	  of	  
most	  commonly	  infections	  in	  primary	  care,	  because	  the	  overuse	  of	  these	  broad-­‐spectrum	  antibiotics	  
is	  associated	  with	  a	  significantly	  increased	  risk	  of	  Clostridium	  difficile	  infection	  [43,44].	  The	  wide	  use	  
of	  quinolones	  in	  our	  cohort	  could	  be	  explained	  by	  the	  finding	  that	  most	  of	  our	  patients	  receiving	  this	  
treatment	   had	   underlying	   chronic	   pulmonary	   diseases,	   such	   as	   cystic	   fibrosis	   or	   secondary	   to	  
immunodeficiencies,	   but	   the	   lack	   of	   data	   about	   their	   microbiological	   status	   did	   not	   allow	   us	   to	  
evaluate	  the	  appropriateness	  of	  these	  prescriptions.	  
Our	   study	   highlights	   many	   feasible	   targets	   that	   need	   a	   prompt	   intervention	   with	   appropriate	  
antimicrobial	  stewardship	  programs.	   International	  guidelines	  for	  stewardship	   identify	  a	  wide	  set	  of	  
interventions	   including:	   disease-­‐specific	   clinical	   pathways,	   audit	   with	   feedback	   and	   formulary	  
restriction	  with	  preauthorization	  of	   select	   agents.	   The	  best	   type	  of	   interventions	  must	  be	   tailored	  
according	  to	  local	  practices,	  resistance	  trends,	  and	  available	  resources	  [4].	  While	  the	  most	  effective	  
antimicrobial	  stewardship	  programs	  are	  built	  on	  proactive	  interventions,	  in	  settings	  where	  a	  robust	  
antimicrobial	   stewardship	   team	   is	   hard	   to	   establish,	   clinical	   pathways	   tool	   represent	   a	   reasonable	  
and	   feasible	   first	   step	   for	   implementation	   standardizing	   care	   without	   adversely	   affecting	   patient	  
safety	  or	  outcomes	  [45,	  46].	  Moreover,	  annual	  PPS	  could	  be	  a	  useful	  tool	  to	  measure	  the	  impact	  of	  
these	   interventions	   on	   antibiotic	   prescribing	   practices	   [18].	   Thus,	   implementation	   of	   clinical	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pathways	  in	  Italian	  paediatric	  hospitals	  associated	  with	  annual	  PPSs	  could	  be	  a	  good	  start	  to	  reduce	  
the	  abuse	  and	  misuse	  of	  antibiotics.	  
Our	  study	  has	  some	  limitations.	  First,	  data	  about	  microbiological	  isolates	  and	  antibiotic	  susceptibility	  
tests,	  length	  of	  therapies	  and	  prophylaxis	  and	  previous	  antibiotic	  courses	  could	  have	  been	  useful	  to	  
better	   define	   the	   appropriateness	   of	   antimicrobial	   prescriptions.	  Moreover,	   the	   characteristics	   of	  
involved	   institutions	   may	   have	   affected	   at	   least	   in	   part	   the	   reliability	   of	   some	   results.	   Most	  
institutions	   are	   in	   fact	   tertiary	   care	   hospitals	   that	   usually	   manage	   more	   complicated	   and	   severe	  
cases,	  which	  might	  significantly	  impact	  antibiotic	  prescriptions.	  In	  addition,	  the	  heterogeneity	  among	  
institutions,	  in	  terms	  of	  presence/absence	  of	  onco-­‐hematology	  departments	  or	  intensive	  care	  units,	  
may	   strongly	   affect	   antimicrobial	   prescription	  patterns.	   Finally,	   the	   survey	  was	   conducted	   in	   2012	  
and	   since	   then	   a	   greater	   awareness	   of	   antibiotic	   stewardship	   programs	   has	   spread	   among	   Italian	  
hospitals	  [47–49].	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Conclusions	  
Our	   study	   took	  a	  picture	  of	   the	   Italian	   situation	   in	   terms	  of	  antibiotic	  prescriptions	   in	  hospitalized	  
neonates	   and	   children	   and	   identified	  many	   feasible	   targets	   that	   require	   a	   prompt	   intervention	   to	  
reduce	   the	   abuse	   and	  misuse	   of	   antibiotics.	   Antibiotic	   stewardship	   programs	   should	   immediately	  
introduce	  measures	   to	   control	  prescription	  patterns	   in	  particular	   for	  prophylaxis,	  both	   in	  neonatal	  
and	  paediatric	  populations,	  and	  to	  limit	  the	  over-­‐use	  of	  third	  generation	  cephalosporins,	  that	  seems	  
to	  persist	  over-­‐time.	   Surveillance	  and	  educational	  programs	  are	  also	  needed	   to	   restrict	   the	  use	  of	  
carbapenems	   to	  more	   severe	   conditions.	   The	   implementation	  of	   disease-­‐specific	   clinical	   pathways	  
associated	  with	  annual	  PPSs	  could	  be	  a	  good	  way	  to	  monitor	  and	  ameliorate	  antibiotic	  prescription	  
patterns	  in	  neonatal	  and	  paediatric	  inpatients	  over	  time,	  in	  order	  to	  reduce	  as	  much	  as	  possible	  the	  
worrisome	  emergence	  of	  MDR	  bacteria	  in	  this	  vulnerable	  population.	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Abstract	  
Background	  
Antibiotics	  are	  the	  most	  common	  prescribed	  drugs	  among	  children	  in	  hospitals	  and	  communities.	  It	  
has	   been	   demonstrated	   that	   a	   great	   number	   of	   these	   prescriptions	   are	   inappropriate	   or	  
unnecessary.	  Antibiotic	  abuse	  and	  misuse	  increases	  the	  risk	  for	  serious	  side	  effects,	  raises	  costs,	  and	  
heavily	   contributes	   to	   the	   antimicrobial	   resistance	   emergency.	   Therefore,	   the	   implementation	   of	  
strategies	   to	   improve	   the	   appropriateness	   of	   antibiotic	   prescription	   has	   become	   an	   urgent	   public	  
health	   priority.	   Antimicrobial	   stewardship	   programs	   (ASPs)	   are	   key	   instruments	   to	   tackle	   this	  
emergency.	  The	  primary	  aim	  of	  this	  systematic	  review	  is	  to	  summarize	  the	  current	  state	  of	  evidence	  
of	   the	  effects	  of	  ASPs	   in	  pediatrics	  worldwide;	  our	  secondary	  aim	   is	   to	  compare	  ASPs	  practice	  and	  
implementation	  between	  US	  and	  Europe.	  
	  Methods	  
PubMed	  and	  Cochrane	  Library	  were	  systematically	  searched	  to	   identify	  studies	  reporting	  on	  ASP	  in	  
children	   aged	   18	   years	   conducted	   in	   outpatients	   or	   in-­‐hospital	   settings.	   Two	   investigators	  
independently	  reviewed	  identified	  articles	  for	  inclusion	  and	  extracted	  relevant	  data.	  
Results	  
Of	   the	   6435	   studies	   screened,	   82	   were	   eligible	   for	   inclusion	   in	   this	   study.	   Most	   of	   the	   studies	  
originated	  from	  the	  US	  (63%),	  while	  a	  minority	  from	  Europe	  (13%).	  Forty-­‐nine	  (60%)	  studies	  used	  a	  
before-­‐and	   after	   design	   and	   only	   ten	   (12%)	   were	   randomized	   trials.	   The	   vast	   majority	   (85%)	  
described	  an	   in-­‐hospital	  ASP,	  half	  of	   the	   interventions	   involved	  mixed	  pediatric	  wards,	   and	  6	   (7%)	  
studies	  were	  performed	  in	  Emergency	  Department.	  Only	  10	  (12%)	  studies	  were	  focused	  on	  the	  costs	  
of	  an	  ASP.	  
	  Conclusions	  
ASPs	  pediatric	  has	  significant	  impact	  on	  reducing	  targeted-­‐	  and	  nontargeted-­‐antimicrobial	  use,	  costs,	  
and	  resistances	  both	  in	  inpatient	  and	  outpatients	  settings.	  Despite	  these	  results,	  pediatric	  ASPs	  are	  
spreading	  rapidly	  in	  the	  US,	  while	  their	  implementation	  in	  Europe	  is	  still	  challenging.	  Further	  efforts	  
in	  developing	  more	  ASPs	  are	  needed.	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Background	  
Antimicrobials	  are	  the	  most	  common	  prescribed	  drugs,	  especially	  in	  paediatrics	  [1-­‐3].	  	  
It	   has	   been	   estimated	   that	   37-­‐61%	   of	   hospitalized	   infants	   and	   children	   receive	   antibiotics	   [4-­‐8].	  
Moreover,	   it	   has	   been	   demonstrated	   that	   from	   20	   to	   50%	   of	   prescriptions	   are	   unnecessary	   or	  
inappropriate	  [9-­‐13].	  Too	  many	  children	  still	  receive	  broad-­‐spectrum	  antibiotics	  for	  viral	  infections	  or	  
antibiotic	  courses	  significantly	  longer	  than	  needed	  [14-­‐18].	  
This	   unnecessary	   exposure	   increases	   the	   risk	   for	   serious	   side	   effects,	   raises	   costs,	   and	   heavily	  
contributes	   to	   the	   antimicrobial	   resistance	   emergency	   [7,	   19].	   	   Although	   antimicrobial	   resistance	  
occurs	   naturally	   or	   can	   be	   acquired	   through	   gene	   transfer,	   antimicrobial	   misuse	   promotes	   the	  
selection	   of	   resistant	   organisms	   [20,	   21]. The	   emergence	   of	   resistant	   pathogens	   and	   their	   rapid	  
global	  spread	  has	  rapidly	  become	  an	  important	  global	  public	  health	  threat	  with	  a	  substantial	  burden	  
for	   patients,	   prolonging	   hospital	   stays,	   increasing	   incidence	   of	   Clostridium	   difficile	   infection	   and	  
mortality	  as	  well	  as	  increasing	  healthcare	  costs	  [22-­‐27].	  Indeed,	  if	  antibiotic	  prescribing	  in	  adults	  and	  
children	   could	   be	   reduced,	   selection	   and	   transmission	   of	   resistant	   strains	  would	   decrease.	   This	   is	  
particularly	   important	   since	   there	   has	   been	   a	   steady	   decline	   in	   the	   number	   of	   new	   antibacterial	  
drugs	  approved	  over	  the	  last	  few	  decades	  on	  both	  sides	  of	  the	  Atlantic	  [28,	  29].	  
The	  World	  Health	  Organization	  and	  the	  United	  Nations	  at	  the	  General	  Assembly	  of	  2016	  identified	  
the	  development	  of	   country-­‐level	   and	   institutional	   antimicrobial	   stewardship	   programs	   (ASPs)	   key	  
instruments	  to	  tackle	  this	  emergency	  [30,	  31].	  
From	  2007,	  the	  Infectious	  Disease	  Society	  of	  America	  (IDSA)	  formally	  introduced	  the	  concept	  of	  ASP	  
as	  a	  set	  of	  coordinated	   interventions	  designed	   for	   improving	  antimicrobial	  use	   (appropriate	  agent,	  
dose,	   route	   of	   administration	   and	   therapy	   duration)	  without	   compromising	   patient	   outcome	   [32].	  
The	   Pediatric	   Infectious	   Diseases	   Committee	   on	   Antimicrobial	   Stewardship	   has	   defined	   the	  
development	  of	  ASPs	  in	  three	  different	  settings—inpatients,	  special	  populations	  (e.g.	  oncology)	  and	  
outpatients.	  Indeed,	  ASPs	  characteristics	  may	  vary	  to	  best	  fit	  the	  needs	  of	  different	  setting	  [33].	  The	  
primary	  aim	  of	  this	  systematic	  review	  is	  to	  summarize	  the	  current	  state	  of	  evidence	  of	  the	  effects	  of	  
ASPs	  in	  paediatrics	  worldwide;	  our	  secondary	  aim	  is	  to	  compare	  ASPs	  practice	  and	  implementation	  
between	  US	  and	  Europe.	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Materials	  and	  methods	  
	  
Study	  design	  and	  Search	  strategy	  
	  
We	   conducted	   a	   systematic	   review	   according	   to	   the	   Preferred	   Reporting	   Items	   for	   Systematic	  
Reviews	   and	  Meta-­‐Analyses	   (PRISMA)	   guidelines	   [34].	   In	   conjunction	  with	   a	  medical	   librarian,	  we	  
conducted	  a	  systematic	  search	  of	  Pubmed	  and	  Cochrane	  Library	  databases	  including	  citations	  from	  
January	  1,	  2007	  to	  October	  23,	  2017	  with	  a	  strategy	  combining	  Medical	  Subject	  Heading	  (MeSH)	  and	  
free-­‐text	  terms	  for	  ‘children’	  AND	  ‘antimicrobial’	  AND	  ‘stewardship’.	  The	  full	  strategy	  is	  provided	  in	  
the	  Supporting	  information.	  
	  
Inclusion	  criteria	  
Studies	  were	  eligible	  for	  full-­‐text	  review	  if	  they	  included	  all	  of	  the	  following:	  patients	  younger	  than	  
18	   years	   and	   conducted	   in	   outpatients	   or	   in-­‐hospital	   settings.	   Randomized	   controlled	   trials,	  
controlled	  and	  non-­‐controlled	  pre-­‐	  and	  post-­‐	  studies,	  controlled	  and	  non-­‐controlled	  interrupted	  time	  
series	  and	  cohort	  studies	  were	  included.	  
	  
Exclusion	  criteria	  
Review	  articles,	  case	  series,	  letters,	  notes,	  conference	  abstracts	  and	  opinion	  articles	  were	  excluded.	  
Papers	  on	  both	  adults	  and	  children	  where	  extraction	  of	  paediatric	  data	  was	  not	  possible	  were	  also	  
excluded.	   	   We	   excluded	   studies	   published	   in	   non-­‐English	   language	   and	   before	   2007	   because	   AS	  
concept	  was	  formally	  introduced	  in	  2007.	  
	  
Study	  selection	  
Title	  and	  abstract	  as	  well	  as	  full-­‐text	  assessment	  was	  conducted	  independently	  by	  two	  investigators	  
(DD	  and	  MD);	  any	  differences	   in	  opinion	  regarding	  study	  selection	  and	  study	  details	  were	  resolved	  
by	  a	  consensus.	  Three	  rounds	  of	  article	  assessment	  were	  conducted	  before	  selecting	  the	  final	  list	  for	  
data	  abstraction.	  The	  selection	  process	  is	  summarized	  in	  Figure	  1.	  	  	  
	  
Data	  collection	  	  
Data	   were	   extracted	   using	   a	   standardized	   data	   collection	   form,	   which	   summarized	   information	  
about:	   authors,	   year	   of	   publication,	   study	   design,	   country,	   study	   period,	   setting,	   multicentric	  
involvement,	  type	  of	  intervention	  and	  main	  results.	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Of	  6435	  title	  and	  abstracts,	  82	  were	  eligible	  for	  inclusion	  in	  this	  study.	  
Most	  of	  the	  studies	  originate	  from	  the	  US	  (52/82,	  63.4%)	  while	  other	  AS	  experiences	  are	  sparse.	  
Only	  11/82	  (13.4%)	  papers	  describe	  an	  implementation	  of	  ASP	  in	  Europe	  while	  seven	  originate	  from	  
low-­‐income	  countries.	  
	  	  
Authors,	  year	  of	  publication,	  study	  design,	  country,	  study	  period,	  setting,	  multicentric	  involvement,	  
type	  of	  intervention	  and	  main	  results	  are	  summarized	  in	  table	  1.	  
	  







Records	  identified	  through	  searching	  
COCHRANE	  =	  5951	  
PUBMED	  =	  474	  
	  
N	  =	  6425	  
Records	  after	  duplicates	  removed	  
N	  =	  6332	  
Records	  screened	  by	  title	  and	  abstract	  	  
N	  =	  6332	  
Records	  excluded	  
N	  =	  6197	  
<	  2007	  =	  1534	  
Non	  English	  =	  422	  
No	  abstract	  available	  =	  23	  
Not	  relevant	  =	  4210	  




N	  =	  135	  	  
Articles	  excluded	  
N	  =	  63	  
No	  data	  or	  unclear	  data	  on	  clinical	  outcome	  =	  6	  
No	  separate	  data	  on	  children	  =	  5	  
Not	  relevant:	  29	  
No	  pediatric	  data:	  21	  
No	  full-­‐text	  available:	  1	  
Non	  English:	  1	  
 
Retrieved	  from	  manual	  reviewing	  of	  
reference	  lists	  
N	  =	  10	  
Studies	  included	  in	  quantitative	  synthesis	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Table	  1	  Included	  studies	  of	  antibiotic	  stewardship	  programs.	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Forty-­‐eight	   (49/82,	   59.8%)	   studies	   used	   before-­‐and-­‐after	   design,	   three	   (3/82,	   3.7%)	   were	  
observational	   studies,	   12/82	   (14.6%)	   were	   retrospective	   studies	   and	   seven	   (7/82,	   8.5%)	   were	  
prospective	  studies.	  Ten	  (10/82,	  12.2%)	  were	  randomized	  trial.	  
Seventy	   studies	   (70/82,	   85.4%)	   describe	   ASP	   implementation	   in	   a	   hospital	   setting.	  Most	   of	   them	  
involve	   mixed	   wards	   in	   a	   Pediatric	   Hospital	   (44/82,	   53.7%)	   while	   some	   of	   them	   are	   focused	   on	  
specific	   settings:	  11	  on	   the	  NICU,	  six	  on	   the	  ED,	   four	  on	   the	  operating	   room,	   two	  on	  the	  oncology	  
ward,	  two	  on	  both	  NICU	  and	  PICU,	  and	  one	  on	  the	  PICU.	  Twelve	  papers	  (12/82,	  14.6%)	  describe	  ASP	  
in	  an	  outpatient	  setting.	  
	  AS	  interventions	  stratified	  for	  different	  settings	  are	  summarized	  in	  table	  2.	  
Sixty-­‐seven	   (67/82,	   81.7%)	   studies	   have	   as	   main	   outcome	   change	   in	   antimicrobial	   prescriptions.	  
Other	   primary	   outcomes	   analyzed	   were:	   change	   in	   antimicrobial	   resistance	   (8/82,	   9.8%),	   costs	  
(10/82,	  12.2%)	  and	  physicians’	  compliance	  (11/82,	  13.4%)	  
Abbreviations:	  US=United	  States,	  PCT=Procalcitonin,	  NICU=Neonatal	  Intensive	  Care	  Unit,	  PICU=Paediatric	  Intensive	  Care	  Unit	  
Table	  2	  Antimicrobial	  stewardship	  programs	  according	  to	  the	  different	  settings	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Discussion	  
	  
We	  performed	  a	  rigorous	  systematic	  review	  of	  all	  published	  studies	  reporting	  ASPs	  on	  the	  pediatric	  
population	   in	  both	  outpatient	  and	   in-­‐hospital	   settings.	  Antimicrobial	   stewardship	   is	   a	   collection	  of	  
strategies	   (including	   policies,	   guidelines,	   surveillance,	   education,	   and	   evaluation)	   that	   collectively	  
result	  in	  optimization	  of	  antibiotic	  prescribing	  practices	  through	  defining	  principles	  for	  antimicrobial	  
empiric	   and	   targeted	   therapy	   and	   focusing	   on	   selection	   of	   appropriate	   antimicrobial	   agent,	   dose,	  
frequency	  and	  route	  of	  administration	  [32].	  
An	   ideal	   antimicrobial	   stewardship	   team	   should	   include	   infectious	   disease	   physicians,	   clinical	  
pharmacists,	   clinical	   microbiologists,	   infection	   control	   professionals,	   hospital	   epidemiologists,	   and	  
Information	   Technology	   specialists	   [32,35].	   In	   adult	   populations,	   ASP	   has	   been	   proven	   to	   reduce	  
inappropriate	   antimicrobial	   use	   and	   resistance,	   enhance	  patients’	   safety	   and	   lower	  drug	   costs.36,37	  
Nevertheless	  only	  82	  studies	  over	  the	  last	  10	  years	  were	  performed	  in	  paediatric	  settings	  and	  data	  
about	  the	  effect	  of	  ASPs	  in	  these	  settings	  are	  still	  limited.	  
Most	   of	   the	   studies	   we	   reviewed	   originated	   from	   the	   US	   while	   other	   ASPs	   experiences	   remain	  
sparse.	  	  
ASPs	   are	   mainly	   based	   on	   two	   core	   strategies:	   prospective	   audit	   and	   feedback,	   which	   involves	  
interaction	  and	  feedback	  between	  an	   infectious	  disease	  physician	  and	  the	  prescriber,	  or	   formulary	  
restriction	  and	  preauthorization	  requirements	  for	  specific	  agents	  [32,35].	  
These	  core	  strategies	  in	  conjunction	  with	  supportive	  tools	  (education,	  decision	  support	  services,	  and	  
treatment	  algorithms)	  ensure	  an	  efficient	  ASP.	  These	  strategies	  and	  supplemental	  components	  are	  
not	   mutually	   exclusive	   and	   varied	   combinations	   are	   possible,	   depending	   on	   the	   setting,	   local	  
resources,	  practices,	  and	  needs	  [33,38].	  	  
Most	   studies	   report	   a	   single-­‐centre	   intervention	   and	   despite	   the	   two	   core	   strategies	   strongly	  
recommended	  by	   the	  ASP	  guidelines,	   in	  our	   systematic	   review	  we	   found	  only	  26/81	   (31.7%)	  audit	  
and	  feedback,	  8/82	  pre-­‐authorization	  (9.8%)	  and	  4.9%	  both	  (4/82).	  
Not	   surprisingly,	   core	   interventions	  were	   usually	   implemented	   in	   the	   US	  with	   only	   two	   programs	  
implemented	  in	  Europe.	  
This	  could	  be	  due	  to	  the	  fact	  that	  guidelines	  published	  so	  far	   (IDSA/SHEA)	  [32,35]	  are	  designed	  for	  
the	  US	  healthcare	  system	  and	  easily	  adopted	  in	  this	  setting,	  while	  the	  diversity	  of	  healthcare	  systems	  
throughout	  Europe	  implies	  a	  wide	  range	  of	  approaches	  to	  the	  same	  problem.	  Second,	  across	  Europe	  
we	  found	  a	  high	  variability	  of	  funding	  opportunities	  and	  specialists	  (infectious	  diseases,	  pharmacist,	  
and	   microbiologist)	   with	   advance	   training	   in	   pediatrics,	   while	   resources	   in	   US	   are	   more	   easily	  
accessible	   [39].	  A	   recent	   survey	  of	  38	  children’s	  hospitals	   in	   the	  US	   revealed	   that	  16	  had	  a	   formal	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ASP,	  and	  15	  were	  planning	  to	  implement	  a	  program	  [40].	  To	  meet	  the	  needs	  of	  European	  countries	  
The	   European	   Society	   of	   Clinical	   Microbiology	   and	   Infectious	   Diseases	   (ESCMID)	   has	   formed	   the	  
ESCMID	   study	   group	   for	   antibiotic	   Policies	   (ESGAP)	   to	   promote	   the	   development	   of	   ASP	   through	  
available	  free	  tools	  (www.escmid.orh/esgap).	  
Moreover,	  facing	  the	  difficulties	  in	  building	  a	  solid	  system	  for	  monitoring	  antimicrobial	  consumption,	  
in	  2010	  the	  Antibiotic	  Resistance	  and	  Prescribing	  in	  European	  Children	  project	  was	  launched	  by	  the	  
European	   Society	   for	   Pediatric	   Infectious	   Diseases	   [41].	   This	   project	  monitoring	   antimicrobial	   use	  
and	   resistance	   in	   European	   children	   has	   proven	   to	   be	   a	   useful	   tool	   to	   assess	   the	   impact	   of	  
antimicrobial	  stewardship	  activities	  in	  different	  countries	  [4].	  
Despite	   the	   slow	   implementation	   of	   the	   ASPs	   core	   strategies,	   minor	   interventions	   based	   on	  
guidelines,	   clinical	   pathways	   along	   with	   educational	   programs	   have	   proven	   to	   be	   reasonable	   and	  
feasible	  first	  steps	  for	  implementation,	  especially	  in	  settings	  where	  resources	  are	  limited	  [42,43].	  A	  
Clinical	  pathway	  is	  a	  task-­‐oriented	  plan	  designed	  to	  support	  the	  implementation	  of	  clinical	  guidelines	  
and	   protocols.	   Their	   use	   can	   change	   antibiotic	   prescribing	   behavior	   in	   primary	   care	   and	   inpatient	  
settings	  without	  adversely	  affecting	  patient	  safety	  or	  outcomes	  [32,44,45].	  However,	  guidelines	  and	  
clinical	  pathways	  can	  affect	  only	  antibiotic	  prescriptions	  for	  the	  diseases	  they	  have	  been	  specifically	  
designed	  for.	  
Indeed,	   the	   combination	   of	   different	   ASP	   is	   always	   suggested.	   The	   use	   of	   biomarker	   (e.g.	  
procalcitonin)	  [46-­‐49]	  or	  rapid	  microbiological	  tests	  [50-­‐52]	  for	  targeting	  or	  shortening	  the	  duration	  
of	   antibiotic	   therapy	   has	   shown	   to	   be	   cost-­‐effective,	   and	   combined	   with	   the	   previous	   strategies	  
could	  enhance	  overall	  AS	  effectiveness.	  	  	  	  
Four	   studies	   in	   our	   review	   (4.9%)	   focused	   on	   perioperative	   prophylaxis.	   Three	   of	   these	   studies	  
showed	   an	   improvement	   of	   antimicrobial	   prescriptions	   after	   the	   implementation	   of	   perioperative	  
guidelines	  [53-­‐55];	  Putnam	  et	  al.	  reported	  no	  improvement	  despite	  multiple	  interventions	  [56].	  This	  
represents	   important	   space	   for	   improvement	   for	   ASP	   on	   both	   side	   of	   Atlantic.	   While	   trends	   in	  
surgical	  prophylaxis	  among	  adult	  patients	  are	  widely	  available,	  only	  a	  few	  studies	   include	  pediatric	  
data.	  This	  limits	  the	  conclusions	  that	  can	  be	  drawn	  about	  efficacy	  and	  safety	  of	  these	  ASP	  strategies.	  	  	  
To	   date,	   pediatric	   ASPs	   have	   primarily	   targeted	   the	   inpatient	   setting,	   and	   there	   is	   a	   paucity	   of	  
literature	   regarding	  antimicrobial	   stewardship	  strategies	   in	   the	  Emergency	  Department	   (ED)	   (6/82,	  
7.3%)	   despite	   the	   great	   number	   of	   children	   who	   receive	   antibiotics	   in	   this	   setting.	   Since	   ED	   are	  
uniquely	   positioned	   at	   the	   interface	   of	   inpatient	   and	   outpatient	   settings,	   ED	   physicians	   have	   the	  
opportunity	  to	  have	  a	  consistent	  impact	  on	  prescribing	  trends	  in	  both	  locations	  [57].	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Identification	   of	   potential	   barriers	   to	   successful	   intervention	   remains	   crucial.	   In	   the	   ED	   setting,	  
challenges	   are	   represented	  mainly	   by	   high	   turnover	   rates	   for	   both	   patients	   and	   practitioners	   and	  
rapid	  decision-­‐making,	  usually	  without	  microbiology	  support	  [58].	  
In	  order	  to	  build	  an	  ASP	  in	  the	  ED,	  at	  least	  one	  ED	  physician	  should	  be	  included	  in	  the	  antimicrobial	  
stewardship	   committee,	   improving	   engagement	   with	   other	   ED	   physicians	   and	   collaborating	   with	  
other	   physicians,	   infectious	   disease	   colleagues,	   pharmacists,	   microbiologists	   and	   epidemiologists	  
[59].	  
Only	  14.6%	  of	  ASPs	  in	  our	  review	  were	  implemented	  in	  outpatient	  settings.	  Despite	  the	  sparse	  data,	  
these	  interventions	  seem	  effective	  in	  reducing	  antimicrobial	  prescriptions.	  Most	  of	  the	  interventions	  
involve	   guidelines	   and	   the	   use	   of	   computerized	   decision	   support	   tools.	   Interestingly,	   two	   studies	  
included	   parents	   in	   education	   activities,	   underling	   how	   they	   could	   be	   a	   key	   component	   of	   a	  
successful	  ASP.	  Also	  in	  this	  case	  only	  one	  intervention	  originated	  from	  a	  European	  country	  [60-­‐71].	  
Clearly,	   the	   possibility	   of	   accessing	  data	   from	   the	   daily	   activities	   of	   pediatric	   general	   practitioners	  
and	   family	   pediatricians	   is	   a	   unique	   resource,	   both	   for	   studying	   individual	   diseases,	   as	   well	   the	  
interactions	  between	  different	  areas	  of	  health	  care	  and	  population	  health.	  However,	  the	  creation	  of	  
a	   network	   is	  more	  difficult	   in	   outpatient	   settings	   than	   in-­‐hospital	   for	   lack	  of	   technical	   and	  human	  
resources	  and	  the	  fragmentation	  of	  the	  primary	  care	  healthcare.	  	  
Pedianet	  is	  an	  example	  of	  an	  efficient	  pediatric	  outpatient	  network	  which	  collects	  specific	  data	  from	  
computerised	   clinical	   files	   filled	  out	  by	  pediatricians	  during	   their	   daily	  professional	   activities.	  With	  
more	  than	  300	  Italian	  pediatricians	  enrolled	  throughout	  the	  country,	  this	  network	  has	  been	  proven	  
to	  be	  able	  to	  carry	  out	  epidemiological	  studies	  on	  major	  pediatric	  diseases	  or	  pharmacovigilance	  and	  
would	  be	  a	  valuable	  resource	  for	  a	  pediatric	  outpatient	  AS	  network	  [72].	  
The	  IDSA	  guidelines	  recommend	  that	  ASPs	  should	  improve	  antimicrobial	  use	  leading	  a	  reductions	  in	  
antimicrobial	   resistance,	   adverse	   drug	   events,	   cost,	   and	   rate	   of	   C.	   difficile	   infections.	   The	   most	  
commonly	   reported	  outcome	   in	   the	  papers	   included	   in	   this	   study	  was	   the	   change	   in	  antimicrobial	  
prescription	  with	  less	  emphasis	  on	  cost,	  safety	  and	  resistance	  [32].	  
Measurement	  of	   this	  outcome	   in	  children	   is	  more	  complex	   than	  adults.	  Dosages	  vary	  according	   to	  
weight	   or	   body	   surface,	   making	   defined	   daily	   dose	   not	   applicable.	   To	   overcome	   this	   issue,	   some	  
authors	  propose	  to	  measure	  the	  duration	  of	  therapy	  by	  days	  of	  therapy	  (DOT)	  and	  length	  of	  therapy	  
(LOT).	  A	  single	  DOT	  is	  calculated	  for	  each	  antimicrobial	  administered	  to	  an	  individual	  subject	  within	  a	  
24	  hour	  time	  period	  regardless	  of	  dose	  and	  frequency	  [73,74].	  LOT	  is	  counted	  for	  each	  day	  a	  subject	  
receives	  any	  systemic	  antimicrobial	  therapy,	  regardless	  of	  the	  number	  of	  agents,	  dose,	  or	  frequency	  
of	  administration.	   	   LOT	  provides	  a	  more	  accurate	  measure	  of	   the	  duration	  of	   therapy	  and	   is	  often	  
coupled	  with	  DOT	  [74].	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Despite	   using	   different	  metrics,	   all	   the	   studies	  we	   reviewed	   evaluating	   antimicrobial	   consumption	  
showed	  a	   significant	   reduction	   [46-­‐49,51-­‐55,59-­‐71,76-­‐118].	  For	   the	   first	   time,	  one	   study	  described	  
an	   ASP	   in	   a	   Paediatric	   HIV	   Clinic.	   This	   program	   through	   a	   comprehensive	   assessment	   tool	   for	  
regimen	  simplification	  showed	  to	  be	  an	  effective	  strategy	  to	  improve	  clinical	  outcomes	  in	  pediatric	  
HIV	  infected	  patients	  [67].	  Only	  two	  studies	  included	  in	  this	  systematic	  review	  report	  a	  decrease	  in	  
use	  of	  antifungals	  as	  part	  of	  an	  antimicrobial	  stewardship	  program.	   	  The	  first	   from	  the	  US	  showed	  
the	   reduction	   in	   use	   of	   caspofungin	   after	   the	   implementation	   of	   audit	   and	   feedback	   strategy	   for	  
selected	   antimicrobials	   [106].	   The	   second	   form	   Japan	   reported	   a	   reduction	   of	   liposomal	  
amphotericin	   B	   and	   fosfluconazole	   prescriptions	   of	   85%	   and	   44%	   respectively	   after	   the	  
implementation	  of	  an	  ASP	  based	  on	  the	  combination	  of	  the	  two	  core	  strategies	  [92].	  No	  antiviral	  or	  
antifungal	  stewardship	  experience	  has	  been	  reported	  so	  far	  in	  European	  pediatric	  patients.	  
Twelve	   papers	   (14.6%)	   reported	   prescribing	   physician	   compliance	   as	   an	   outcome	  
[56,70,76,87,99,119-­‐125].	  
Compliance	   after	   ASP	   implementation	  was	   high,	   showing	   that	   ASP	   intervention	   are	   generally	  well	  
tolerated	  despite	  theoretical	  concerns	  about	  prescriber	  opposition	  [126].	  Moreover,	  as	  suggested	  by	  
some	  authors,	  a	  successful	  AS	  strategy	  should	  include	  prescribers	  from	  the	  setting	  where	  the	  ASP	  is	  
going	   to	   be	   implemented	   [127].	   This	   can	   improve	   the	   acceptance	   rate,	   helping	   determine	   which	  
metrics	  are	  meaningful	  to	  their	  colleagues	  and	  which	  interventions	  are	  preferred.	  At	  the	  same	  time,	  
physicians	  may	  be	  more	  receptive	  to	  implementing	  changes	  in	  their	  practice	  if	  they	  are	  suggested	  by	  
a	  colleague	  rather	  than	  other	  physicians	  external	  to	  the	  ward.	  
Ten	   of	   the	   included	   studies	   (12.2%)	   quantified	   cost	   savings	   related	   to	   the	   intervention	  
[79,88,91,93,96,110,112,116,128,129].	   Decrease	   in	   cost	   was	   most	   often	   due	   to	   lower	   drug	  
administration	   rates.	   	   However,	   the	   cost	   saving	   of	   ASPs	   should	   also	   include	   the	   reduction	   due	   to	  
intravenous	   to	   oral	   shift,	   the	   reduction	   in	   length	   of	   hospital	   stay	   and	   in	   rate	   of	   infections	   due	   to	  
multidrug	   resistant	   bacteria.	   Indeed,	   the	   total	   cost	   of	   hospital	   care	   rather	   than	   antimicrobial	   cost	  
saving	  alone	  would	  be	  the	  best	  metric	  for	  antimicrobial	  stewardship	  [130].	  	  
For	   this	   reason,	   formal	   economic	   studies	   are	   also	   needed	   in	   paediatrics	   to	   show	   how	   ASP	  
implementation	  impacts	  all	  cost,	  not	  just	  costs	  of	  antibiotics.	  	  	  	  
None	  of	   the	  papers	   included	   in	   this	   systematic	   review	  analysed	   the	   cost	  of	  ASP	  development	   and	  
implementation.	   As	   detailed	   above,	   despite	   the	   fact	   that	   the	   costs	   of	   implementation	   would	   be	  
covered	   after	   few	  months	   of	   stewardship	   activities,	   set-­‐up	   cost	   is	   still	   a	   limit	   for	   countries	  which	  
suffer	  of	  lack	  from	  funding	  in	  this	  area.	  
Eight	  papers	  included	  in	  this	  review	  (9.8%)	  take	  into	  consideration	  change	  in	  antimicrobial	  resistance	  
as	  an	  outcome	   [76,91,92,96,98,102,117,118].	   In	   three	   cases,	  no	   changes	  were	   reported,	  while	   the	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other	  five	  studies	  showed	  an	  increased	  susceptibility	  of	  the	  bacteria	  analysed.	  This	  outcome	  is	   less	  
consistently	   reported	   in	   the	   paediatric	   population.	   	   No	   study	   assessed	   the	   rate	   of	   C.	   difficile	  
infections	  after	  the	  implementation	  of	  a	  paediatric	  ASP.	  In	  this	  case,	  a	  fundamental	  supportive	  role	  
could	   be	   played	   by	   the	   infection	   prevention	   and	   control	   team.	   It	   can	   assist	   the	   AS	   team	   in	   the	  
evaluation	  of	  the	  outcomes	  of	  their	  strategies	  by	  monitoring	  all	  healthcare	  associated	  infections	  and	  
trends	  of	  multi-­‐drug	  resistant	  organisms	  and	  by	  providing	  advice	  to	  manage	  eventual	  outbreaks	  [32].	  
This	   systematic	   review	   has	   strengths	   and	   limitations.	   This	   is	   the	   first	   review	   that	   evaluates	   the	  
effectiveness	  of	  ASPs	  in	  all	  different	  pediatric	  settings.	  Furthermore,	  since	  no	  MeSH	  term	  is	  provided	  
for	  antimicrobial	  stewardship,	  a	  wide	  search	  term	  strategy	  was	  used	  to	  be	  sure	  to	  retrieve	  all	  studies	  
with	  an	  intervention	  on	  antimicrobial	  use	  even	  if	  not	  explicitly	  defined	  as	  antimicrobial	  stewardship.	  	  
The	  primary	  limitation	  of	  our	  study	  is	  that	  only	  two	  databases	  were	  searched	  and	  we	  may	  not	  have	  
identified	   all	   paediatric	   stewardship	   studies.	   Secondly,	   we	   were	   limited	   to	   the	   available	   search	  
indices	  and	  methods;	  unpublished,	  unreported	  data	  and	  case	  reports	  were	  not	  included.	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CONCLUSIONS	  
	  
This	   systematic	   review	   describes	   the	   impact	   of	   paediatric	   ASPs	   worldwide.	   Mirroring	   what	   has	  
previously	  been	  reported	  for	  adults,	  paediatric	  ASPs	  can	  reduce	  antimicrobial	  utilization,	  increasing	  
cost	   savings	   and	   having	   a	   positive	   effect	   on	   antimicrobial	   resistance.	   Despite	   these	   outstanding	  
results,	  paediatric	  ASPs	  are	  spreading	  rapidly	  in	  the	  US,	  while	  their	  implementation	  in	  Europe	  is	  still	  
challenging.	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   AND	   ("Anti-­‐Bacterial	   Agents"[Mesh]	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"Anti-­‐Bacterial	   Agents"	   [Pharmacological	   Action]	   OR	   "Antifungal	   Agents"[Mesh]	   OR	   "Antifungal	  
Agents"	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  anti-­‐bacterial*	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  antibacterial*	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   treatment*	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   therap*	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   OR	   perioperative*	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   stewardship	   NOT	  
case	   reports[pt])	   NOT	   ("HIV	   Infections"[Mesh]	   OR	   HIV[Mesh]	   OR	   HIV[ti]	   OR	   human	  
immunodeficiency	  virus[ti]))	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Abstract	  
Antimicrobial	  prescriptions	  in	  neonatal	  intensive	  care	  units	  (NICUs)	  represent	  a	  point	  of	  concern	  for	  
the	   emergence	   of	  MDROs	   and	   for	   morbidity	   associated	   with	   prolonged	   antibiotic	   exposure	   (e.g.,	  
invasive	   candidiasis,	   necrotizing	   enterocolitis,	   and	   late-­‐onset	   sepsis).	   Antimicrobial	   stewardship	  
programs	  (ASPs)	  have	  shown	  to	  be	  a	  valuable	  tool	  for	  the	  prevention	  of	  resistance	  with	  the	  goals	  of	  
optimizing	   clinical	   outcomes	   while	   decreasing	   unnecessary	   prescribing.	   The	   most	   frequent	   ASP	  
strategies	   include	   the	   correct	   collection	   and	   interpretation	   of	   microbiological	   specimens,	  
prescription	   of	   the	   narrowest-­‐spectrum	   antibiotic	   appropriate	   for	   a	   particular	   case,	   and	   de-­‐
escalation	   or	   discontinuation	   of	   therapy	   in	   defined	   situations.	   A	   robust	   ASP	   requires	   everyday	  
multidisciplinary	   collaboration	   between	   ID	   physicians,	   neonatologist,	   clinical	   pharmacists,	   clinical	  
microbiologists,	   infection	   control	   professionals,	   hospital	   epidemiologists,	   and	   information	   services	  
specialists.	   Education	   and	   clinical	   pathways	   (e.g.,	   sepsis	   or	   surgical	   prophylaxis	   pathways)	   are	   an	  
excellent	   starting	   point	   if	   followed	   by	   proactive	   interventions	   such	   as	   prospective	   audits	   and	  
feedback	   and	   formulary	   restriction	   with	   prior	   antimicrobial	   authorization.	   The	   current	   review	  
outlines	   the	  problems	   faced	   in	  NICU	  antimicrobial	  prescribing	  and	  presents	  various	   solutions	   from	  
the	  literature.	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Antimicrobials	   are	   the	  most	   commonly	   prescribed	   drugs	   in	   both	   the	   community	   and	   in	   hospitals,	  
especially	   among	   neonates	   [1].	   Grohskopf	   et	   al,	   with	   a	   2-­‐day	   point	   prevalence	   survey	   of	  
antimicrobial	   consumption	   in	   29	   U.S.	   NICUs,	   showed	   that	   43.3%	   of	   infants	   received	   at	   least	   one	  
antibiotic.[2]	  Hshieh	  et	   al	   performed	  a	   retrospective	   review	   (2005–2010)	   to	  provide	  an	  update	  on	  
medication	  use	   in	   infants	  admitted	   to	   the	  neonatal	   intensive	  care	  unit	   (NICU)	   in	   the	  United	  States	  
and	  found	  that	  antimicrobials	  were	  predominant	  [3].	  	  
Even	  more	  evidence	  suggests	  that	  major	  neonatal	  causes	  of	  morbidity	  such	  as	  invasive	  candidiasis,	  
necrotizing	  enterocolitis	  (NEC),	  and	  late-­‐onset	  sepsis	  (LOS)	  in	  infants	  admitted	  to	  the	  NICU	  could	  be	  
associated	  to	  an	  altered	  neonatal	  microbiome	  pattern	  due	  to	  a	  prolonged	  antibiotic	  exposure,	  which	  
is	  often	  unnecessary	  [4	  -­‐8].	  	  
It	  is	  known	  that	  although	  antimicrobial	  resistance	  occurs	  naturally	  or	  can	  be	  acquired	  through	  gene	  
transferring,	   prolonged	   antimicrobial	   use	   promotes	   the	   selection	   of	  multidrug-­‐resistant	   organisms	  
(MDROs).	   The	   emergence	   of	   such	   pathogens	   and	   their	   rapid	   global	   spread	   have	   transformed	  
resistance	  from	  a	  challenge	  to	  an	  effective	  prescription	  to	  an	  important	  global	  public	  health	  threat	  
with	  a	  substantial	  impact	  on	  patient	  outcomes	  such	  as	  length	  of	  hospital	  stay	  and	  mortality,	  as	  well	  
as	   on	   health	   care	   costs	   [9-­‐12].	   Furthermore,	   infants	   colonized	   or	   infected	  with	  MRDOs	   can	   cause	  
poor	  outcome	  also	  in	  previously	  well	  infants	  through	  the	  horizontal	  transmission	  of	  those	  pathogens	  
[13,14].	  	  
In	   the	   past,	   antimicrobial	   resistance	   has	   been	   overcome	   with	   the	   introduction	   of	   new,	   broad-­‐
spectrum	   agents,	   but	   this	   option	   is	   no	   longer	   viable	   given	   the	   difficulties	   in	   developing	   new	  
molecules	  [15].	  Indeed,	  the	  cost	  of	  pharmaceutical	  research	  (estimated	  to	  be	  $400–800	  million	  per	  
approved	   agent)	   represents	   the	   first	   barrier.[16]	   The	   aging	   of	   the	   population,	   resulting	   in	   a	   shift	  
toward	   agents	   for	   the	   treatment	   of	   chronic	   medical	   conditions,	   and	   the	   large	   number	   of	  
antimicrobials	   already	   approved	   make	   the	   development	   of	   new	   antimicrobials	   even	   less	  
economically	  attractive	  [17,18].	  	  
Furthermore,	   few	   pharmacokinetic	   (PK)	   and	   clinical	   studies	   on	   efficacy	   of	   antibiotics	   have	   been	  
performed	   in	   infants	   [19,20]	   although	   adverse	   drug	   events	   and	   excessive	   costs	   of	   treatment	   are	  
major	   reasons	   of	   concern[21,22]	   in	   the	   first	   months	   of	   life.	   In	   a	   review	   including	   eight	   studies	  
conducted	  in	  European	  and	  Australian	  neonatal	  wards,	  Lindell-­‐Osuagwu	  et	  al	  showed	  that	  80	  to	  93%	  
of	  prescriptions	  were	  for	  off-­‐label	  or	  unlicensed	  antimicrobials	  [23].	  	  
Therefore,	   the	   European	   Union	   had	   funded	   several	   projects	   to	   define	   PK	   of	   antibiotics	   and	  
determine	   dosing	   recommendations	   in	   children	   and	   infants,	   especially	   for	   critically	   important	  
antibiotics	   as	   vancomycin	   and	  meropenem.	   The	   first	   project,	   called	   NeoMero-­‐1,	   is	   an	   open-­‐label,	  
randomized	   controlled	   superiority	   trial	   to	   compare	   the	   efficacy	   of	  meropenem	  with	   a	   predefined	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standard	   of	   care	   (SOC)	   for	   the	   treatment	   of	   LOS	   in	   infants	   and	   infants	   aged < 90	   days	   (inclusive)	  
admitted	  to	  an	  NICU.[24]	  The	  second	  study,	  NeoVanc,	  is	  a	  multicenter	  randomized	  open-­‐label	  phase	  
IIb	   study	   to	   evaluate	   an	   optimized	   dosing	   regimen	   for	   vancomycin	   in	   infants	   aged < 3	   months	  
affected	  by	  late-­‐onset	  bacterial	  sepsis	  [25].	  	  
For	  all	  the	  aforementioned	  reasons,	  during	  the	  MDROs-­‐era	  the	  key	  point	  for	  limiting	  the	  emergence	  
of	  resistance	  of	  antibiotics	  and	  minimizing	  adverse	  events	  in	  the	  NICU	  setting	  is	  represented	  by	  the	  
judicious	  use	  of	  antimicrobials	  among	  neonates.	  
Antimicrobial	  stewardship	  (AS)	  was	  formally	  introduced	  in	  2007	  and,	  if	  used,	  properly	  has	  shown	  to	  
be	   a	   valuable	   tool	   for	   the	   prevention	   of	   resistance	  with	   the	   goals	   of	   optimizing	   clinical	   outcomes	  
while	   decreasing	   unnecessary	   prescribing.	   AS	   practices	   define	   principles	   for	   antimicrobial	   empiric	  
therapy,	   targeted	   therapy,	   and	   prophylaxis,	   focusing	   on	   antimicrobial	   agent	   selection,	   dose,	  
frequency,	  and	  route	  of	  administration	  [26].	  	  
A	  well-­‐established	  AS	  program	  usually	  is	  built	  on	  proactive	  interventions	  such	  as	  prospective	  audits	  
and	   feedback	   to	   prescribers	   and	   formulary	   restriction	  with	   prior	   antimicrobial	   authorization.	   Each	  
has	   been	   shown	   to	   decrease	   unnecessary	   antimicrobial	   exposure,	   reduce	   costs,	   and	   improved	  
patient	  outcomes	  [26].	  	  
An	  NICU	  AS	  ideal	  team	  should	  involve	  infectious	  disease	  (ID)	  physicians,	  neonatologist,	  nurse,	  clinical	  
pharmacists,	   clinical	   microbiologists,	   infection	   control	   professionals,	   hospital	   epidemiologists,	   and	  
information	  services	  specialists	  tracking	  antimicrobial	  resistance	  patterns	  and	  identifying	  nosocomial	  
infections	  and	  outbreaks[26-­‐28]	  (Fig.	  1).	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Figure	  1.	  Antimicrobial	  stewardship	  strategies	   in	  the	  NICU.	  ID,	   infectious	  disease;	  NICU,	  neonatal	   intensive	  
care	  unit.	  
In	  resource-­‐limited	  settings	  where	  a	  robust	  AS	  team	  is	  hard	  to	  establish,	  clinical	  pathways	  represent	  
a	  reasonable	  and	  feasible	  first	  step	  for	  AS	  implementation	  (Fig.	  1).	  Clinical	  pathways	  are	  an	  effective	  
means	   to	   change	   antibiotic	   prescribing	   behavior,	   standardizing	   care	   without	   adversely	   affecting	  
patient	  safety	  [29-­‐32].	  	  
Clinical	  pathways	  must	  be	  developed	  by	  a	  multidisciplinary	  team	  to	  guarantee	  the	  best	  quality	  and	  a	  
high	  level	  of	  coordination	  of	  interventions.	  For	  instance,	  an	  infectious	  disease	  specialist	  could	  act	  in	  
concert	   with	   a	   clinical	   pharmacist	   and	   a	   microbiologist	   to	   create	   specific	   clinical	   pathways,	   and,	  
especially	   for	   NICUs,	   a	   neonatologist	   can	   play	   a	   key	   role	   in	   helping	   and	   monitoring	   their	  
implementation.	   As	   suggested	   by	   Cantey	   and	   Patel,	   a	   neonatologist	   on	   the	   AS	   team	   can	   help	  
determine	  which	  metrics	  are	  meaningful	  to	  their	  colleagues	  and	  which	  interventions	  are	  preferred.	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At	  the	  same	  time,	  neonatologists	  may	  be	  more	  receptive	  to	  implementing	  changes	  in	  their	  practice	  if	  
they	  are	  suggested	  by	  a	  colleague	  rather	  than	  other	  physicians	  external	  to	  the	  ward	  [33]	  ([Fig.	  1]).	  
	  
Challenges	  in	  Diagnosis	  
The	  major	  challenge	   in	  prescribing	  antibiotics	   in	  NICUs	   is	   that	  signs	  and	  symptoms	  of	   infection	  are	  
not	  specific	  in	  the	  neonatal	  population.	  Indeed,	  septic	  infants	  can	  present	  with	  clinical	  findings	  that	  
extensively	  overlap	  with	  noninfectious	  conditions	  such	  as	  apnea	  of	  prematurity,	  respiratory	  distress,	  
hypotension,	   or	   temperature	   instability	   [34].	   On	   the	   other	   hand,	   bacteremia	   could	   occur	   in	   the	  
absence	  of	   clinical	   signs	   [35].	   In	  a	   recent	  meta-­‐analysis,	  Verstraete	  et	  al	   showed	   that	  even	   if	   signs	  
such	   as	   lethargy	   and	   pallor	   and/or	   mottling	   for	   infants	   and	   apnea	   and/or	   bradycardia	   and	   poor	  
peripheral	   perfusion	   for	   very	   low-­‐birth-­‐weight	   infants	   are	   the	   most	   powerful	   clinical	   signs	   for	  
predicting	  sepsis,	  no	  prediction	  models	  should	  be	  considered	  as	  an	  absolute	   indicator	  due	  to	  their	  
limited	  diagnostic	  accuracy	  [36].	  	  
Despite	   a	   wide	   variety	   of	   acute-­‐phase	   reactants	   having	   been	   evaluated	   in	   infants	   with	   suspected	  
sepsis	   and	   some	   of	   them	   have	   showed	   promising	   results	   (e.g.,	   interleukin	   8,	   urinary	   neutrophil	  
gelatinase-­‐associated	   lipocalin),[37,38]	  C-­‐reactive	  protein	  (CRP)	  and	  procalcitonin	  (PCT)	  still	  are	  the	  
most	  used	  inflammatory	  markers.	  
In	  the	  healthy	  adult,	  after	  an	  infectious	  episode,	  PCT	  increases	  within	  2	  hours,	  peaks	  at	  12	  hours,	  and	  
normalizes	  within	  2	  to	  3	  days	  [39-­‐41].	  PCT	  does	  not	  pass	  through	  the	  placenta,	  and	  in	  the	  neonatal	  
period	   its	   production	   depends	   on	   intestinal	   bacterial	   colonization.	   Therefore,	   PCT	   physiologic	  
increase	  in	  the	  first	  24	  hours	  of	  life	  can	  give	  false-­‐positive	  results	  in	  case	  of	  noninfectious	  conditions	  
(e.g.,	   neonatal	   respiratory	   distress	   syndrome,	   pneumothorax).	   Some	   authors	   pointed	   out	   the	  
difficulty	  of	  interpreting	  this	  marker	  during	  the	  first	  48	  to	  72	  hour	  of	  life,	  which	  is	  the	  same	  period	  in	  
which	  early-­‐onset	  sepsis	  (EOS)	  diagnosis	  should	  be	  made	  [42,43].	  Chiesa	  et	  al	  found	  that	  PCT	  shows	  
79%	   of	   sensitivity	   and	   95%	   of	   specificity	   for	   neonatal	   EOS,	   but	   in	   the	   same	   publication	   authors	  
identified	  age-­‐dependent	  variations	  of	  CRP	  and	  PCT,	  thus	  making	  it	  difficult	  to	  establish	  any	  specific	  
threshold.[42]	   A	   study	   regarding	   2,151	   newborns	   suspected	   of	   having	   EOS	   showed	   that	   umbilical	  
cord	   PCT	   value,	   reflecting	   the	   antenatal	   infectious	   process,	   allows	   to	   distinguish	   infected	   infants	  
from	  healthy	  ones	  with	  a	  cutoff	  value	  of	  0.6	  ng/mL.[44]	  The	  same	  authors	  also	  demonstrated	  that	  
umbilical	  cord	  PCT	  at	  6	  hours	  of	  life	  had	  a	  specificity	  of	  98.5%	  and	  a	  predictive	  negative	  value	  of	  99%	  
[45].	  	  
On	   the	  other	  hand,	  CRP	  concentration	   increases	  within	  6	   to	  8	  hours	   from	  an	   infectious	  episode	   in	  
infants	  and	  peaks	  at	  24	  hours	  [46];	  thus	  CRP	  sensitivity	  increases	  if	  its	  determination	  is	  made	  6	  to	  12	  
hours	  after	  birth.	  Benitz	  et	   al	   have	  demonstrated	   that	  excluding	  a	   value	  at	  birth,	   two	  normal	  CRP	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determinations	   (8–24	  hours	   after	  birth	   and	  24	  hours	   later)	   have	  a	  negative	  predictive	   accuracy	  of	  
99.7%	  and	  a	  negative	  likelihood	  ratio	  of	  0.15	  for	  proven	  neonatal	  sepsis	  [47].	  	  
In	  a	  recent	  commentary,	  Benitz	  et	  al	  argue	  how	  currently	  available	  laboratory	  tests	  (e.g.,	  blood	  cell	  
counts,	  CRP,	  and	  PCT)	  are	  not	  sufficiently	  sensitive	  or	  specific	  to	  justify	  their	  use	  to	  decide	  whether	  
to	   initiate	  or	  withhold	  empiric	  treatment	  of	  babies	  with	  clinical	  signs	  of	   illness;	   laboratory	  markers	  
are	  more	  useful	  to	  support	  early	  discontinuation	  of	  empiric	  treatment	  in	  presence	  of	  a	  normal	  result	  
for	  identification	  of	  infants	  without	  sepsis	  [48].	  	  
Some	  authors	  posit	  that	  vital	  signs	  can	  be	  helpful	  to	  assist	  in	  the	  early	  diagnosis	  of	  sepsis.	  Moorman	  
et	   al	   observed	   abnormal	   heart	   rate	   characteristics	   (HRC),	   reduced	   variability,	   and	   transient	  
decelerations	   in	   the	   hours	   to	   days	   prior	   to	   the	   clinical	   appearance	   of	   illness,	   and	   found	   that	  
measurements	  of	  standard	  deviation,	  sample	  asymmetry,	  and	  sample	  entropy	  are	  highly	  related	  to	  
imminent	  clinical	  illness	  [49].	  	  
Puopolo	  and	  Escobar	  developed	  a	  predictive	  model	  of	  sepsis	  risk	  among	  infants	  born	  at ≥ 34	  weeks'	  
gestation	  based	  on	  information	  available	  in	  the	  immediate	  perinatal	  period	  (maternal	  fever,	  use	  of	  
epidural	   analgesia,	   prolonged	   premature	   rupture	   of	   membranes	   [ROM],	   intrapartum	   use	   of	  
antibiotics).	  Use	  of	  this	  model	  can	  establish	  a	  prior	  probability	  of	  infection	  at	  the	  time	  of	  birth,	  which	  
can	  aid	   the	   clinician	   in	   subsequent	  decisions	   regarding	  neonatal	  management	  and	   safely	  decrease	  
the	  number	  of	  infants	  evaluated	  for	  infection	  [50].	  	  
According	   to	   the	   aforementioned	   findings,	   in	   2010	   an	   expert	  meeting	   organized	   by	   the	   European	  
Medicines	  Agency	   (EMA)	  defined	   the	  diagnostic	   criteria	  of	   LOS	   for	   infants.[51]	   These	   criteria	  have	  
been	   formulated	   in	   an	   effort	   to	   address	   several	   issues	   regarding	   clinical	   trials	   in	   the	   neonatal	  
population	  with	  sepsis	  and	  have	  been	  tested	  in	  a	  clinical	  setting	  by	  Lutsar	  et	  al,[24]	  with	  a	  predictive	  
value	  of	  61%	  to	  identify	  patients	  with	  culture-­‐proven	  LOS.	  
According	   to	   the	   experts'	   panel,	   clinical	   sepsis	   was	   defined	   for	   infants	   up	   to	   44	   weeks	   of	  
postmenstrual	   age	   by	   the	   combination	   of	   at	   least	   two	   clinical	   symptoms	   (e.g.,	   modified	   body	  
temperature,	   cardiovascular	   instability,	   respiratory	   instability)	   and	   at	   least	   two	   laboratory	   signs	  
(white	  blood	  cell	  count,	  CRP,	  or	  PCT).	  
The	  diagnosis	  becomes	  even	  more	  challenging	  when	  the	  blood	  cultures	  are	  negative,	  but	  a	  neonate	  
shows	   clinical	   signs	   or	   laboratory	   values	   compatible	  with	   sepsis.	   This	   situation	   can	   represent	   two	  
opposites:	  the	  cultures	  drawn	  are	  negative	  because	  the	  neonate	  does	  not	  have	  an	  infection	  or	  the	  
cultures	  drawn	  are	  negative	  because	  they	  have	  not	  been	  appropriately	  collected.	  
As	   such,	   standardized	   best	   practices	   for	   blood	   culture	   collection	   are	   a	   useful	   AS	   tool.	   Optimizing	  
blood	   cultures	   can	   improve	   use	   of	   antibiotics,	   because	   the	   detection	   of	   an	   organism	   can	   allow	  
targeted	  antibiotic	  therapy	  [52].	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The	  American	  Academy	  of	  Pediatrics'	  guidelines	  on	  the	  management	  of	  infants	  with	  suspected	  sepsis	  
recommend	  obtaining	  a	  minimum	  of	  1	  mL	  of	  blood	  for	  culture	  when	  sepsis	  is	  suspected	  [39].	  	  
Although	  0.5	  mL	  has	  previously	  been	  considered	  acceptable,	  Schelonka	  et	  al	  demonstrated	  that	  0.5	  
mL	   would	   not	   reliably	   detect	   low-­‐level	   bacteremia	   (≤ 4	   colony-­‐forming	   units	   [CFU]/mL).[53]	  
Furthermore,	  audits	  of	  NICU	  blood	  cultures	  showed	  that	  the	  median	  volumes	  are	  often	  too	  low	  [53,	  
54].	  	  
Challenges	  in	  Treatment	  
The	   problems	   related	   to	   determining	   the	   best	   antimicrobial	   therapy	   involve	   therapeutic	   agent	  
selection,	  dosing,	  and	  duration	  of	  therapeutic	  treatment.	  
Despite	  advances	  in	  neonatal	  care,	  neonatal	  sepsis	  remains	  a	  major	  cause	  of	  mortality	  and	  morbidity	  
in	  NICU	  [55].	  This	   leads	  to	  the	  tendency	  to	  administer	  empiric	  therapy	  even	  when	  sepsis	  signs	  and	  
symptoms	   are	   minimal.	   Because	   cultures	   often	   turn	   back	   positive	   after > 48	   hours,	   immediate	  
empiric	   treatment	   when	   appropriate	   is	   imperative;	   this	   represents	   a	   key	   point	   for	   AS	   policy	  
implementation.[48]	   ID	   specialists	   and	   microbiologists	   should	   define	   the	   best	   empiric	   antibiotic	  
therapy	   for	   each	   case	   based	   on	   guidelines	   and	   unit-­‐specific	   resistance	   data	   from	   cumulative	  
antibiograms	  and	  outbreak	   surveys,	   especially	   as	  outbreaks	  of	  methicillin-­‐resistant	   Staphylococcus	  
aureus	   (MRSA),	   ampicillin-­‐resistant	   Escherichia	   coli,	   vancomycin-­‐resistant	   enterococci,	   and	  
multidrug-­‐resistant	  gram-­‐negative	  bacteria	  are	  increasingly	  reported	  from	  NICUs	  [56,57].	  	  
In	  a	  2-­‐year	  surveillance	  study	  conducted	   in	   the	  United	  States, > 90%	  of	  all	  blood	   isolates	   in	   infants	  
admitted	  to	  NICU	  were	  susceptible	  to	  the	  combination	  therapy	  of	  ampicillin	  and	  aminoglycoside.[58]	  
In	   one	   review	   from	   a	   single	   center	   [59],	   90%	   of	   EOS	   were	   susceptible	   to	   the	   aforementioned	  
combination	  therapy.	  Unfortunately,	  European	  data	  on	  antimicrobial	  resistance	  in	  NICU	  are	  missing.	  
Data	  from	  the	  UK	  Health	  Protection	  Agency's	  national	  bacteremia	  survey	  in	  2010	  demonstrated	  that,	  
in	   England	   and	   Wales,	   EOS	   organisms	   were	   susceptible	   in	   94%	   of	   cases	   to	   the	   combination	   of	  
penicillin	   plus	   gentamicin,	   100%	   of	   cases	   to	   amoxicillin	   plus	   cefotaxime,	   and	   96%	   of	   cases	   to	  
monotherapy	   with	   cefotaxime.[58]	   To	   the	   best	   of	   our	   knowledge,	   combination	   of	   ampicillin	   and	  
aminoglycoside	  still	  represents	  the	  first-­‐line	  treatment	  for	  EOS	  [39],	  guaranteeing	  the	  best	  coverage	  
for	   group	   B	   Streptococcus	   (GBS),	   E.	   coli,	   and	   Listeria	   monocytogenes.	   Third-­‐generation	  
cephalosporins	  (e.g.,	  cefotaxime)	  could	  represent	  the	  best	  choice	  for	  proven	  MDROs	  and	  in	  case	  of	  
suspected	  or	  proven	  meningitis	  because	  of	  its	  excellent	  CSF	  penetration	  [60].	  However,	  its	  routinely	  
use	   is	   not	   recommended	   because	   of	   the	   risk	   of	   rapid	   development	   of	   resistance	   [61]	   and	   the	  
increased	  rates	  of	  invasive	  candidiasis,	  especially	  in	  low-­‐birth-­‐weight	  infants	  [62].	  Ceftriaxone	  is	  not	  
indicated	  in	  infants	  because	  it	  strongly	  binds	  to	  albumin	  and	  could	  displace	  bilirubin	  leading	  to	  a	  risk	  
of	  kernicterus	  [39].	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Whereas	  EOS	  is	  considered	  to	  be	  acquired	  at	  delivery,	  LOS	  is	  secondary	  to	  a	  postnatal	  exposure	  to	  
organisms	  associated	  with	  nosocomial	  infections	  [63,64].	  	  
According	   to	   literature,	   all	   LOS	   organisms,	  with	   the	   exclusion	   of	   coagulase-­‐negative	   staphylococci	  
(CoNS),	  were	  still	  sensitive	  to	  semisynthetic	  penicillin	  combined	  with	  aminoglycoside,	  ampicillin,	  or	  
third-­‐generation	  cephalosporin	  [58,65].	  	  
A	   further	   prospective	   observational	   study	   conducted	   in	   18	   NICUs	   in	   five	   European	   countries	  
reported	  that	  90%	  of	  Enterobacteriaceae	  collected	  during	  LOS	  were	  susceptible	  to	  meropenem	  and	  
about	  two-­‐thirds	  to	  amikacin,	  ciprofloxacin,	  and	  cefotaxime	  plus	  gentamicin.[66]	  Approximately	  95%	  
of	  Enterobacteriaceae	  were	  resistant	  to	  ampicillin	  (median	  minimum	  inhibitory	  concentration	  [MIC]	  
value	  of	  32	  g/mL),	  and	  MIC	  values	  for	  cefotaxime	  and	  gentamicin	  were	  relatively	  low	  (MIC	  1	  and	  2	  
g/mL,	  respectively),	  as	  demonstrated	  in	  [Table	  1].	  
	  
Abbreviations:	   CoNS,	   coagulase-­‐negative	   staphylococci;	   EUCAST,	   European	  Committee	  on	  Antimicrobial	   Susceptibility	   Testing;	   LOS,	   late-­‐
onset	  sepsis;	  NA,	  not	  available.	  
Table	  1.	  LOS	  antimicrobial	  resistance	  (R)	  based	  on	  EUCAST	  criteria	  of	  Enterobacteriaceae,	  nonfermentative	  
gram-­‐negative	  microorganisms,	  and	  CoNS	  (Vergnano	  et	  al.[65];	  Lusar	  et	  al.[66])	  
	  
According	  to	  surveillance	  performed	  in	  NICUs	  of	  England	  and	  Wales,	  CoNS	  accounted	  for	  22%	  of	  EOS	  
and	   around	   50%	   of	   LOS.	   Despite	   the	   fact	   that	   some	   authors	   have	   reported	   that > 50%	   of	   CoNS	  
neonatal	   bacteremia	   were	   considered	   to	   be	   true	   infections	   [67].	   CoNS	   are	   usually	   considered	  
contaminants,	  especially	  when	   they	  are	   found	  during	  an	  EOS	  episode.	  Because	  of	   the	  presence	  of	  
the	  mecA	  gene,	  most	  CoNS	  isolates	  are	  resistant	  to	  semisynthetic	  penicillins	  [68].	  Therefore,	  many	  
NICUs	  include	  vancomycin	  as	  empiric	  antibiotic	  regimen	  for	  LOS.	  Other	  NICUs,	  owing	  to	  low	  neonatal	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mortality	   rate	   after	   CoNS	   infection,[69]	   have	   adopted	   a	   vancomycin-­‐reduction	   protocol.	   This	  
protocol	   includes	   a	   semisynthetic	   penicillin	   as	   empiric	   therapy	   with	   an	   eventual	   switch	   to	  
vancomycin	  only	  in	  case	  of	  proven	  CoNS	  infection	  (more	  than	  two	  positive	  blood	  cultures	  for	  CoNS)	  
or	  when	  MRSA	  is	  suspected	  [70].	  	  
Therefore,	   an	   LOS	   antibiotic	   first-­‐line	   therapy	   including	   a	   semisynthetic	   penicillin	   combined	   with	  
aminoglycoside	  is	  still	  reasonable.	  The	  use	  of	  vancomycin	  should	  be	  reserved	  for	  severely	  ill	  patients,	  
if	  MRSA	   infection	   is	   suspected,	   or	   if	   CoNS	   is	   proven	   and	   stopped	   if	   cultures	   suggest	   a	   narrower-­‐
spectrum	   antibiotic	   could	   be	   used.	   A	   prompt	   interruption	   is	   advisable	   not	   only	   for	   stemming	   the	  
growth	   of	   resistance	   but	   also	   for	   concerns	   regarding	   drug	   toxicity	   and	   the	   risk	   of	   gram-­‐negative	  
bacteria	  bloodstream	  infection	  due	  to	  the	  alteration	  of	  gastrointestinal	  tract	  flora	  by	  this	  agent	  [71].	  
In	  addition,	  when	  gram-­‐negative	  organisms	  are	  suspected	  (e.g.,	  previous	  colonization)	  or	  the	  course	  
of	   sepsis	   is	   fulminant,	   anti-­‐pseudomonal	   lactams	   such	  as	  penicillin	  with	  a	  β-­‐lactamase	   inhibitor	  or	  
cefepime	  could	  represent	  a	  reasonable	  choice	  [69].	  	  
	  
Antimicrobial	  Stewardship	  Strategies	  Relevant	  to	  Antibiotic	  Prescription	  in	  the	  NICU	  
Optimization	   of	   antimicrobial	   dosing	   based	   on	   individual	   patient	   characteristics	   (gestational	   age,	  
chronological	   age,	   and	   body	   weight),	   causative	   organism,	   site	   of	   infection,	   and	   PK	   and	  
pharmacodynamic	  characteristics	  of	  the	  drug	  is	  an	  important	  part	  of	  AS	  [26,27].	  	  
Moreover,	   for	   certain	   antimicrobials,	   such	   as	   aminoglycosides	   and	   vancomycin,	   blood	   drug	  
monitoring	  must	  be	  performed	  to	  detect	  efficacy	  and	  toxicity.	  
Aminoglycosides	   are	   concentration-­‐dependent	   antibiotics,	   and	   thus	   peak	   and	   trough	   levels	   are	  
necessary	   for	   monitoring.	   For	   gentamicin	   in	   patients	   with	   normal	   renal	   function	   receiving	  
conventional	  aminoglycoside	  multiple-­‐dose	  regimens,	  peak	  level	  could	  be	  collected	  30	  minutes	  after	  
the	   end	   of	   infusion,	  with	   6	   to	   10	   µg/mL	   as	   expected	   value.	  Otherwise,	   trough	   samples	   should	   be	  
collected	  at	  the	  steady	  state	  (before	  the	  fourth	  dose)	  with	  a	  recommended	  level	  of < 2	  µg/mL	  [72].	  	  
Vancomycin	   peak	   levels	   are	   not	   recommended	   for	   monitoring	   because	   they	   lack	   correlation	   to	  
efficacy;	   therefore,	   trough	  concentration	   is	   the	  most	  accurate	  method	  for	  vigilance	  of	  efficacy	  and	  
toxicity.	   Current	   recommendations	   for	   vancomycin	   monitoring	   include	   checking	   trough	  
concentration	   before	   the	   fourth	   dose.	   For	   therapeutic	   effect,	   blood	   concentration	   should	   be	  
maintained	  at > 10	  µg/mL,	  whereas	   for	  complicated	   infections	  secondary	  to	  S.	  aureus	   (bacteremia,	  
endocarditis,	  osteomyelitis,	  meningitis,	  and	  hospital-­‐acquired	  pneumonia),	  trough	  concentration	  of	  
15	  to	  20	  µg/mL	  is	  recommended	  to	  improve	  drug	  penetration	  and	  clinical	  outcome	  [72,73].	  	  
Concerning	   the	   duration	   of	   therapy,	   recent	   neonatal	   guidelines	   suggest	   a	   10-­‐day	   therapy	   for	  
bacteremia	   without	   an	   identifiable	   focus	   of	   infection,	   a	   minimum	   of	   14	   days	   for	   uncomplicated	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meningitis	  attributable	  to	  GBS	  and	  minimum	  of	  21	  days	   for	  gram-­‐negative	  meningitis.	   In	  the	   latter	  
case,	   the	   optimal	   empiric	   treatment	   option	   should	   include	   both	   a	   third-­‐generation	   cephalosporin	  
and	  an	  aminoglycoside	  until	  the	  results	  of	  susceptibility	  testing	  are	  known	  [39,	  74].	  	  
Every	  institution,	  according	  to	  their	  capacity,	  should	  implement	  an	  AS	  program	  for	  guiding	  physicians	  
through	  everyday	  challenges	   in	  diagnosis	  and	   treatment.	  This	  process	   could	  be	  established	  also	   in	  
resource-­‐limited	   settings,	   applying	   as	   a	   first	   step	   one	   or	   more	   of	   the	   supplemental	   strategies	  
described	  previously.	  
The	  duration	  of	  antimicrobial	  therapy	  in	  infants	  with	  negative	  blood	  cultures	  is	  still	  controversial.	  In	  
this	   situation,	   the	   decision	   should	   be	   based	   on	   the	   consideration	   of	   benefits	   and	   risks	   associated	  
with	  a	  longer	  course	  of	  antibiotic.	  Even	  more	  challenging	  is	  to	  define	  the	  best	  therapy	  duration	  for	  
infants	  born	  to	  mothers	  with	  chorioamnionitis.	  Maternal	  chorioamnionitis	  is	  a	  recognized	  risk	  factor	  
for	  EOS,	  but,	  at	  present,	  there	  is	  a	  lack	  of	  studies	  defining	  the	  management	  of	  well-­‐appearing	  infants	  
whose	  mothers	  received	  inadequate	  intrapartum	  antibiotic	  prophylaxis	  [39,75].	  Neonatal	  guidelines	  
recommend	   continuing	   antimicrobial	   therapy	   as	   long	   as	   blood	   culture	   and	   laboratory	   data	   result	  
negative.	   At	   present,	   antibiotic	   therapy	   could	   be	   avoided	   only	   in	  well-­‐appearing	   infants	   at	   risk	   of	  
group	  B	  streptococcal	  infection	  because	  of	  prematurity	  or	  prolonged	  rupture	  of	  membranes.	  In	  this	  
case,	   evaluation	   should	   be	   limited	   to	   a	   blood	   culture,	  markers	   of	   infections,	   and	   complete	   blood	  
count	  with	  differential	  and	  platelet	  count	  [75].	  Furthermore,	  even	  more	  reports	  have	  suggested	  an	  
association	   with	   prolonged	   administration	   of	   antimicrobial	   agents	   (> 5	   days)	   in	   infants	   with	  
suspected	   EOS	   (and	   negative	   blood	   cultures)	   with	   death	   and	   NEC	   [6,7,39].	   Benitz	   et	   al	   recently	  
reviewed	   data	   concerning	   risk	   of	   EOS	   in	   asymptomatic	   late-­‐preterm	   and	   term	   infants	   born	   to	   a	  
mother	  diagnosed	  with	  chorioamnionitis	  prior	  to	  delivery,	  leading	  to	  the	  conclusion	  that	  it	  is	  time	  to	  
abandon	   the	   policy	   of	   treating	   well-­‐appearing	   infants	   [3]	   34	   weeks'	   gestation	   because	   of	  
chorioamnionitis	   alone.[48]	   Some	   authors	   show	   that	   routine	   antibiotic	   use	   for	   prophylaxis	   for	  
invasive	  neonatal	  management	  (e.g.,	  indwelling	  catheters,	  invasive	  mechanical	  ventilation)	  does	  not	  
appear	   to	  have	  any	  protective	  effect	   [76,	  77].	  The	  most	   concerning	  aspect	  of	   this	   situation	   is	   that	  
even	   more	   evidence	   in	   the	   literature	   has	   shown	   that	   a	   prolonged	   perioperative	   antibiotic	  
prophylaxis	  does	  not	  prevent	  bacterial	   infection	  but	   could	   increase	   the	   risk	  of	  MRDO	   [78,79].	   The	  
editing	   of	   surgical	   procedure	   clinical	   pathways	   could	   reduce	   interprofessional	   variation	   optimizing	  
the	  perioperative	  antimicrobial	  administration.	  
	  
Toward	  Effective	  Antibiotic	  Stewardship	  
AS	   programs	   can	   guide	   the	   neonatologist	   to	   the	   best	   antimicrobial	   choice,	   avoiding	   overlapping	  
spectrum	   antibiotic	   combinations	   and	   unnecessary	   prolonged	   treatment	   [26,27].	   The	   use	   of	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antimicrobial	  order	  forms	  where	  neonatologists	  have	  to	  justify	  the	  antibiotics	  requested,	  dosage	  and	  
duration	   of	   therapy	   can	   be	   an	   effective	   component	   of	   AS	   and	   these	   strategies	   have	   been	  
demonstrated	  to	  facilitate	  implementation	  of	  practice	  clinical	  pathways	  [80].	  	  
The	  microbiology	   report	  with	  antibiotic	   susceptibility	   testing	   is	  an	  essential	   tool	   to	  define	   the	  best	  
treatment.	  
A	   supplemental	   AS	   strategy	   based	   on	   streamlining	   or	   de-­‐escalating	   of	   empirical	   antimicrobial	  
therapy	  on	  the	  basis	  of	  culture	  results	  and	  elimination	  of	  redundant	  combination	  therapy	  has	  shown	  
satisfying	  results.[26,27]	  In	  a	  study	  by	  Briceland	  et	  al,	  the	  review	  by	  a	  pharmacist	  and	  an	  ID	  physician	  
of	   patients'	   antimicrobial	   therapy	   led	   to	   streamlining	   recommendations	   in	   54%	   of	   antimicrobial	  
courses	  over	  7	  months	  [81].	  	  
An	   AS	   program	   should	   help	   neonatologists	   go	   through	   these	   really	   simple	   but	   efficient	  
considerations.[82]	  Antimicrobial	  therapy	  should	  be	  discontinued	  if	  all	  cultures	  turn	  back	  negative	  by	  
48	  hours	  and	  the	  child's	  clinical	  conditions	  are	  improving	  [39]:	  
• The	   timing	   of	   the	   report	   is	   important,	   because	   growth	   of	   cultures	   after	   48	   hours	   is	  more	  
likely	   to	  be	  contaminated	   [83].	   If	  cultures	   from	  a	  nonsterile	  body	  site	   turn	  back	  positive,	  a	  
complete	  reevaluation	  must	  be	  done	  to	  be	  sure	  to	  treat	  an	  infection	  and	  not	  a	  colonization.	  
Recently	   Messacar	   et	   al	   evaluated	   the	   clinical	   impact	   and	   provider	   acceptability	   of	  
implementing	  real-­‐time	  AS	  decision	  support	  for	  children	  with	  positive	  blood	  culture	  results	  
according	  to	  the	  FilmArray	  blood	  culture	  identification	  panel	  and	  found	  that	  among	  children	  
with	   blood	   cultures	   that	   contained	   true	   pathogens,	   the	   time	   to	   effective	   antimicrobial	  
therapy	  decreased	  significantly;	  moreover,	  unnecessary	  antibiotic	  initiation	  for	  children	  with	  
a	   culture	   that	   contained	   organisms	   considered	   to	   be	   contaminants	   decreased	   from	   76	   to	  
26%	  [84].	  	  
• When	   susceptibility	   result	   is	   ready,	   clinicians	   must	   reevaluate	   the	   ongoing	   antimicrobial	  
therapy	  switching	  to	  a	  narrow-­‐spectrum	  one,	  if	  possible.	  
• AS	   programs	   must	   indicate	   the	   most	   appropriate	   antibiotic	   and	   dosage	   based	   on	   MIC.	  
Physicians	   must	   pay	   attention	   because	   antimicrobials	   do	   not	   achieve	   the	   same	  
concentration	  at	  any	  body	  site,	  so	  antimicrobial	  with	  MICs	  near	  the	  clinical	  breakpoint	  would	  
not	  be	  recommended	  or	  should	  be	  recommended	  with	  a	  nonconventional	  dosage.	  
	  
Conclusion	  
Infants	   represent	   a	   vulnerable	  population	  at	  high	   risk	   for	   infections.	  Antimicrobial	   prescriptions	   in	  
NICUs	   still	   represent	   a	   point	   of	   concern	   for	   the	   emergence	   of	   MDROs	   and	   difficult	   area	   of	  
implementation.	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Correct	   collection	   and	   interpretation	   of	   microbiological	   specimen,	   prescription	   of	   narrowest-­‐
spectrum	  antibiotic,	  and	  de-­‐escalation	  or	  discontinuation	  of	  therapy	  represent	   important	  areas	   for	  
quality	  improvement.	  
A	   robust	   AS	   program	   requires	   everyday	   multidisciplinary	   collaboration	   between	   ID	   physicians,	  
neonatologist,	   clinical	  pharmacists,	   clinical	  microbiologists,	   infection	  control	  professionals,	  hospital	  
epidemiologists,	   and	   information	   services	   specialists.	   Everyone	   plays	   a	   key	   role	   in	   building	   a	  
stewardship	  team.	  Education	  and	  clinical	  pathways	  (e.g.,	  sepsis	  or	  surgical	  prophylaxis	  pathways)	  are	  
excellent	   starting	   points	   if	   followed	  by	   proactive	   interventions	   of	  AS	   program	   such	   as	   prospective	  
audits	  and	  feedback	  and	  formulary	  restriction	  with	  prior	  antimicrobial	  authorization.	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Background	  
Antibiotics	  represent	  the	  most	  widely	  prescribed	  therapeutic	  agents	   in	  children	  worldwide,	  both	  in	  
hospital	   and	   community	   settings,	   especially	   in	   preschool	   age	   [1,2].	   Although	   antibiotics	   are	  
prescribed	   more	   frequently	   in	   Italy	   than	   in	   other	   European	   countries,	   with	   an	   overuse	   of	   third	  
generation	  cephalosporins	  and	  penicillin	  plus	  beta-­‐lactamase	  inhibitors	  [3],	  to	  our	  knowledge	  this	  is	  
the	  first	  study	  to	  assess	  implementation	  of	  Antimicrobial	  Stewardship	  Program	  (ASP)	  measures	  in	  an	  
Italian	  Pediatric	  Emergency	  Department	  (PED).	  
In	  the	  US,	  ASPs	  have	  been	  shown	  to	  reduce	  inappropriate	  antimicrobial	  use	  and	  resistance,	  enhance	  
patient	   safety	   and	   lower	   drug	   costs	   [4,5].	   A	   well-­‐established	   ASP	   typically	   includes	   proactive	  
interventions	  like	  prospective	  audits	  and	  feedback	  to	  prescribers	  and	  formulary	  restriction	  with	  prior	  
antimicrobial	   authorization.	   Each	   of	   these	   interventions	   has	   shown	   to	   decrease	   unnecessary	  
antimicrobial	   exposure,	   reduce	   costs,	   and	   improve	   patient	   outcomes.	   In	   limited	   resource	   settings	  
where	  a	  robust	  antimicrobial	  stewardship	  team	  may	  be	  difficult	  to	  establish,	  clinical	  pathways	  (CPs)	  
represent	  the	  most	  reasonable	  and	  feasible	  first	  step	  for	  implementation	  [6].	  
A	  CP	  is	  a	  task-­‐oriented	  plan	  that	  details	  essential	  steps	  in	  the	  care	  of	  patients	  with	  a	  specific	  clinical	  
problem	   and	   describes	   the	   patient’s	   expected	   clinical	   course.	   Evidence	   indicates	   that	   CPs	   are	   an	  
effective	  means	  to	  change	  antibiotic	  prescribing	  behavior	  in	  primary	  care	  and	  inpatient	  settings	  [6-­‐
10]	  	  and	  to	  standardize	  care	  without	  adversely	  affecting	  patient	  safety	  or	  outcomes	  [9].	  	  
Since	   CPs	   have	   proven	   a	   promising	   tool	   to	   reduce	   antibiotic	   prescriptions	   in	   primary	   care	   and	   in-­‐
hospital	   settings,	   we	   hypothesized	   that	   their	   implementation	   in	   the	   PED	   would	   decrease	   overall	  
prescription	   and	   cost	   of	   antibiotics,	   especially	   broad-­‐spectrum,	   for	   common	   childhood	   infections	  
acute	  otitis	  media	  (AOM)	  and	  group	  A	  streptococcus	  (GAS)	  pharyngitis.	  	  
Since	   PED	   are	   uniquely	   positioned	   at	   the	   interface	   of	   inpatient	   and	   outpatient	   settings,	   PED	  
physicians	  could	  influence	  prescribing	  trends	  in	  both	  locations.	  Challenges	  in	  antibiotic	  prescribing	  in	  
the	  PED	  setting	   include	  high	   turnover	   rates	   for	  both	  patients	  and	  practitioners	  and	  rapid	  decision-­‐
making,	   making	   application	   of	   some	   ASP	   interventions	   like	   prospective	   audits	   and	   feedback	   or	  
formulary	  restriction	  quite	  difficult	  [11].	  	  
The	   primary	   aim	   of	   this	   study	   was	   to	   assess	   changes	   in	   antibiotic	   prescription,	   especially	   broad-­‐
spectrum,	   before	   and	   after	   CP	   implementation	   for	   AOM	   and	   pharyngitis	   in	   a	   large	   Italian	   PED.	  
Secondary	  aims	  were	  to	  compare	  treatment	  failures	  and	  to	  assess	  the	  change	  in	  the	  total	  antibiotics	  
costs	  before	  and	  after	  CP	  implementation.	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MATERIAL	  AND	  METHODS	  
Study	  Design	  
CPs	  were	   implemented	   from	  1	  October	  2015	   through	  15	  October	  2015.	  We	  conducted	  a	  pre-­‐post	  
quasi-­‐experimental	  study	  to	  assess	  changes	  in	  antibiotic	  prescribing	  during	  the	  6-­‐month	  period	  prior	  
to	  CP	   implementation	  (pre-­‐intervention:	  15	  October	  2014	  through	  15	  April	  2015)	  and	  during	  the	  6	  
months	   after	   intervention	   (post-­‐intervention:	   15	   October	   2015	   through	   15	   April	   2016).	   The	   same	  
months	   have	   been	   analyzed	   in	   each	   period	   to	   control	   for	   effects	   of	   seasonality.	   The	   study	   was	  
conducted	  at	  the	  PED	  of	  the	  Department	  for	  Woman	  and	  Child	  Health	  at	  Padua	  University	  Hospital.	  	  
AOM	  and	  pharyngitis	  CPs	  were	  developed	  by	  the	  Division	  of	  Pediatric	  Infectious	  Diseases	  and	  PED	  of	  
Padua	  in	  collaboration	  with	  the	  Division	  of	  Pediatric	  Infectious	  Diseases	  of	  the	  Children’s	  Hospital	  of	  
Philadelphia	  (see	  Figures,	  Supplemental	  Digital	  Content	  1	  and	  Supplemental	  Digital	  Content	  2).	  CPs	  
were	   delivered	   as	   laminated	   pocket	   cards	   and	   three	   educational	   lectures	   were	   presented	   to	  
physicians	  and	  residents	  on	  how	  to	   implement	  these	  tools	   in	  practice.	  This	  study	  was	  approved	  by	  




All	  patients	  aged	  2	  months	  to	  15	  years	  with	  an	  International	  Classification	  of	  Diseases,	  9th	  Revision,	  
Clinical	  Modification	   (ICD-­‐9-­‐CM)	  code	  or	  descriptive	  diagnosis	  of	  AOM	  or	  pharyngitis	  at	   the	  PED	   in	  
Padua	  during	  the	  pre-­‐	  and	  post-­‐intervention	  periods	  were	  included	  in	  the	  study.	  	  
AOM	   exclusion	   criteria	   were	   immunodeficiency	   or	   immunosuppressive	   therapy,	   tympanostomy	  
tubes	   at	   the	   time	   of	   diagnosis,	   craniofacial	   abnormalities,	   cystic	   fibrosis,	   concomitant	   bacterial	  
infections	   involving	  other	  sites	  or	  systemic	  bacterial	   infection,	  diabetes,	  chronic	  otitis	  media,	  AOM	  
complicated	  by	  mastoiditis	  and	  AOM	  with	  an	  ongoing	  antibiotic	  therapy	  at	  admission.	  	  
Pharyngitis	  exclusion	  criteria	  were	   immunodeficiency	  or	   immunosuppressive	   therapy,	   concomitant	  
bacterial	   infections	   involving	   other	   sites	   or	   systemic	   bacterial	   infection,	   previous	   tonsillectomy,	  
chronic	   diseases,	   admission	   to	   the	   Pediatric	   Department	   or	   to	   Short-­‐Stay	   Emergency	   Department	  
Observation	  Unit	   for	   feeding	   difficulties	   and	  pharyngitis	  with	   an	   ongoing	   antibiotic	   therapy	   at	   the	  
time	  of	  admission.	  	  
Considering	  admissions	  numbers	  in	  the	  Padua	  PED	  from	  November	  2014	  to	  April	  2015	  for	  both	  AOM	  
and	   pharyngitis,	   we	   anticipated	   a	   population	   of	   300	   eligible	   patients	   in	   both	   pre-­‐	   and	   post-­‐
implementation	   periods	   for	   both	   conditions.	   Power	  was	   calculated	   using	   the	   sampsi	   command	   in	  
STATA	   12	   (College	   Station,	   TX),	   assuming	   a	   potential	   25%	   change	   in	   the	   primary	   outcome	   of	  
proportion	   of	   broad-­‐spectrum	   antibiotic	   prescriptions.	   The	   anticipated	   change	   in	   prescription	   of	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broad-­‐spectrum	   antibiotics	   is	   based	   on	   changes	   in	   primary	   outcomes	   from	   pre-­‐	   to	   post-­‐
implementation	  periods	  in	  a	  retrospective	  assessment	  of	  the	  impact	  of	  an	  inpatient	  CP	  for	  cellulitis	  
and	  cutaneous	  abscess	  ranging	  from	  15%	  to	  35%	  (7).	  Given	  these	  parameters,	  power	  for	  AOM	  was	  
estimated	  to	  be	  98%,	  while	  for	  pharyngitis	  it	  was	  estimated	  at	  85%.	  
	  
Data	  Source	  
Antimicrobial	  use	  and	  clinical	  and	  demographic	  data	  for	  all	  patients	  were	  extracted	  manually	   from	  
electronic	  medical	  records	  using	  REDCap®	  data	  collection	  forms	  designed	  for	  the	  two	  conditions.	  	  
Broad-­‐spectrum	  antimicrobials	  were	  defined	  as:	   β-­‐lactam	  and	  β-­‐lactamase	   inhibitor	   combinations,	  
second-­‐	  and	  third-­‐generation	  cephalosporins,	  fluoroquinolones	  and	  macrolides.	  	  
A	  survey	  number	  was	  assigned	  to	  each	  patient	  to	  ensure	  data	  privacy.	  No	  personally	  identifying	  data	  
were	  collected.	  	  
Admissions	   occurring	   for	   the	   same	   patient	   greater	   than	   30	   days	   apart	  were	   analyzed	   as	   separate	  
events.	  	  
Two	   different	   authors	   independently	   collect	   the	   data	   (MB,	   GB).	   Disagreements	   were	   resolved	   by	  
consensus.	  
To	   evaluate	   the	   safety	   of	   the	   intervention,	  we	   collected	   data	   on	   treatment	   failure	  within	   30	   days	  
after	  discharge	   through	  a	   standardized	   telephone	  survey	   to	   the	   family.	  An	   informed	  consent	   form	  
was	  sent	  to	  the	  families,	  and	  follow-­‐up	  data	  were	  included	  only	  when	  authorized.	  
To	   assess	   treatment	   costs,	   generic	   drug	   price	   for	   each	   antibiotic	   prescribed	  was	   based	   on	   official	  




The	   following	   aspects	   of	   antibiotic	   prescriptions	   for	   AOM	   and	   pharyngitis	   were	   assessed:	   1)	  
proportion	  of	   ‘wait	   and	   see’	   approach	   (AOM	  only);	  2)	  proportion	  of	  antimicrobial	  prescriptions	  by	  
specific	   disease	   and	   active	   agent;	   3)	   dosage	   of	   the	   most	   prescribed	   antibiotics,	   expressed	   in	  
mg/kg/day	  and	  4)	  duration	  of	  therapy,	  expressed	  in	  days	  of	  therapy	  (DOTs).	  
	  
Secondary	  outcome:	  
Any	  of	  the	  following	  at	  30	  days	  follow	  up	  were	  considered	  treatment	  failure:	  1)	  change	  in	  antibiotic	  
prescription	   for	   persistence	   or	   worsening	   of	   symptoms;	   2)	   treatment	   change	   for	   antibiotic	   side	  
effects;	  3)	  new	  antibiotic	  prescription	  within	  30	  days	  from	  discharge	  for	  relapse	  of	  symptoms;	  4)	  in	  
case	  of	  AOM,	  new	  antibiotic	  prescription	  after	  “wait	  and	  see”	  approach.	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The	  economic	  impact	  of	  CPs	  was	  investigated	  using	  total	  cost	  of	  overall	  antibiotic	  therapy	  and	  each	  
class	  of	  antibiotic	  per	  1000	  Patient	  Day	  (PD)	   in	  both	  periods.	  For	  oral	  antibiotics,	   two	  formulations	  
were	  considered:	  oral	  suspension	  and	  tablets.	  Oral	  suspension	  was	  used	  for	  children	  less	  than	  40kg	  
and	  tablets	  for	  those	  40kg	  or	  more.	  Starting	  from	  total	  mg/patient/episode,	  the	  number	  of	  packages	  
needed	   for	   completing	   the	   treatment	   course	   was	   computed.	   This	   was	   possible	   because	   in	   Italy	  
antibiotics	  are	  sold	  pre-­‐packaged	  in	  specific	  quantities.	  	  
	  
Data	  analysis:	  
Data	  were	  analyzed	  using	  STATA®13	  and	  QI	  macros	  p-­‐chart	  software.	  	  
Results	  were	  summarized	  as	   frequencies	  and	  percentages	   for	  categorical	  variables	  and	  as	  median,	  
minimum	  and	  maximum	  for	  continuous	  variables.	  Comparison	  of	  categorical	  variables	  in	  the	  pre-­‐	  vs.	  
post-­‐intervention	  period	  were	  conducted	  with	  chi-­‐square	  or	  Fisher’s	  exact	  test.	  Continuous	  variables	  
were	   compared	   with	  Wilcoxon	   rank	   sum	   test.	   In	   this	   analysis,	   the	   dependent	   outcome	   variables	  
were	  summarized	  for	  each	  month	  in	  the	  time	  series.	  	  
	  
	   	  





Over	  the	  6-­‐month	  pre-­‐intervention	  period,	  13,262	  children	  were	  seen	  in	  the	  PED,	  in	  comparison	  to	  
12,335	  children	  during	  the	  6-­‐month	  post-­‐intervention	  period.	  
During	   the	   pre-­‐intervention	   period	   334	   patients	   were	   evaluated	   for	   AOM,	   accounting	   for	   2.5%	  
(334/13,262)	  of	  total	  PED	  visits.	  The	  same	  proportion	  was	  observed	  in	  the	  post-­‐intervention	  period	  
(332/12,335	   (2.7%),	   p=0.4).	   The	   study	   population	   pre-­‐	   and	   post-­‐intervention	   is	   shown	   in	  
Supplemental	  Digital	  Content	  3.	  
The	  two	  populations	  were	  similar	  with	  respect	  to	  sex	  and	  age,	  with	  an	  overall	  male	  predominance	  
and	  an	  increased	  incidence	  of	  AOM	  in	  children	  younger	  than	  5	  years	  (Supplemental	  Digital	  Content	  
4).	  
	  
Antimicrobial	  prescription	  rate	  for	  AOM	  
For	  AOM	  there	  was	  an	  increase	  of	  proportion	  of	  "	  wait	  and	  see"	  approach	  in	  the	  post-­‐CP	  period	  as	  
compared	   to	   the	  pre-­‐CP	  period	   (21.7%	   (64/295)	   vs	   33.1%	   (92/278),	   p<0.01)	   and,	  when	  antibiotics	  
were	   prescribed,	   an	   increase	   of	   amoxicillin	   prescriptions	   (32.0%	   (74/231)	   vs	   51.6%	   (96/186),	  
p<0.001)	  with	  a	  concomitant	  decrease	   in	  broad-­‐spectrum	  antibiotics	  prescription	  (68.0%	  (157/231)	  
vs	   48.4%	   (90/186),	   p<0.001).	   This	   included	   a	   statistically	   significant	   reduction	   in	   cephalosporin	  
prescriptions	  (20.3%	  (47/231)	  vs	  8.6%	  (16/186),	  p<0.001)	  (Table	  1).	  	  
	  
Abbreviations:	   n=indicates	   the	   number	   of	   patient	   for	   each	   category;	   AOM=Acute	  Otitis	  Media;	   GAS	   Pharyngitis=Group	  A	   Streptococcus	  
Pharyngitis	  
Table	  1.	  Treatment	  option	  of	  Acute	  Otitis	  Media	  and	  GAS	  pharyngitis	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A	   significant	   and	   stable	   difference	   in	   antibiotic	   prescribing	   for	   AOM	   between	   pre-­‐	   and	   post-­‐
intervention	   groups	   was	   reported	   (Figure	   1A),	   especially	   for	   uncomplicated	   AOM	   (AOM	   without	  
otorrhea)	  (Figure	  1B).	  
	  
	  
Abbreviations:	   UCL=	   Upper	   Control	   Limit;	   CL=Control	   Limit;	   LCL=Low	   Control	   Limit;	   𝜎	   =the	   standard	   deviation	   of	   the	   sample	   data;	  
AOM=Acute	  Otitis	  Media;	  CP=Clinical	  Pathway;	  GAS	  Pharyngitis=	  Group	  A	  Streptococcus	  Pharyngitis.	  
	  
Figure	  1.	  p	  control	  chart	  describing	  the	  variation	  of	  broad-­‐spectrum	  antibiotics	  prescription	  for	  acute	  otitis	  
media	  (A);	  uncomplicated	  acute	  otitis	  media	  (B);	  GAS	  Pharyngitis	  (C).	  The	  line	  represents	  the	  broad-­‐spectrum	  
antibiotic	  prescriptions.	  
	  
Antibiotics	  dosage	  for	  AOM	  
Dosage	   comparison	   was	   conducted	   for	   amoxicillin	   and	   amoxicillin-­‐clavulanate	   as	   these	   were	   the	  
most	   commonly	   prescribed	   antibiotics.	  Wilcoxon	   rank	   sum	   test	   comparing	   overall	   pre-­‐	   and	   post-­‐
intervention	  median	  dose	  found	  a	  significant	  increase	  in	  dose	  for	  both	  drugs	  (p<0.001)	  and	  the	  trend	  
analysis	  showed	  that	  the	  optimal	  dosage	  recommended	  by	  the	  CP	  was	  reached	  by	  both	  antibiotics	  
within	   one	   month	   post	   CP	   implementation	   and	   remained	   stable	   during	   the	   6-­‐month	   post-­‐
intervention	  period	  (Supplemental	  Digital	  Content	  5).	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Treatment	  duration	  for	  AOM	  
In	   line	   with	   the	   AOM	   CP,	   analysis	   was	   stratified	   by	   age	   (<2	   years	   old,	   ≥2	   years	   old)	   and	   disease	  
severity	  (complicated	  vs.	  uncomplicated	  AOM),	  independently	  from	  the	  prescribed	  oral	  agent.	  
In	  children	  <2	  years	  old,	  median	  DOT	  fluctuated	  between	  8	  and	  10	  for	  the	  first	  three	  months	  after	  CP	  
implementation	  and	  then	  met	  the	  recommended	  duration	  of	  10	  days	  in	  the	  last	  three	  months	  both	  
for	   uncomplicated	   and	   complicated	   AOM.	   Wilcoxon	   rank	   sum	   test	   comparing	   pre-­‐	   and	   post-­‐
intervention	   median	   DOTs	   found	   a	   significant	   increase	   (p<0.001)	   in	   the	   post	   intervention	   group	  
(Figure	  2A).	  
In	  children	  ≥2	  years	  old	  with	  uncomplicated	  AOM,	  median	  DOT	  decreased	  after	  CP	  implementation	  
and	   met	   the	   recommended	   duration	   of	   5	   days	   only	   in	   the	   last	   two	   months	   of	   the	   post-­‐
implementation	   period.	   The	   difference	   between	  median	   DOT	   in	   the	   two	   periods	   was	   statistically	  
significant	  (p<0.001)	  (Figure	  2B).	  
For	   children	   ≥2	   years	   old	   with	   complicated	   AOM,	   median	   DOT	   was	   in	   line	   with	   recommended	  
treatment	  duration	   in	  both	  pre-­‐	   and	  post-­‐intervention	  periods,	  with	  no	   significant	  difference	  over	  
time	  (Figure	  2C).	  
	  
Abbreviations:	  CP=Clinical	  Pathways;	  DOT=Days	  of	  Therapy;	  AOM=Acute	  Otitis	  Media;	  GAS	  Pharyngitis=Group	  A	  Streptococcus	  Pharyngitis;	  
n=the	  sample	  size	  
	  
Figure	   2.	   Duration	   of	   therapy	   in	   median	   DOT	   and	   interquartile	   range	   each	   month	   in	   pre-­‐	   and	   post-­‐
intervention	   period:	   for	   children	   <2	   years	   with	   acute	   otitis	   media	   (A);	   for	   children	   ≥2	   years	   with	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uncomplicated	  AOM	  (B);	  for	  children	  ≥2	  years	  with	  complicated	  AOM	  (C);	  for	  children	  with	  GAS	  Pharyngitis	  
(D).	  	  
.	  
During	  the	  pre-­‐intervention	  period,	  388	  patients	  were	  evaluated	  for	  pharyngitis,	  accounting	  for	  2.9%	  
(388/13,262)	   of	   total	   PED	   visits,	   while	   in	   the	   post-­‐intervention	   period	   patient	   were	   448/12,335,	  
(3.6%),	  p<0.002.	  (Supplemental	  Digital	  Content	  6).	  
The	   groups	   included	   in	   each	   study	   period	   were	   similar	   with	   respect	   to	   sex,	   with	   a	   slight	   male	  
predominance	  and	  with	  a	  higher	  incidence	  among	  older	  children	  (Supplemental	  Digital	  Content	  7).	  
	  
Antimicrobial	  prescription	  rate	  for	  pharyngitis	  
CP	  implementation	  was	  associated	  with	  an	  increase	  in	  proportion	  of	  amoxicillin	  prescriptions	  (53.6%	  
(81/151)	   vs	   93.4%	   (155/166),	   p<0.001)	  with	   a	   concomitant	   decrease	   in	   broad-­‐spectrum	   antibiotic	  
prescription	   (46.4%	   (70/151)	   vs	   6.6%	   (11/166),	   p<0.001).	   This	   included	   a	   statistically	   significant	  
reduction	   in	  amoxicillin-­‐clavulanate	  prescriptions	   (39.7%	  (60/151)	  vs	  3.0%	  (5/166),	  p<0.001)	   (Table	  
1).	  
Analyzing	  pharyngitis	  prescriptions	  by	  month,	  a	  remarkable	  and	  stable	  reduction	  in	  broad-­‐spectrum	  
antibiotic	  prescriptions	  was	  reported	  in	  the	  post-­‐intervention	  period	  (Figure	  1C).	  	  
	  
Antibiotic	  dosage	  for	  GAS	  pharyngitis	  
Amoxicillin	  dose	  was	  in	  line	  with	  50mg/kg/day	  guidelines	  in	  both	  pre-­‐	  and	  post-­‐intervention	  periods,	  
with	  no	  significant	  change	  between	  the	  two.	  
	  
Treatment	  duration	  for	  GAS	  pharyngitis	  	  
Median	  DOT	  for	  GAS	  pharyngitis	  met	  the	  recommended	  10	  days	  in	  the	  last	  two	  months	  of	  the	  pre-­‐
implementation	   period	   and	   remained	   stable	   in	   the	   post-­‐implementation	   period	   (Figure	   2D).	  
Wilcoxon	  rank	  sum	  test	  comparing	  overall	  pre-­‐and	  post-­‐intervention	  median	  DOT	  found	  a	  significant	  
increase	  post-­‐intervention	  (p<0.001).	  
	  
Secondary	  Aim	  
AOM	  treatment	  failure	  
AOM	   follow-­‐up	   for	   treatment	   failure	   evaluation	  was	   available	   for	   214/295	   (72.5%)	   and	   206/278	  
(74.1%)	   children	   in	   pre-­‐	   and	   post-­‐intervention	   periods,	   respectively.	   The	   sub-­‐groups	   available	   for	  
follow-­‐up	   were	   similar	   to	   the	   starting	   populations	   in	   terms	   of	   demographic	   data	   and	   treatment	  
choices.	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The	  difference	  between	  overall	  treatment	  failure	  rates	  in	  pre-­‐	  and	  post-­‐intervention	  groups	  was	  not	  
statistically	   significant	   (12.1%	   (26/214)	  vs	  11.2%	   (23/206),	  p=0.75),	  both	   in	   the	  group	   treated	  with	  
antibiotics	  (p=0.10)	  and	  in	  the	  “wait	  and	  see”	  group	  (p=0.14)	  (Table	  2).	  
	  
	  
Abbreviations: n=the number of patient for each category; AOM=Acute Otitis Media; GAS Pharyngitis=Group A Streptococcus 
Pharyngitis 
Table	  2.	  Treatment	  and	  treatment	  failure	  during	  follow-­‐up	  of	  patients	  with	  AOM	  and	  GAS	  Pharyngitis	  
	  
Pharyngitis	  treatment	  failure	  
For	  pharyngitis	  treated	  with	  antibiotics,	  treatment	  failure	  follow-­‐up	  was	  available	  for	  98/151	  (64.9%)	  
and	  118/166	  (71.1%)	  children	  in	  pre-­‐	  and	  post-­‐intervention	  periods,	  respectively.	  	  
Also	  for	  GAS	  pharyngitis,	  sub-­‐groups	  available	  for	  follow-­‐up	  were	  similar	  to	  the	  starting	  populations	  
in	  terms	  of	  demographic	  data	  and	  treatment	  choices.	  
The	  difference	  between	  overall	  treatment	  failure	  rates	  in	  pre-­‐	  and	  post-­‐intervention	  groups	  was	  not	  
statistically	  significant	  (6.1%	  (6/98)	  vs	  6.8%	  (8/118),	  p=0.93)	  (Table	  2).	  
	  
Total	  cost	  for	  AOM	  
In	   the	   period	   prior	   to	   CP	   implementation,	   AOM	  antibiotics	   cost	   per	   1000	   PD	  was	   8,033.08€,	  with	  
7,014.20€	  (87.3%	  of	  total	  antibiotics	  costs)	  for	  broad-­‐spectrum.	  Following	  CP	  implementation,	  total	  
cost	  per	  1000PD	  reduced	  to	  5,878.30€,	  with	  4,382.67€	  for	  broad-­‐spectrum	  antibiotics	  (Table	  3).	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Abbreviations:	  n=indicates	  the	  number	  of	  patient	  for	  each	  category;	  GAS	  Pharyngitis=Group	  A	  Streptococcus	  Pharyngitis;	  PD=Patient	  Day	  
Table	  3.	  Antibiotic	  prescription	   indication,	   type	  and	  expenditure	  per	  1000	  Patient-­‐Days	   for	  AOM	  and	  GAS	  
pharyngitis	  
	  
The	  proportion	  of	  total	  antibiotics	  costs	  for	  cephalosporins,	  which	  represented	  an	  important	  part	  of	  
broad	  spectrum	  costs	  in	  the	  pre-­‐intervention	  period,	  decreased	  dramatically	  in	  the	  post-­‐intervention	  
(2,921.05€	   (36.4%)	   vs.	   794.51€	   (13.5%),	   p<0.001),	  with	   a	   concurrent	   increase	   in	   the	  proportion	  of	  
antibiotics	  costs	  for	  amoxicillin-­‐clavulanate	  (3,965.36€	  (49.4%)	  vs.	  3,441.81€	  (58.6%),	  p<0.001).	  
Trend	  analysis	  confirmed	  a	  stable	  reduction	  after	  CP	   implementation,	  especially	  for	  the	  proportion	  
of	  antibiotics	  costs	  for	  broad-­‐spectrum	  antibiotics	  (Supplemental	  Digital	  Content	  8).	  	  
	  
Total	  cost	  for	  pharyngitis	  
Prior	   to	   CP	   implementation,	   antibiotics	   for	   pharyngitis	   cost	   per	   1000	   PD	   amounted	   to	   9,337.68€,	  
with	  6,738.61€	  (72.2%)	  for	  broad-­‐spectrum	  antibiotics.	  During	  the	  post-­‐implementation	  period,	  the	  
total	   cost	  decreased	   to	  6,247.23€,	  with	  a	  dramatic	   reduction	   in	   the	  proportion	  of	  antibiotics	  costs	  
from	  broad-­‐spectrum	  antibiotics	  (1,060.78€)	  (Table	  3).	  	  
By	   drug,	   the	   proportion	   of	   antibiotics	   costs	   from	   amoxicillin-­‐clavulanate	   reduced	   dramatically	  
(5,752.58€	   (61.1%)	   vs.	   531.45€	   (8.5%),	   p<0.001).	   Also	   proportion	   of	   antibiotics	   costs	   from	  
cephalosporins	  significantly	  reduced	  (986.03€	  (10.6%)	  vs.	  529.34€	  (8.5%),	  p<0.001).	  
Trend	   analysis	   over	   time	   demonstrates	   an	   immediate	   decrease	   in	   overall	   and	   the	   proportion	   of	  
broad-­‐spectrum	  antibiotics	  costs	  after	  CP	  implementation	  (Supplemental	  Digital	  Content	  9).	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Discussion	  
Our	   study	   showed	   sustained	   changes	   in	   physician	   prescribing	   behaviors	   for	   AOM	   after	  
implementation	  of	  a	  clinical	  pathway.	  Prescribing	  changes	  included	  an	  immediate	  increase	  in	  “wait	  
and	   see”	   approach	   and	   amoxicillin	   prescriptions	   with	   a	   concomitant	   decrease	   in	   broad-­‐spectrum	  
antibiotic	   prescriptions.	   This	   difference	   was	   more	   pronounced	   among	   uncomplicated	   AOM	   cases	  
than	   all	   cases,	   indicating	   that	   AOM	   CP	   implementation	   was	   associated	   with	   a	   lower	   reduction	   in	  
prescription	   of	   broad-­‐spectrum	   antibiotics	   for	   AOM	   with	   otorrhea	   (complicated	   AOM).	   Further	  
analysis	   of	   broad-­‐spectrum	   antibiotic	   prescriptions	   showed	   a	   statistically	   significant	   reduction	   in	  
cephalosporin	   prescription	   after	   intervention,	   as	   expected.	   While	   amoxicillin-­‐clavulanate	   is	   the	  
recommended	   first-­‐line	   antibiotic	   for	   complicated	   AOM,	   oral	   second	   and	   third	   generation	  
cephalosporins	  are	  considered	  an	  option	  only	  in	  the	  case	  of	  non-­‐IgE	  mediated	  penicillin	  allergy	  [13].	  
Indeed,	  according	  to	  a	  meta-­‐analysis	  by	  Pichichero	  et	  al.	  [14],	  cross	  reaction	  between	  penicillins	  and	  
second	  or	  third	  generation	  cephalosporins	  is	  a	  rare	  event	  (incidence	  of	  less	  than	  2%).	  It	  is	  important	  
to	   note	   that	   these	   alternative	   antibiotics	   vary	   in	   their	   efficacy	   against	   AOM	   pathogens.	   The	   only	  
cephalosporin	  that	  has	  been	  demonstrated	  superior	  to	  penicillin	  in	  S.	  pneumoniae	  eradication,	  even	  
if	   resistant,	   is	   ceftriaxone.	   For	   this	   reason,	   it	   is	   suggested	   as	   last	   line	   therapy	   after	   amoxicillin-­‐
clavulanate	   treatment	   failure.	  Macrolides	   are	   indicated	   only	   in	   the	   case	   of	   IgE-­‐mediated	   penicillin	  
allergy.	   Due	   to	   high	   prevalence	   of	   resistant	   S.	   pneumoniae	   (around	   50%)	   [15]	   this	   drug	   could	   be	  
ineffective.	   Indeed,	   according	   to	   epidemiology	   and	   resistance	   data,	   no	   international	   and	   national	  
guidelines	  recommend	  the	  use	  of	  macrolides	  as	  first	  line	  therapy	  [13,16].	  
Regarding	   antibiotic	   dosage	   for	   AOM,	   our	   CP	   recommends	   an	   amoxicillin	   dose	   of	   75	   mg/kg/day	  
administered	  every	  8	  hours.	  No	  clear	  consensus	  has	  been	  expressed	  on	  dosage	  and	  administration	  
intervals	   in	   the	   literature.	   The	   recommendation	   for	   75	  mg/kg/day	  was	  made	   based	   upon	   local	   S.	  
pneumoniae	   resistance	  patterns	  and	  previous	  pharmacokinetic	  and	  pharmacodynamic	   studies	   that	  
have	   showed	   maximum	   eradication	   rate	   only	   at	   high	   doses	   of	   amoxicillin	   administered	   in	   three	  
divided	   doses	   [16].	   Dosage	   recommendations	   for	   the	   amoxicillin	   component	   of	   amoxicillin-­‐
clavulanate	  were	  75	  mg/kg	  in	  our	  AOM	  CP.	  In	  Italy	  the	  only	  available	  formulation	  is	  7:1,	  which	  means	  
that	   an	   excessive	   increase	   in	   the	   amoxicillin	   component	   could	   be	   accompanied	   by	   clavulanate-­‐
related	  gastro-­‐intestinal	  side	  effects.	  However,	  despite	  the	  increase	  in	  dosage	  post-­‐implementation,	  
no	  difference	  in	  terms	  of	  side	  effects	  were	  observed	  between	  pre-­‐	  and	  post-­‐intervention	  groups.	  
In	   contrast	  with	   rapid	  adoption	  of	   the	   recommended	   therapy	  duration	  of	  10	  days	   for	   children	  <	  2	  
years	   old	   in	   the	   post-­‐implementation	   period,	   recommended	   treatment	   duration	   for	   children	   >	   2	  
years	  old	  with	  uncomplicated	  AOM	  of	  5	  days	  was	  slower	  to	  catch	  on	  after	  CP	  implementation,	  with	  
higher	  adherence	  rates	  observed	  only	  after	  3-­‐4	  months.	  Although	  we	  don’t	  have	  data	  on	  prescriber’s	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motivations,	  we	   speculate	   that	   this	   could	   reflect	   pediatricians’	   initial	   discomfort	  with	   AOM	   short-­‐
course	  treatment.	  
According	  to	  pharyngitis	  CP,	  given	  the	  high	  susceptibility	  of	  GAS	  to	  penicillin	  and	  the	  unavailability	  of	  
phenoxymethylpenicillin	  on	  the	  Italian	  market,	  amoxicillin	  was	  always	  the	  first	  antibiotic	  treatment	  
choice	  suggested.	   	  A	  dramatic	   increase	   in	  amoxicillin	  prescriptions	  was	  documented	   in	  the	  post-­‐CP	  
implementation	  period,	  with	  a	  concomitant	  decrease	  in	  broad-­‐spectrum	  antibiotic	  use.	  This	  included	  
a	   statistically	   significant	   reduction	   in	   amoxicillin-­‐clavulanate	   prescriptions.	   No	   guideline	   considers	  
amoxicillin-­‐clavulanate	   suitable	   for	   acute	   GAS	   pharyngitis	   because	   S.	   pyogenes	   does	   not	   produce	  
beta-­‐lactamase	   and	   the	   use	   of	   clavulanate	   would	   only	   increase	   related	   side	   effects.	   Despite	   no	  
indication	  in	  the	  pre-­‐intervention	  period	  46%	  of	  patients	  received	  it.	  
As	  with	  patients	  diagnosed	  with	  AOM,	  despite	  a	  remarkable	  decrease	  in	  broad-­‐spectrum	  antibiotic	  
prescription,	   no	   significant	   difference	   in	   treatment	   failures	  was	   observed	   between	   pre-­‐	   and	   post-­‐
intervention	  periods.	  
Our	   results	   are	   in	   line	   with	   previous	   experience	   (8,10),	   showing	   similar	   significant	   changes	   in	  
antibiotic	   prescription	   after	   CP	   implementation	   for	   common	   illnesses.	   In	   contrast	   with	   what	   was	  
reported	  by	  Samore	  et	  al.	  [8],	  where	  significant	  effects	  were	  achieved	  only	  during	  the	  second	  year	  of	  
the	  intervention,	  in	  our	  study	  changes	  took	  place	  immediately	  after	  CP	  implementation.	  
Furthermore,	   for	   both	   diseases,	   despite	   less	   overall	   antibiotic	   exposure	   in	   the	   post-­‐intervention	  
group,	  adverse	  events	  did	  not	  increase.	  
Regarding	  costs	  per	  1000PD,	  after	  AOM	  CP	  implementation	  there	  was	  a	  significant	  reduction	  in	  total	  
expense	   per	   1000PD,	   with	   a	   savings	   of	   more	   than	   2000€.	   In	   particular,	   there	   was	   a	   significant	  
reduction	   of	   spending	   on	   broad	   spectrum	   antibiotics,	   which	   decreased	   more	   than	   2500€,	   in	  
agreement	   with	   several	   studies	   that	   reported	   an	   important	   decrease	   in	   the	   expense	   for	   broad	  
spectrum	   antibiotics	   after	   CP	   implementation	   [20-­‐22].	   For	   pharyngitis,	   the	   expense	   for	   generic	  
antibiotics	   alone	   decreased	   more	   than	   3000€,	   with	   a	   reduction	   in	   broad-­‐spectrum	   antibiotics	   of	  
around	  5,500€	  and	  a	  tenfold	  decrease	  seen	  in	  amoxicillin-­‐clavulanate	  costs.	  	  
These	  data	  confirm	  that	  amoxicillin	  represents	  the	  most	  cost-­‐effective	  first-­‐line	  treatment	  choice	  for	  
both	  diseases.	  	  
Furthermore,	   this	   was	   a	   low-­‐cost	   intervention.	   CPs	   were	   delivered	   as	   laminated	   pocket	   cards	  
(around	  0.90	  €	  each)	  and	  three	  educational	  lectures	  were	  presented	  during	  weekly	  rounds	  with	  low	  
impact	   on	   physicians’	   and	   residents’	   clinical	   activities.	   However,	   a	   periodical	   recall	   programs	  may	  
substantially	  contribute	  to	  keep	  the	  results	  achieved,	  as	  reported	  by	  Potocky	  et	  al	  [23].	  
This	   intervention	   could	   be	   repeatable	   and	   quickly	   diffusible	   to	   other	   Italian	   centers.	   It	  would	   also	  
likely	  be	  useful	  in	  primary	  care	  settings	  because	  AOM	  and	  pharyngitis	  are	  almost	  always	  managed	  in	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primary	   care	   by	   family	   pediatricians	   in	   Italy,	   so	   the	   relevance	  of	   the	   cost	   reduction	   in	   this	   setting	  
would	  be	  much	  higher	  with	  a	  much	  larger	  population	  of	  patients	  treated,	  as	  reported	  by	  Piovani	  et	  al	  
[24].	  
In	  summary,	  our	  data	  show	  that	  clinical	  pathways	  for	  AOM	  and	  GAS	  pharyngitis	  are	  associated	  with	  
reduced	   rates	   of	   antimicrobial	   prescription	   and	   antibiotics	   costs	   with	   no	   significant	   change	   in	  
treatment	  failure	  rates.	  
This	   study	   has	   strengths	   and	   limitations.	   This	   is	   the	   first	   study	   that	   evaluates	   the	   effectiveness	   of	  
antimicrobial	   stewardship	   through	   clinical	   pathways	   in	   an	   Italian	   hospital.	   This	   intervention	   was	  
designed	  to	  be	  feasible,	  generalizable	  and	  was	  developed	  by	  a	  multidisciplinary	  team	  to	  guarantee	  
the	  best	  quality	  and	  a	  high	  level	  of	  coordination	  of	  interventions.	  
For	   a	   deeper	   comprehension	   of	   PED	   physician	   behavior,	   all	   patients	   with	   ongoing	   therapy	   were	  
excluded,	  to	  minimize	  influences	  in	  treatment	  choices	  by	  other	  physicians.	  
This	   is	   the	   first	   study	  with	   a	   phone	   call	   follow-­‐up	   to	   assess	   antimicrobial	   stewardship	   in	   the	   PED	  
context.	   This	   allowed	   us	   to	   collect	   information	   about	   treatment	   failure	   directly	   speaking	   to	   the	  
families,	   collecting	   granular	   details	   about	   treatment	   outcome,	   such	   as	   antibiotic	   change	   for	  
persistence	  of	  symptoms	  or	  for	  side	  effects.	  
The	  primary	  limitation	  of	  our	  study	  is	  the	  retrospective	  nature	  of	  the	  analysis.	  Despite	  the	  fact	  that	  
CPs	  included	  information	  on	  how	  to	  diagnose	  AOM	  and	  pharyngitis,	  identifying	  patients	  through	  ICD-­‐
9	   or	   descriptive	   diagnosis,	   it	   is	   possible	   that	   we	   included	   misdiagnoses.	   Furthermore,	   this	   was	   a	  
single-­‐center	  study,	  so	  further	  validation	  of	  this	  tool	  should	  include	  other	  Italian	  PEDs.	  The	  quality	  of	  
single	  antimicrobial	  prescriptions	  was	  not	  evaluated.	  Moreover,	  our	  analysis	  of	  treatment	  failure	  was	  
underpowered	  due	  to	  the	  high	  number	  of	  children	  lost	  to	  follow-­‐up	  for	  wrong	  or	  no	  available	  phone	  
number.	   Lastly,	   the	   persistence	   of	   intervention	   impact	   at	   periods	   longer	   than	   6	   months	   post-­‐
implementation	  was	  not	  evaluated.	  
For	  cost	  analysis,	  we	  considered	  only	  the	  direct	  cost	  of	  antibiotics,	  without	  considering	  the	  indirect	  
costs	  that	  could	  arise	  from	  side	  effects	  and	  treatment	  failure,	  which,	  anyway,	  were	  similar	  between	  
the	  two	  groups.	  Moreover,	  only	  two	  types	  of	  oral	  formulation	  were	  considered.	  Furthermore,	  only	  
the	  cost	  of	  the	  generic	  antibiotic	  was	  considered,	  at	  the	  expense	  of	  the	  national	  Health	  Care	  System,	  
and	  we	  did	  not	   investigate	  whether	   the	   families	  had	  bought	   the	  generic	   form	  or	  not.	  Since	   Italian	  
pharmacies	   sell	  only	  pre-­‐established	  quantities	  of	  antibiotics	   the	  costs	  of	  prescribed	   therapy	  were	  
overestimated	  because	  not	  related	  to	  the	  exact	  amount	  of	  drugs	  mg	  but	  to	  the	  costs	  of	  antibiotics	  
packages	  bought	  by	  each	  family.	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Conclusions	  
CP	   represents	   a	   promising,	   resource	   efficient	   antimicrobial	   stewardship	   tool,	   especially	   in	   a	   PED	  
setting.	  
Evidence-­‐based	  CP	  supported	  by	  adequate	  provider	  education	  can	  effectively	   influence	  prescribing	  
practices,	   reducing	   overall	   and	   broad-­‐spectrum	   antibiotic	   prescription,	   improving	   the	   efficiency	   of	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  Figure	  
Flowchart	  of	  children	  with	  Acute	  Otitis	  Media	  enrolled	  during	  pre	  and	  post-­‐intervention	  period.	  	  
	  
Abbreviations:	  PED	  visits=Pediatric	  visits;	  AOM=Acute	  Otitis	  Media	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Characteristics	  of	  Study	  Population	  with	  AOM	  
	  
Abbreviations:	  PED	  visits=Pediatric	  Emergency	  Department	  visits;	  AOM=Acute	  Otitis	  Media;	  ED=Emergency	  Department;	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  the	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patient	  for	  each	  category	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  5.	  Figure	  
Amoxicillin	  and	  Amoxicillin-­‐clavulanate	  dosage	  for	  Acute	  Otitis	  Media	  and	  interquartile	  range	  
changing	  over	  time.	  
	  
Abbreviations:	  AOM=Acute	  Otitis	  Media;	  CP=Clinical	  Pathways;	  n1=the	  sample	  size	  of	  amoxicillin	  group;	  n2=the	  sample	  size	  of	  amoxicillin-­‐
clavulanate	  group.	  
	   	  
	  114	  
Supplemental	  Digital	  Content	  6.	  Figure	  
Flowchart	  of	  children	  enrolled	  for	  Pharyngitis	  during	  pre-­‐	  and	  post-­‐intervention	  period.	  	  
	  
	  
Abbreviations:	  PED	  visits=Paediatric	  Visits;	  GAS	  Pharyngitis=Group	  A	  Streptococcus	  Pharyngitis	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  of	  Study	  Population	  with	  GAS	  Pharyngitis	  
	  
	  
Abbreviations: PED visits=Pediatric Emergency Department visits; ED=Emergency Department; GAS Pharyngitis=Group A Streptococcus 
Pharyngitis; n=the number of children for each category 
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  Digital	  Content	  9.	  Figure	  
GAS	  Pharyngitis	  total	  cost	  per	  1000	  PD	  for	  overall	  antibiotic	  (A)	  and	  for	  broad-­‐spectrum	  ones	  (B)	  
for	  each	  month.	  
	  
Abbreviations:	  PD=	  Patient	  Day;	  GAS	  Pharyngitis=Group	  A	  Streptococcus	  Pharyngitis;	  circle	  =	  data;	  dashed	  line=	  the	  linear	  trend	  line	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Background.	  Pneumonia	  represents	  an	  important	  threat	  to	  children’s	  health	  in	  both	  developed	  and	  
developing	   countries.	   In	   the	   last	   10	   years,	   many	   national	   and	   international	   guidelines	   on	   the	  
treatment	  of	  pediatric	  CAP	  have	  been	  published,	  in	  order	  to	  optimize	  the	  prescription	  of	  antibiotics	  
and	   limit	   their	   cost	   and	   side	  effects.	  However,	   the	  practical	   implementation	  of	   these	  guidelines	   is	  
still	   limited.	   Main	   Text.	   We	   analyzed	   the	   current	   recommendations	   for	   the	   therapy	   of	   pediatric	  
community-­‐acquired	  pneumonia	  (CAP)	  that	  all	  converge	  on	  the	  identification	  of	  aminopenicillins	  and	  
beta-­‐lactams	  as	  the	  optimal	  treatment	  for	  CAP.	  We	  also	  conducted	  a	  review	  of	  the	  current	  literature	  
on	   antibiotic	   regimens	   used	   for	   pediatric	   CAP	   to	   identify	   the	   current	   state	   of	   guidelines	  
implementation	  in	  different	  settings.	  We	  selected	  37	  studies	  published	  from	  2010	  to	  2016,	  including	  
both	   retrospective	   and	  prospective	   studies,	  mainly	   cross-­‐sectional	   and	  hospital	   based.	   The	   results	  
show	   a	   global	   heterogeneity	   in	   the	   antibiotics	   prescription	   for	   pediatric	   CAP,	   with	   application	   of	  
guidelines	  varying	  from	  0%	  to	  more	  than	  91%	  and	  with	  important	  differences	  even	  within	  the	  same	  
country.	  Conclusions.	  Our	  review	  has	  demonstrated	  that	  the	  implementation	  of	  the	  guidelines	  is	  still	  
limited	   but	   also	   that	   achieving	   the	   optimal	   prescription	   is	   possible	   and	   can	   be	   done	   in	   both	  
developed	  and	  developing	  countries.	  




Pneumonia	  is	  the	  single	  greatest	  cause	  of	  death	  in	  children	  worldwide,	  with	  an	  estimated	  1.3	  million	  
deaths	  in	  2011	  and	  more	  than	  90%	  occurring	  in	  developing	  countries	  [1–3].	  It	  is	  responsible	  for	  4%	  
of	  deaths	  in	  newborns	  and	  14%	  of	  deaths	  in	  pediatric	  patients	  [4].	  The	  incidence	  of	  CAP	  is	  lower	  in	  
developed	   countries:	   in	   the	   US	   it	   is	   about	   35–40/1000/person-­‐years	   in	   children	   <	   5	   years	   old,	  
20/1000	  person-­‐years	   in	  children	  5–10	  years	  old,	  and	  10/1000	  person-­‐years	   in	  children	  >	  10	  years	  
old.	  Despite	   this,	  approximately	  50%	  of	   children	  with	  CAP	  <	  5	  years	  old,	  20%	  between	  5–10	  years	  
old,	  and	  10%	  of	  children	  >	  10	  years	  old	  need	  to	  be	  hospitalized	  [5].	  These	  numbers	  demonstrate	  the	  
burden	  that	  CAP	  represents	  for	  society	  and	  for	  economic	  healthcare	  resources.	  
	  
Materials	  and	  Methods	  
	  
In	   the	   first	   part	   of	   the	   study,	   we	   compared	   the	   latest	   national	   and	   international	   guidelines	   on	  
pediatric	   CAP,	   including	   all	   those	   who	   were	   published	   since	   2005	   to	   2016,	   focusing	   on	   their	  
recommendations	  for	  first-­‐line	  therapies.	  
Then	  we	  performed	  a	  search	  on	  PubMed	  and	  Scopus	  databases,	  looking	  for	  studies	  published	  from	  
2010	  to	  2016	  about	  CAP	  antimicrobial	  therapy	  in	  children,	  trying	  to	  get	  data	  from	  as	  many	  different	  
countries	  as	  possible.	  We	  also	  performed	  hand-­‐search	  of	  references	  of	  relevant	  articles.	  Our	  search	  
included	   both	   retrospective	   and	   prospective	   studies,	   mainly	   cross-­‐sectional	   and	   hospital	   based,	  
including	  both	  inpatients	  and	  outpatients.	  All	  of	  them	  except	  for	  one	  [6]	  included	  pediatric	  patients	  
only.	  
To	   get	   a	  more	   extensive	   review	   of	   CAP	   prescribing	   behaviour,	   for	   those	   countries	   where	   specific	  
studies	   on	   antimicrobial	   prescriptions	   for	   CAP	   were	   not	   available,	   a	   search	   for	   articles	   on	  
antimicrobial	   prescriptions	   in	   pediatric	   age	   groups	   was	   performed.	   All	   articles	   including	   CAP	   as	  
reason	  for	  treatment	  were	  included.	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Results	  and	  Discussion	  
	  
Different	  Countries,	  Same	  Pathogens	  
Organisms	   responsible	   for	  CAP	  vary	   stratifying	  children	  by	  age	  because	  of	   the	  developing	   immune	  
system	  and	  age-­‐related	  exposures:	  viruses	  or	  mixed	  infections	  are	  more	  common	  amongst	  younger	  
patients	  (children	  under	  5	  years	  of	  age),	  while	  exclusive	  bacterial	  origin	  and	  atypical	  etiology	  (mainly	  
Mycoplasma	   pneumoniae	   and	   Chlamydophila	   pneumoniae)	   are	   more	   often	   identified	   in	   older	  
children	  [7,	  8].	  S.	  pneumoniae	  and	  Haemophilus	  influenzae	  are	  the	  commonest	  bacterial	  pathogens	  
isolated	   in	  children	  under	  five	  years	  with	  CAP	  accounting	  for	  30%–50%	  and	  10%–30%,	  respectively	  
[9].	  Around	  50%	  of	  deaths	  due	  to	  pneumonia	  are	  attributable	  to	  these	  organisms	  [10].	  
Viral	  etiology	  has	  been	  documented	  in	  up	  to	  80%	  of	  CAP	  cases	  in	  children	  younger	  than	  2	  years	  and	  
much	  less	  in	  older	  children	  (10–16	  years).	  The	  most	  frequently	  identified	  viral	  pathogen	  in	  younger	  
children	   is	   Respiratory	   Syncytial	   Virus	   (RSV),	   rarely	   detected	   in	   older	   children.	   Less	   frequent	   are	  
Adenoviruses,	   Bocavirus,	   Human	   Metapneumovirus,	   Influenza	   A	   and	   B	   Viruses,	   Parainfluenza	  
Viruses,	   Coronaviruses,	   and	   Rhinovirus.	   Up	   to	   33%	   of	   hospitalized	   children	   are	   simultaneously	  
infected	   by	   2	   or	   more	   viruses.	   Mixed	   infections	   (both	   of	   viral	   and	   bacterial	   etiology)	   have	   been	  
documented	  in	  2–50%	  of	  children	  with	  CAP,	  more	  frequently	  in	  inpatients,	  which	  are	  more	  seriously	  
ill	  than	  outpatients	  [3,	  11].	  
Atypical	   pneumonia	   caused	   by	   different	   pathogens	   is	   characterized	   by	   a	   different	   clinical	   course:	  
slowly	  progressing,	  with	  malaise,	  sore	  throat,	  low-­‐grade	  fever,	  and	  cough	  developing	  over	  3–5	  days.	  
The	  main	  organisms	  responsible	  for	  atypical	  pneumonia	  are	  M.	  pneumoniae	  in	  older	  children	  and	  C.	  
pneumoniae	  in	  infants.	  Legionella	  species	  are	  rarely	  identified	  in	  children	  [8,	  12,	  13].	  
The	  etiologic	  definition	  is	  difficult	  for	  many	  reasons,	  such	  as	  low	  yield	  of	  blood	  cultures,	  difficulty	  in	  
obtaining	  adequate	  sputum	  specimens	  from	  younger	  children,	  frequent	  specimen	  contaminations	  by	  
upper	   airways	   bacterial	   flora	   and	   invasiveness	   of	   pulmonary	   biopsy,	   lung	   aspiration,	   and	  
bronchoalveolar	  lavage	  which	  are	  rarely	  performed	  [13].	  However,	  over	  the	  last	  10	  years,	  there	  have	  
been	   improvements	   in	   PCR	   techniques	   for	   viral	   identification	   on	   nasopharyngeal	   aspirates	   or	  
secretion,	  and	  molecular	  assays	  are	  now	  commonly	  used	  in	  Europe	  and	  in	  the	  US.	  
Vaccines	   are	   the	  most	   effective	   strategy	   for	   prevention	   of	   pediatric	   CAP.	   Haemophilus	   influenzae	  
type	  B	   (HiB)	   conjugate	  vaccine	  and	  7-­‐valent	  pneumococcal	   conjugate	  vaccines	   (PCV7)	  dramatically	  
decreased	  the	  incidence	  of	  bacterial	  CAP	  after	  introduction	  of	  universal	  vaccination	  campaigns	  [14,	  
15].	  PCVs	  have	  been	  included	  for	  some	  years	  in	  the	  immunization	  schedules	  of	  children	  in	  their	  first	  
year	   of	   life	   in	   many	   countries	   and	   they	   have	   completely	   modified	   the	   burden	   of	   pneumococcal	  
diseases	   among	   these	   children	   and	   their	   unvaccinated	   contacts	   of	   any	   age	   [16].	   Currently,	   the	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polyvalent	   pneumococcal	   vaccine	   (PCV13)	   confers	   immunity	   to	   approximately	   85%	   of	   serotypes	  
responsible	  for	  most	  invasive	  pneumococcal	  diseases	  [17].	  
	  
Same	  Pathogens,	  Same	  Treatment:	  International	  CAP	  Recommendations	  
	  
Since	  its	  introduction	  during	  the	  20th	  century,	  antibiotic	  therapy,	  along	  with	  vaccines,	  has	  decreased	  
CAP	  mortality	  of	  97%	  in	  developed	  countries	   [14].	  Most	  of	   the	  time	  the	  choice	  of	  an	  antimicrobial	  
agent	   is	   empirical	   and	   based	   on	   the	   most	   common	   etiologies	   for	   each	   age	   group,	   on	   the	   local	  
prevalence	   of	   causative	   organisms,	   and	   on	   the	   presence	   of	   risk	   factors	   for	   atypical	   or	   resistant	  
bacteria	  [18].	  
During	   the	   last	   10	   years,	  many	   guidelines	   have	  defined	   the	  best	   antimicrobial	   regimen	   for	   CAP	   in	  
children	   considering	   spectrum	   of	   activity,	   antimicrobial	   susceptibility,	   tolerability,	   bioavailability,	  
safety,	   and	   cost	   [19,	   20].	   As	   already	   highlighted	   by	   other	   authors,	   these	   guidelines	   present	   some	  
differences	   in	   treatment	   strategies,	   but	   almost	   all	   agree	   on	   the	   first-­‐line	   therapy	   to	   administer	   in	  
case	  of	  CAP	  (Figure	  1)	  [19].	  
	  
Figure	  1:	  Pediatric	  CAP	  guidelines	  timeline	  [adapted	  by	  Berti	  et	  al.,	  2013	  [19]].	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For	   infants	   <	   2	   months	   of	   age,	   the	   association	   with	   ampicillin	   and	   aminoglycosides	   is	   the	   most	  
suggested	   therapy,	   ensuring	   coverage	   for	   Group	   B	   streptococci	   and	   Gram-­‐negatives.	   In	   case	   of	  
atypical	   pneumonia,	   in	   this	   period	   of	   life,	   because	   of	   the	   possibility	   of	   Chlamydia	   trachomatis	  
infection,	  macrolides	  are	  recommended	  [3,	  19,	  21–23].	  
For	  all	  children	  >	  3	  months	  of	  age,	  the	  narrowest	  regimen	  with	  S.	  pneumoniae	  activity	  is	  suggested	  
worldwide.	   Penicillin	   is	   the	   ideal	   first-­‐line	   therapy,	   being	   a	   narrow-­‐spectrum	   agent	   achieving	  
therapeutic	  concentrations	  for	  S.	  pneumoniae	  in	  the	  lung	  up	  to	  MIC	  of	  4 mg/ml	  [24].	  However,	  due	  
to	   its	   limited	  bioavailability,	  oral	  amoxicillin	   is	   reported	  as	  an	  equivalent	  and	  more	   feasible	  option	  
[24,	  25].	  
Despite	   general	   agreement	   on	   the	   agent,	   differences	   in	   dose	   and	   posology	   have	   been	   reported,	  
varying	   according	   to	   pneumococcal	   resistance	   [19].	   Indeed,	   beta-­‐lactam	   effectiveness	   is	   time	  
dependent	   and	   S.	   pneumoniae	   does	   not	   develop	   resistance	   through	   β-­‐lactamase	   enzyme	  
production,	   but	   through	   the	   alteration	   of	   the	   cell	   wall’s	   antimicrobial	   targets	   (penicillin-­‐binding	  
proteins)	  [26].	  Thus,	  in	  the	  setting	  of	  resistant	  S.	  pneumoniae	  serotype,	  higher	  concentration	  at	  the	  
infection	  site	   is	  needed	   in	  order	  to	  saturate	  penicillin-­‐binding	  proteins	  and	  to	  overcome	  resistance	  
[27].	  
A	  study	  of	  children	  with	  pulmonary	  pneumococcal	  infection	  [28]	  provided	  data	  to	  develop	  a	  model	  
for	   describing	   amoxicillin	   pharmacokinetics	   administered	  with	   different	   patterns:	   50 mg/kg/day	   in	  
two	   or	   three	   administrations	   daily.	   The	   resulting	   curve,	   integrated	   with	   S.	   pneumoniae	   MIC	   for	  
amoxicillin,	   showed	   that,	   for	   intermediate	   resistant	   S.	   pneumoniae	   (MIC	   4 mg/ml)	   CAP,	   the	  
amoxicillin	   plasma	   concentration	   remained	   above	   the	   pneumococcal	  MIC	   level	   for	   about	   4	   hours.	  
Therefore,	  amoxicillin	  administered	  every	  8	  hours	  maintains	  blood	  and	  lung	  concentrations	  that	  are	  
above	   S.	   pneumoniae	  MIC	   for	   enough	   time	   to	   allow	   S.	   pneumoniae	   eradication.	   A	   longer	   interval	  
between	   administrations	   (every	   12	   hours),	   in	   case	   of	   intermediate	   resistant	   serotypes,	  would	   not	  
permit	  having	  a	  sufficient	  antimicrobial	  plasma	  concentration	  [28].	  Similarly,	  penicillin	  G	  needs	  more	  
frequent	  administrations	  than	  other	  beta-­‐lactams,	  because	  of	  its	  shorter	  half-­‐life	  [13].	  
Beta-­‐lactam	  dose	  is	  the	  other	  key	  factor	  for	  pathogen	  eradication.	  Through	  the	  different	  guidelines,	  
amoxicillin	  daily	  dose	  varies	  from	  40–50 mg/kg	  to	  90–100 mg/kg,	  with	  higher	  dosage	  recommended	  
in	  areas	  with	  higher	  risk	  for	  antibiotic-­‐resistant	  serotype,	  as	  in	  the	  US	  [13,	  19].	  In	  the	  same	  way,	  for	  
inpatient	  parenteral	  therapy,	  higher	  doses	  of	  penicillin	  G	  or	  ampicillin	  are	  recommended	  [13].	  
The	  only	  two	  guidelines	  which	  suggest	  an	  aminopenicillin	  plus	  beta-­‐lactamase	   inhibitor	  as	  first	   line	  
are	  the	  Taiwan	  Pediatric	  Working	  Group	  and	  Asociacion	  Espanola	  de	  Pediatria	  de	  Atencion	  Primaria	  
[29,	  30].	  Unlike	  the	  first	  one,	  in	  which	  aminopenicillin	  plus	  beta-­‐lactamase	  inhibitor	  (e.g.,	  amoxicillin-­‐
clavulanate)	   is	   suggested	   as	   first-­‐line	   therapy	   for	   all	   children	   treated	   as	   outpatient,	   the	   Spanish	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guidelines	   recommend	   coamoxiclav	  only	   for	   children	  who	  are	  not	   fully	   immunized	  with	   conjugate	  
vaccines	  for	  type	  B	  H.	  influenzae	  and	  for	  S.	  pneumoniae.	  Indeed,	  this	  population	  is	  at	  increased	  risk	  
to	  develop	  a	  CAP	  by	  aggressive	  S.	  pneumoniae	  serotypes	  and	  other	   less	  common	  organisms,	  as	  H.	  
influenza.	  Unlike	  Pneumococcus,	  type	  B	  and	  nontypeable	  H.	  influenzae	  became	  resistant	  to	  penicillin	  
through	  the	  production	  of	  β-­‐lactamase.	  Therefore,	  treatment	  with	  the	  association	  of	  amoxicillin	  with	  
a	  β-­‐lactamase	  inhibitor	  ensures	  a	  broader	  coverage	  [30].	  It	  should	  be	  noted	  that	  the	  addition	  of	  a	  β-­‐
lactamase	  inhibitor	  does	  not	  change	  the	  amoxicillin	  kinetic	  curve;	  as	  a	  consequence,	  in	  order	  to	  treat	  
a	  pneumococcal	  infection	  with	  the	  association	  of	  amoxicillin	  with	  clavulanate,	  the	  therapy	  should	  be	  
administered	  every	  8	  hours	  [26].	  
The	   WHO	   guidelines	   are	   the	   only	   one	   suggesting	   cotrimoxazole	   as	   alternative	   to	   amoxicillin	   in	  
outpatient	   treatment.	   This	   recommendation	   derived	   from	   evidence	   of	   no	   difference	   in	   treatment	  
failure	  rates	  between	  amoxicillin	  and	  cotrimoxazole	  [31–33].	  Despite	  concerns	  about	  the	  increase	  of	  
S.	  pneumoniae	  and	  H.	  influenzae	  resistant	  to	  cotrimoxazole,	  as	  demonstrated	  by	  some	  authors	  [34],	  
the	  reason	  for	  this	  indication	  is	  mainly	  attributable	  to	  economic	  factors.	  Indeed,	  for	  children	  <10 kg,	  
the	  cost	  of	  a	  five-­‐day	  treatment	  with	  amoxicillin	  is	  higher	  than	  the	  same	  duration	  on	  cotrimoxazole	  
[35–37].	  
No	   guidelines	   recommend	   oral	   cephalosporins	   as	   first-­‐line	   therapy.	   Indeed,	   pharmacokinetic	   and	  
pharmacodynamic	  studies	  showed	  that	  none	  of	  the	  available	  oral	  cephalosporins	   is	  able	  to	  exceed	  
the	  pneumococcal	  MIC	  for	  more	  than	  50%	  of	  the	  time	  between	  two	  administrations	  [26].	  Moreover,	  
recent	   US	   data	   on	   S.	   pneumoniae	   susceptibility	   to	   cefdinir	   and	   cefuroxime	   indicated	   only	   70%	   to	  
80%	  efficacy,	  compared	  with	  84%	  to	  92%	  amoxicillin	  efficacy	  [38,	  39].	  
The	   only	   cephalosporin	   that	   has	   been	   demonstrated	   superior	   to	   penicillin	   in	   S.	   pneumoniae	  
eradication,	  even	  if	  resistant,	  is	  ceftriaxone	  [40].	  No	  microbiologic	  failures	  have	  been	  reported	  for	  S.	  
pneumoniae	  with	  ceftriaxone	  MIC	  of	  4.0 mg/mL	  [13,	  41].	  Thus,	  ceftriaxone	  or	  cefotaxime	  in	  standard	  
doses	   is	   suggested	   by	   all	   guidelines	   as	   alternatives	   in	   case	   of	   first-­‐line	   treatment	   failure,	   severe	  
clinical	  conditions,	  or	  not	  fully	  immunized	  children	  [3,	  7,	  13,	  21–23,	  29,	  30,	  41].	  
Due	  to	  high	  prevalence	  of	  macrolide	  resistance	  circulating	  strains	  of	  S.	  pneumoniae,	  macrolides	  are	  
not	  recommended	  as	  empiric	  therapy	  for	  CAP.	  Their	  use	  is	  suggested	  only	  when	  atypical	  etiology	  is	  
suspected	  or	  in	  case	  of	  persistence	  of	  symptoms	  despite	  beta-­‐lactams	  administration	  [7,	  13,	  42].	  This	  
strict	   indication	   for	  macrolides	   use	   derives	   from	   the	   evidence	   that	  Mycoplasma	   lower	   respiratory	  
tract	   infection	  (LRTI)	  has	  a	  high	  rate	  of	  spontaneous	  clinical	   remission	  and	  the	  use	  of	  azithromycin	  
has	   been	   associated	   with	   the	   selection	   of	   resistant	   organisms	   because	   of	   its	   prolonged	   serum	  
elimination	  half-­‐life	  [13].	  Moreover,	  no	  significant	  benefits	  of	  antibiotic	  treatment	  in	  M.	  pneumonia	  
infection	  have	  been	  documented	  [37].	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For	   complicated	   pneumonia	   (i.e.,	  moderate	   parapneumonic	   effusion	   and	   necrotizing	   pneumonia),	  
antimicrobial	  therapy	  must	  be	  broadened	  to	  cover	  less	  common	  but	  highly	  aggressive	  pathogens	  as	  
Streptococcus	  pyogenes	  and	  S.	  aureus.	  As	   for	  S.	  pneumoniae,	  macrolides	  cannot	  be	  considered	  an	  
effective	  empiric	  therapy	  because	  of	  the	  high	  level	  of	  resistance	  [13].	  
Despite	   the	   fact	   that	   no	  penicillin	   or	   cephalosporin	   resistance	  has	  been	   reported	   for	   S.	   pyogenes,	  
some	  authors	  suggest	  that,	  in	  case	  of	  concomitant	  symptoms	  attributable	  to	  toxic	  shock	  syndrome,	  
combination	   therapy	   with	   clindamycin	   decreases	   the	   severity	   of	   symptoms	   [43].	   In	   fact,	   since	  
clindamycin	   inhibits	   protein	   synthesis	   (by	   binding	   the	   50S	   subunit	   of	   the	   bacterial	   ribosome),	   it	  
inhibits	  the	  production	  of	  S.	  aureus	  toxins,	  resulting	   in	  a	   lower	   inflammatory	  reaction.	  Clindamycin	  
may	   be	   bacteriostatic	   or	   bactericidal	   depending	   on	   the	   organism	   and	   drug	   concentration	   and	   is	  
indicated	  by	  US	  guidelines	   as	   a	   good	  option	   for	  both	  methicillin	   susceptible	   S.	   aureus	   (MSSA)	   and	  
community-­‐acquired	  methicillin-­‐resistant	  S.	  aureus	  (CA-­‐MRSA)	  strains	  [13].	  
Nowadays	  almost	  all	  MSSA	  have	  penicillin	  resistance	  which	  can	  be	  overcome	  with	  the	  addition	  of	  a	  
β-­‐lactamase	   inhibitor	   or	   through	   penicillinase-­‐resistant	   beta-­‐lactams,	   such	   as	   oxacillin	   or	   first-­‐
generation	  cephalosporins.	  MRSA	  strains	  have	  mecA	  gene	  that	  encodes	  penicillin-­‐binding	  protein	  2a,	  
an	  enzyme	  that	  has	  low	  affinity	  for	  beta-­‐lactams,	  leading	  to	  resistance	  to	  all	  antibiotics	  active	  against	  
MSSA.	   During	   the	   last	   decade,	   both	   community-­‐associated	   and	   hospital-­‐acquired	   infections	   with	  
MRSA	  have	  increased.	  MRSA,	  accounting	  for	  20%–40%	  of	  all	  hospital-­‐acquired	  pneumonia	  (HAP)	  and	  
ventilator-­‐associated	  pneumonia	  (VAP),	  have	  demonstrated	  a	  rapid	  increase	  as	  cause	  of	  pneumonia	  
even	   in	   patients	   without	   exposure	   to	   the	   healthcare	   system	   [44].	   This	   CA-­‐MRSA	   has	   become	   an	  
important	  cause	  of	  CAP	  complicated	  by	  empyema	  and	  necrosis	  [45].	  
Since	  erythromycin	  resistance	  predicts	  inducible	  clindamycin	  resistance	  in	  many	  isolates,	  a	  D-­‐test	  to	  
assess	  clindamycin	  susceptibility	  should	  always	  be	  performed.	  In	  case	  of	  D-­‐test	  positivity,	  the	  use	  of	  
clindamycin	   should	   be	   avoided,	   since	   it	   is	   highly	   possible	   that	   the	   organism	  will	   become	   resistant	  
during	  the	  infectious	  process,	  especially	   in	  high-­‐inoculum	  infections	  such	  as	  empyema	  [45].	  On	  the	  
other	  hand,	  all	  CA-­‐MRSA	  strains	  are	  susceptible	  to	  vancomycin,	  which	  is	  considered	  by	  all	  guidelines	  
as	   the	   drug	   of	   choice	   if	   MRSA	   is	   suspected	   [7,	   13].	   Although	   linezolid	   has	   been	   recently	  
demonstrated	  as	  efficient	  as	  vancomycin	  for	  the	  treatment	  of	  MRSA	  pneumonia,	   its	  use	  should	  be	  
considered	  as	  a	   second-­‐line	   treatment	   for	   cost	   consideration	   (linezolid	   costs	  >10	   times	  more	   than	  
vancomycin)	  and	  because	  linezolid-­‐resistant	  MRSA	  has	  already	  been	  described	  [46,	  47].	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Different	  Countries,	  Same	  Treatment?	  
A	   worldwide	   review	   about	   CAP	   antimicrobial	   therapy	   in	   children	   includes	   37	   studies	   about	  










Table	  1:	  Papers	  on	  CAP	  antibiotic	  treatment	  in	  children	  from	  2010	  to	  2016.	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Figure	  2:	  World	  map	  of	  papers	  on	  CAP	  treatment	  in	  children	  stratified	  by	  year	  of	  publication.	  
	  
Even	  if	  the	  studies	  were	  different	  in	  design	  and	  study	  population,	  their	  results	  give	  a	  good	  picture	  of	  
the	  antibiotic	  prescription	  patterns	  in	  different	  environments,	  and	  they	  show	  the	  global	  
heterogeneity	  in	  the	  application	  of	  the	  guidelines	  for	  the	  treatment	  of	  childhood	  pneumonia.	  
In	  fact,	  the	  first	  important	  result	  of	  our	  review	  is	  that	  the	  correct	  implementation	  of	  the	  guidelines	  is	  
not	  confined	  to	  specific	  areas	  but	  may	  be	  variable	  even	  inside	  the	  same	  country.	  For	  example,	  Iroh	  
Tam	  et	  al.,	  through	  a	  2-­‐year	  retrospective	  study	  on	  hospitalized	  children	  with	  CAP	  in	  six	  US	  centres,	  
showed	  that	  the	  most	  used	  antibiotics	  were	  third-­‐generation	  cephalosporins	  (73%),	  and	  only	  1%	  of	  
the	   patients	   received	   amoxicillin.	   These	   findings	   during	   the	   first	   2	   years	   after	   US	   guidelines	  
publication	  led	  the	  authors	  to	  recommend	  more	  strategies	  for	  educating	  healthcare	  providers	  [71].	  
On	   the	   other	   hand,	   Thomson	   et	   al.	   in	   another	   retrospective	   study	   set	   in	   an	  US	   hospital,	  with	   the	  
same	   population	   (hospitalized	   children	   between	   3	   months	   old	   and	   18	   years	   old)	   in	   a	   15-­‐month	  
period	  (May	  2011–July	  2012),	  had	  an	  opposite	  result,	  reporting	  that	  63,6%	  of	  the	  pediatric	  CAP	  were	  
treated	  with	  aminopenicillins	  and	  only	  16.8%	  with	  third-­‐generation	  cephalosporins	  [80].	  
We	  found	  a	  similar	  situation	  comparing	  studies	  from	  France	  [63,	  78]	  and	  India	  [57,	  65].	  
Interestingly,	  in	  France	  our	  data	  about	  CAP	  prescriptions	  derive	  from	  two	  different	  settings.	  Launay	  
and	  colleagues	  investigated	  antimicrobial	  prescriptions	  and	  recommendations	  adherence	  in	  a	  French	  
Emergency	   Pediatrics	   Department	   through	   a	   prospective	   two-­‐period	   study,	   including	   all	   children	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aged	  one	  month	   to	   15	   years.	   The	   results	  were	   encouraging,	  with	   an	   increase	  of	   recommendation	  
compliance	   from	  18.8%	  to	  48%	  between	  2009	  and	  2012,	  and	  a	  consequent	   increase	  of	  amoxicillin	  
monotherapy	  prescription	  from	  54.2%	  to	  71%	  [78].	  Dubos	  et	  al.,	  on	  the	  other	  hand,	  give	  us	  a	  picture	  
of	   CAP	   antimicrobial	   prescriptions	   through	   general	   practitioners	   (GPs),	   private	   pediatricians,	   and	  
pediatric	   fellows.	   The	   results	   of	   the	   standardized	   questionnaire	   submitted	   to	   every	   participant	  
showed	   that	   CAP	   guidelines	  were	   insufficiently	   followed,	  with	   high	   rate	   of	   amoxicillin/clavulanate	  
prescriptions	   (amoxicillin	   in	   monotherapy	   was	   prescribed	   in	   only	   29%	   of	   cases,	   for	   54%	   of	   cases	  
associated	  with	  clavulanic	  acid)	  [63].	  
In	  India,	  in	  addition,	  we	  found	  some	  of	  the	  lowest	  rates	  of	  prescription	  on	  aminopenicillins	  as	  single	  
therapy.	  Choudry	  and	  Bezbaruah,	  in	  a	  prospective	  observational	  study	  based	  in	  a	  university	  hospital	  
in	  Assam,	  including	  inpatients	  up	  to	  12	  years,	  reported	  0%	  use	  of	  penicillin	  as	  single	  therapy	  in	  cases	  
of	   pediatric	   pneumonia.	   The	   therapy	   mostly	   used	   (54%	   of	   cases)	   was	   the	   combination	   of	  
amoxicillin/clavulanate	   [58].	  Another	  prospective	   study	  by	  Moinuddin	  et	  al.	  was	  conducted	  over	  9	  
months	   in	   2012,	   in	   two	   hospitals	   in	   Bangalore.	   The	   most	   widely	   used	   therapy	   was	   amoxicillin	   +	  
clavulanate	  (43,8%),	  with	  third-­‐generation	  cephalosporins	  as	  the	  most	  prescribed	  class	  (ceftriaxone	  
36.2%,	  cefotaxime	  21%).	  Penicillin	  in	  single	  therapy	  accounted	  only	  for	  1%	  of	  prescriptions	  [57].	  
Cephalosporins	   were	   often	   reported	   to	   be	   the	   class	   with	   higher	   rates	   of	   prescription	   for	   CAP	  
treatment,	  as	  reported	  by	  many	  centres	  in	  different	  countries,	   like	  Ethiopia	  [60],	  Saudi	  Arabia	  [62],	  
Nepal	  [73],	  Serbia	  [83],	  Sudan	  [67],	  US	  [54,	  71,	  74],	  Italy	  [76],	  and	  other	  European	  countries	  [48,	  82].	  
Feleke	  and	  colleagues	  conducted	  their	  5-­‐month	  prospective	  study	  in	  a	  large	  government	  hospital	  in	  
Ethiopia.	  The	  study	  includes	  all	  children	  admitted	  in	  that	  period	  and	  CAP	  accounted	  for	  56.3%	  of	  all	  
drug	   prescriptions.	   Ceftriaxone	   was	   the	   most	   prescribed	   drug	   (43.5%)	   followed	   by	   gentamicin	  
(25.6%),	  and	  penicillin	  and	  ampicillin	  ranked	  the	  third	  and	  fourth	  place	  [62].	  In	  a	  retrospective	  study	  
by	  Zec	  et	  al.,	  during	  a	  6-­‐month	  period	  in	  2014,	  first-­‐	  and	  third-­‐generation	  cephalosporins	  were	  given	  
to	  children	  with	  CAP	  in	  40.4%	  and	  31.7%	  of	  cases,	  respectively.	  Penicillin	  was	  used	  in	  25%	  of	  cases	  
[83].	   In	  an	   Italian	  1-­‐day	  point-­‐prevalence	  survey	  on	  antimicrobial	  use	   in	  hospitalized	  neonates	  and	  
children	   in	   2012,	   the	   main	   indication	   for	   treatment	   in	   children	   was	   LRTI	   (34%),	   with	   higher	  
prevalence	  of	  third-­‐generation	  cephalosporins	  (43.3%)	  followed	  by	  macrolides	  accounting	  for	  26.8%.	  
No	  ampicillin/amoxicillin	  prescription	  was	  reported	  [76].	  
Association	   of	   aminopenicillins	   was	   found	   to	   be	   often	   prescribed:	   amoxicillin	   +	   clavulanate	   was	  
reported	   to	  be	   the	  most	  used	   therapy	  by	  studies	  conducted	   in	  Saudi	  Arabia	   [51],	  France	   [63],	  and	  
India	  [58],	  and	  a	  study	  conducted	  in	  Iraq,	  by	  Younis,	  reported	  that	  ampicillin	  +	  cloxacillin,	  alone	  and	  
in	  combination,	  accounted	   for	  50%	  of	   the	  antibiotic	  prescriptions	   for	   the	  children	  with	   respiratory	  
tract	  infections	  [50].	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One	   study,	   in	   particular,	   reported	   a	   high	   rate	   of	   prescriptions	   of	  macrolides.	   It	   was	   conducted	   in	  
Norway,	  by	  Fossum	  and	  colleagues,	  and	  included	  the	  prescriptions	  of	  general	  practitioners	  in	  case	  of	  
respiratory	  tract	  infections	  in	  patients	  <	  6	  years.	  They	  found	  that	  macrolides	  were	  prescribed	  in	  44%	  
of	   the	   cases	   of	   pneumonia,	   more	   than	   penicillin	   V,	   which	   was	   used	   in	   31%,	   and	   that	   extended	  
spectrum	  penicillin	  accounted	  for	  24%	  of	  the	  prescriptions	  [55].	  
Studies	  on	  the	  appropriateness	  of	  prescriptions	  or	  prescriber	  behavior	  were	  also	  found.	  In	  addition	  
to	   the	   aforementioned	   French	   study,	   Maltezou	   et	   al.	   showed	   how	   Greek	   private-­‐practice	  
pediatricians	   guidelines	   compliance	   is	   only	   around	   30.6%	   [64].	   Moreover,	   Ceyhan	   et	   al.,	   in	   a	  
multicenter	   point-­‐prevalence	   survey	   with	   respiratory	   infection	   as	   main	   diagnosis,	   showed	   how	  
cephalosporins	   and	   penicillin	   (most	   of	   the	   time	   combined	   with	   b-­‐lactamase	   inhibitors)	   were	  
improperly	   prescribed	   in	   36.1%	  and	  43.7%	  of	   cases,	   respectively.	   These	   analyses	  highlighted	  how,	  
even	  now,	  adherence	  to	  guidelines	  is	  still	   low.	  On	  the	  other	  hand,	  Usonis	  and	  colleagues	  through	  a	  
questionnaire	  developed	  and	  distributed	  by	  the	  CAP	  Pediatric	  Research	  Initiative	  (CAP-­‐PRI)	  working	  
group	   and	   distributed	   across	   Europe	   showed	   high	   adherence	   to	   CAP	   guidelines,	   with	   a	   high	  
prescription	  rate	  of	  narrow-­‐spectrum	  penicillin	  for	  inpatients	  (amoxicillin	  (32%)	  and	  ampicillin	  (37%))	  
and	  outpatients	  (amoxicillin	  (84%))	  [81].	  
An	  encouraging	   result	   is	   that	  almost	  a	  half	   (15/38)	  of	   the	   studies	   included	   in	   this	   review	   reported	  
high	  rates	  of	  single	  therapy	  aminopenicillin	  or	  penicillin	  prescriptions.	  These	  studies	  were	  conducted	  
in	  Brasil	   [75],	  Guyana	   [79],	   India	   [65],	  Mongolia	   [6],	  Nigeria	   [70],	   Tanzania	   [56],	  USA	   [80],	  Uganda	  
[69],	   and	   France	   [78],	   showing	   that	   the	   current	   guidelines	   are	   applied	   in	   both	   developed	   and	  
developing	   countries.	   The	   study	   by	   Awor	   et	   al.	   in	   Uganda	   in	   2015	   offers	   an	   important	   cause	   for	  
reflection,	  since	   it	   shows	  that	  adherence	  to	  guidelines	  may	  be	  successfully	   implemented	  even	   in	  a	  
nonhospital	  environment.	   In	  their	  8-­‐month	  quasi-­‐experimental	  analysis,	  they	  investigated	  the	  visits	  
and	  the	  prescriptions	  made	  by	  drug	  shop	  sellers,	  underlining	  how	  this	  class	  of	  health	  workers	  plays	  
an	  important	  role	  in	  providing	  healthcare	  to	  populations	  in	  rural	  areas.	  Their	  result	  is	  that	  91%	  of	  the	  
children	  with	  pneumonia	  that	  were	  visited	  by	  drug	  shop	  sellers	  received	  amoxicillin,	  the	  highest	  rate	  
of	  its	  prescription	  among	  all	  the	  studies	  included	  in	  this	  review	  [69].	  
Some	   data	   of	   antimicrobial	   prescriptions	   have	   been	   derived	   from	   point-­‐prevalence	   surveys	   (PPS),	  
including	  Australia	   [66,	   82],	  Mexico,	   Colombia,	   Argentina,	   Singapore,	   and	   European	   countries	   [48,	  
49,	  81,	  82].	  CAP	  was	  not	  the	  only	  analyzed	  disease,	  but	  the	  LRTI	  category	  was	  the	  most	  represented.	  
Even	  though	  antimicrobial	  prescriptions	  were	  not	  specific	  only	  to	  CAP,	  PPS	  data	  were	  similar	  to	  the	  
results	  of	  those	  other	  studies	  that	  were	  performed	  in	  the	  same	  country,	  but	  specifically	  designed	  for	  
CAP.	  
	  133	  
Another	   interesting	   result	   is	   that	   the	   development	   of	   a	   local	   antimicrobial	   stewardship	   program	  
could	  reduce	  inappropriate	  antimicrobial	  use	  and	  bacterial	  resistance,	  enhance	  patients’	  safety,	  and	  
lower	   drug	   costs	   [84].	   Moreover,	   global	   PPS	   could	   be	   a	   reliable	   and	   feasible	   tool	   for	   monitoring	  
antimicrobial	  prescriptions	  all	  over	  the	  world.	  
	  
Finally,	  it	  is	  also	  worthy	  of	  notice	  how	  data	  from	  certain	  countries	  were	  not	  available	  despite	  interest	  
in	   the	   improvement	   of	   antibiotic	   prescription.	   For	   example,	   we	   did	   not	   find	   any	   report	   about	  
pediatric	  CAP	  antibiotic	  treatment	  in	  Canada,	  even	  extending	  the	  research	  to	  2005–2010.	  Likewise,	  
we	   did	   not	   find	   any	   study	   set	   in	   other	   important	   countries,	   like	   China	   and	   Russia.	   It	   is	   worth	  
remembering	   that	   the	   reduction	   of	   antimicrobial	   therapy	   and	   of	   microbial	   resistance	   is	   a	   global	  




In	   the	   last	   10	   years,	   many	   guidelines	   on	   the	   optimal	   treatment	   for	   childhood	   CAP	   have	   been	  
published,	   with	   the	   aim	   of	   optimizing	   pediatric	   CAP	   antibiotic	   prescriptions.	   Our	   review	  
demonstrates	  that	  the	  implementation	  of	  these	  guidelines	  is	  still	  limited	  but	  also	  that	  achieving	  the	  
optimal	  prescription	  is	  possible	  and	  can	  be	  done	  in	  both	  developed	  and	  developing	  countries.	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Background:	  Italian	  pediatric	  antimicrobial	  prescription	  rates	  are	  among	  the	  highest	  in	  Europe.	  As	  a	  
first	   step	   in	   an	   Antimicrobial	   Stewardship	   Program,	   we	   implemented	   a	   Clinical	   Pathway	   (CP)	   for	  
Community	   Acquired	   Pneumonia	   with	   the	   aim	   of	   decreasing	   overall	   prescription	   of	   antibiotics,	  
especially	  broad-­‐spectrum.	  
Materials	   and	   methods:	   The	   CP	   was	   implemented	   on	   10/01/2015.	   We	   collected	   antibiotic	  
prescribing	   and	   outcomes	   data	   from	   children	   aged	   3	   months-­‐15	   years	   diagnosed	   with	   CAP	   from	  
10/15/2014	   to	   04/15/2015	   (pre-­‐intervention	   period)	   and	   from	   10/15/2015	   to	   04/15/2016	   (post-­‐
intervention	  period).	  	  
We	   assessed	   antibiotic	   prescription	   differences	   pre-­‐	   and	   post-­‐CP	   including	   rates,	   breadth	   of	  
spectrum,	  and	  duration	  of	   therapy.	  As	  balancing	  measures,	  we	  determined	   length	  of	  hospital	   stay	  
for	  inpatients	  and	  treatment	  failure	  for	  inpatients	  and	  outpatients.	  Chi-­‐square	  and	  Fisher’s	  exact	  test	  
were	   used	   to	   compare	   categorical	   variables	   and	   Wilcoxon	   rank	   sum	   test	   was	   used	   to	   compare	  
quantitative	  outcomes.	  	  
Results:	  120	   pre-­‐	   and	   86	   post-­‐intervention	   clinic	   visits	  were	   identified	  with	   a	   diagnosis	   of	   CAP.	   In	  
outpatients,	  we	  observed	   a	  decrease	   in	   broad-­‐spectrum	   regimens	   (50%	  pre-­‐CP	   vs.	   26.8%	  post-­‐CP,	  
p=0.02),	  in	  particular	  macrolides,	  and	  an	  increase	  in	  narrow-­‐spectrum	  (amoxicillin)	  post-­‐CP.	  Post-­‐CP	  
children	  received	  fewer	  antibiotic	  courses	  (median	  DOT	  from	  10	  pre-­‐CP	  to	  8	  post-­‐CP,	  p<0.0001)	  for	  
fewer	   days	   (median	   LOT	   from	   10	   pre-­‐CP	   to	   8	   post-­‐CP,	   p<0.0001)	   than	   their	   pre-­‐CP	   counterparts.	  
Physicians	   prescribed	   narrow-­‐spectrum	   monotherapy	   more	   frequently	   than	   broad-­‐spectrum	  
combination	   therapy	   (DOT/LOT	   ratio	   1.157	   pre-­‐CP	   vs.	   1.065	   post-­‐CP).	   No	   difference	   in	   treatment	  
failure	   was	   reported	   before	   and	   after	   implementation	   (2.3%	   pre-­‐CP	   vs.	   11.8%	   post-­‐CP,	   p=0.29).	  
Among	   inpatients	  we	   also	   noted	   a	   decrease	   in	   broad-­‐spectrum	   regimens	   (100%	   pre-­‐CP	   vs.	   66.7%	  
post-­‐CP,	  p=0.02)	  and	  the	   introduction	  of	  narrow-­‐spectrum	  regimens	  (0%	  pre-­‐CP	  vs.	  33.3%	  post-­‐CP,	  
p=0.02)	  post-­‐CP.	  Hospitalized	  patients	  received	  fewer	  antibiotic	  courses	  post-­‐CP	  (median	  DOT	  from	  
18.5	  pre-­‐CP	   to	  10	  post-­‐CP,	  p=0.004),	  while	   there	  was	  no	   statistical	  difference	   in	   length	  of	   therapy	  
(median	  LOT	  from	  11	  pre-­‐CP	  to	  10	  post-­‐CP,	  p=0.06).	   In	  particular,	  days	  of	  broad-­‐spectrum	  therapy	  
were	  notably	  lower	  post-­‐CP	  (median	  bsDOT	  from	  17	  pre-­‐CP	  to	  4.5	  post-­‐CP,	  p	  <0.0001).	  No	  difference	  
in	  treatment	  failure	  was	  reported	  before	  and	  after	  CP	  implementation	  (16.7%	  pre-­‐CP	  vs.	  15.4%	  post-­‐
CP,	  p	  =	  1).	  
Conclusions:	   Introduction	  of	  a	  CP	  for	  CAP	  in	  a	  Pediatric	  Emergency	  Department	  led	  to	  reduction	  of	  
broad-­‐spectrum	  antibiotic	  prescriptions,	  of	  combination	  therapy	  and	  of	  duration	  of	  treatment	  both	  




Pneumonia	   is	   the	   single	   greatest	   cause	   of	   death	   in	   children	   worldwide:	   1-­‐4%	   of	   the	   pediatric	  
population	   is	   treated	   every	   year	   for	   community	   acquired	   pneumonia	   (CAP)	   and	   0.1-­‐2%	   of	   those	  
children	  are	  hospitalized	  [1-­‐3].	  
Inpatient	  healthcare	  costs	  associated	  with	  CAP	  are	  estimated	  to	  be	  more	  than	  one	  billion	  dollars	  per	  
year	  [4].	  
Inappropriate	  antibiotic	  prescribing	  for	  CAP	  has	  been	  frequently	  reported,	  as	  many	  patients	  receive	  
antibiotics	   for	   viral	   pneumonia	   or	   broad-­‐spectrum	   antibiotics	   for	   uncomplicated	   bacterial	  
pneumonia	  [5].	  The	  Italian	  antimicrobial	  prescription	  rate	  is	  one	  of	  highest	  in	  the	  EU	  (52%)	  [6],	  and	  
antibiotic	   resistance	   has	   become	   a	   serious	   health	   threat	   with	   high	   social	   costs	   and	   severe	  
consequences	   including	   prolonged	   illness,	   increased	   length	   of	   hospitalization	   and	   mortality	   [6].	  
Increasing	   penicillin	   and	   macrolide	   resistance	   of	   Streptococcus	   pneumoniae	   strains	   pose	   an	  
important	   threat	   to	   effective	   treatment	   [7].	   There	   is	   also	   widespread	   β-­‐lactamase	   production	   in	  
Haemophilus	  influenzae	  and	  macrolide	  resistance	  in	  Streptococcus	  pyogenes	  [8].	  	  
Thus,	   it	   is	   imperative	   to	   reduce	   improper	   use	   of	   these	   drugs.	   Clinical	   Pathways	   (CPs)	   along	   with	  
educational	   programs	   have	   shown	   to	   be	   a	   reasonable	   and	   feasible	   first	   step	   for	   Antimicrobial	  
Stewardship	  Program	  (ASP)	  implementation	  by	  reducing	  antibiotic	  prescriptions	  in	  both	  community	  
and	  in-­‐hospital	  settings	  [9-­‐13].	  
To	   date,	   ASPs	   have	   primarily	   targeted	   the	   inpatient	   setting,	   and	   there	   is	   a	   paucity	   of	   literature	  
regarding	   antimicrobial	   stewardship	   strategies	   in	   the	   Pediatric	   Emergency	   Department	   (PED),	  
despite	  the	  substantial	  proportion	  of	  antibiotics	  prescribed	  to	  children	  in	  this	  setting	  [14-­‐17].	  Since	  
PEDs	   are	  uniquely	  positioned	  at	   the	   interface	  of	   inpatient	   and	  outpatient	   settings,	   PED	  physicians	  
could	  have	  a	  consistent	  impact	  on	  prescribing	  trends	  in	  both	  locations.	  	  
In	   the	   PED	   setting,	   challenges	   include	  high	   turnover	   rates	   for	   both	   patients	   and	  practitioners,	   the	  
need	  for	  rapid	  decision-­‐making,	  and	  diagnostic	  uncertainty	  in	  empiric	  prescription	  [18].	  
Since	   CPs	   have	   been	   effective	   in	   reducing	   antibiotic	   prescriptions	   in	   primary	   care	   and	   in	   hospital	  
settings,	  we	  hypothesized	  that	  their	  implementation	  in	  the	  PED	  could	  decrease	  overall	  prescription	  
of	  antibiotics,	  especially	  broad-­‐spectrum,	  for	  common	  infectious	  diseases	  such	  as	  CAP	  [9-­‐13].	  	  
	  
The	  primary	  aim	  of	   this	   study	  was	   to	  assess	  changes	   in	  antibiotic	  prescription	  before	  and	  after	  CP	  
implementation	  for	  CAP	  in	  a	  large	  Italian	  PED.	  Secondary	  aims	  were	  to	  compare	  treatment	  failures	  
before	  and	  after	  CP	  implementation.	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Materials	  and	  methods	  
	  
Study	  design	  
The	  study	  was	  set	  at	  the	  PED	  of	  the	  Department	  for	  Women	  and	  Children	  Health	  at	  Padua	  University	  
Hospital.	   Our	   Children’s	   Hospital	   provides	   primary	   and	   secondary	   care	   for	   a	  metropolitan	   area	   of	  
350,000	  people	   (45,000	  younger	   than	  15	  years)	  and	   tertiary	   care	   for	  a	   regional	  and	  extra-­‐regional	  
population,	  with	   approximately	   26,000	   PED	   visits	   per	   year	   and	   an	   overall	   hospital	   admission	   rate	  
from	  PED	  of	  around	  7	  out	  of	  100	  visits.	  
From	  the	  PED,	  children	  with	  moderate-­‐severe	  CAP	  are	  usually	  admitted	  to	  the	  Pediatric	  Acute	  Care	  
Unit	   (PACU),	   an	   acute	   care	   unit	   near	   the	   emergency	   department,	  which	   shares	  the	   same	  medical	  
staff.	  
This	   is	   a	   pre-­‐post	   quasi-­‐experimental	   study	   that	   assesses	   the	   changes	   in	   antibiotic	   prescribing	   for	  
CAP	  during	  a	  6-­‐month	  period	  preceding	  CP	  implementation	  (pre-­‐intervention,	  from	  15	  October	  2014	  
to	   15	  April	   2015)	   and	   during	   the	   six	  months	   after	   CP	   implementation	   (post	   intervention,	   from	  15	  
October	  2015	  to	  15	  April	  2016).	  The	  decision	  to	  analyse	  the	  same	  period	  in	  different	  years	  was	  made	  
in	  order	  to	  limit	  the	  effects	  of	  seasonality.	  
	  
Intervention	  
On	  1	  October	  2015	  CPs	  for	  the	  management	  of	  CAP	  were	  implemented.	  	  
The	  CP	  is	  a	  one-­‐page	  decision	  support	  algorithm	  designed	  to	  assist	  providers	  in	  determining	  whether	  
an	  antibiotic	  should	  be	  prescribed,	  and	  if	  so,	  the	  optimal	  agent	  and	  duration	  of	  therapy.	  
The	   CP	   summarizes	   international	   guidelines	   [1,8]	   for	   the	   diagnosis	   and	   treatment	   of	   the	   clinical	  
condition	   and	   was	   developed	   by	   the	   Division	   of	   Pediatric	   Infectious	   Diseases	   and	   Pediatric	  
Emergency	  Department	  of	  Padua	  in	  collaboration	  with	  the	  Division	  of	  Pediatric	  Infectious	  Diseases	  of	  
the	  Children’s	  Hospital	  of	  Philadelphia.	  
Three	  CP	  training	  sessions	  (two	  during	  the	  first	  weeks	  of	  October	  and	  one	  during	  the	  first	  week	  of	  
November)	  were	  presented	   to	  PED	  and	  Pediatric	  Acute	  Care	  Unit	   (PACU)	  physicians	  and	   residents	  
along	  with	  an	  overview	  of	  the	  guidelines,	  the	  rationale	  behind	  the	  treatment.	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Study	  population	  
All	  patients	  aged	  between	  3	  months	  and	  15	  years	  with	   International	  Classification	  of	  Diseases,	  9th	  
Revision,	   Clinical	  Modification	   (ICD-­‐9-­‐CM)	   codes	  485	  and	  486	  at	   discharge	  diagnosis	   or	   descriptive	  
diagnosis	  of	  CAP	  were	  included.	  
Exclusion	   criteria	   were:	   cystic	   fibrosis	   or	   other	   chronic	   pulmonary	   diseases	   (except	   for	   asthma),	  
immunodeficiency	  or	  immunosuppressive	  therapy,	  sickle	  cell	  disease,	  tracheostomy,	  patients	  at	  risk	  
for	  aspiration	  pneumonia,	  hospitalization	  during	  previous	  30	  days,	  concomitant	   infections,	  ongoing	  
antibiotic	  therapy.	  
Participating	  patients	  were	  divided	  in	  two	  groups:	  -­‐ Outpatients:	  patients	  evaluated	  at	  the	  PED	  and	  discharged;	  -­‐ Inpatients:	  patients	  admitted	  to	  the	  PACU.	  
	  
Data	  source	  
All	  patients	  with	  a	  clinical	  diagnosis	  of	  pneumonia	  (medical	  progress	  notes)	  or	  documentation	  of	  a	  
chest	   infiltrate	   (radiology	   notes)	   were	   included.	   All	   clinical,	   demographic,	   diagnostic	   and	  
antimicrobial	   data	   were	   manually	   collected	   from	   electronic	   medical	   records,	   using	   a	   password	  
protected	  REDCap®	  data	  collection	  form	  and	  stored	  in	  the	  secure	  server	  at	  the	  University	  of	  Padua.	  
We	   considered	   treatment	   based	   on	   amoxicillin	   or	   ampicillin	   alone	   narrow-­‐spectrum.	   Broad-­‐
spectrum	  antimicrobials	  were	  defined	  as:	  β-­‐lactam	  and	  β-­‐lactamase	  inhibitor	  combinations,	  second-­‐	  
and	  third-­‐generation	  cephalosporins,	  clindamycin,	  glycopeptides,	   fluoroquinolones	  and	  macrolides.	  
Therapeutic	   regimens	   including	   at	   least	   one	   broad-­‐spectrum	   prescription,	   despite	   the	   association	  
with	  amoxicillin,	  were	  considered	  broad-­‐spectrum.	  In	  line	  with	  expert	  consensus	  CAP	  guidelines	  [1],	  
our	  CP	  suggested	  a	  dosage	  of	  amoxicillin	  of	  90	  mg/kg/day	  divided	  every	  8	  hours.	  
Amoxicillin	   per	   os	   rather	   than	   penicillin	   G	   is	   recommended	   due	   to	   its	   better	   gastrointestinal	  
absorption	  and	  higher	  levels	  in	  blood	  and	  lung	  parenchyma	  [1,19].	  	  
Privacy	  was	  guaranteed	   in	  two	  ways:	  a	  unique,	  study	  specific	  survey	  number	  was	  assigned	  to	  each	  
patient	  and	  no	  personally	  identifying	  data	  were	  collected.	  
To	  evaluate	  the	  effectiveness	  and	  safety	  of	  the	  intervention,	  follow	  up	  phone	  calls	  to	  the	  family	  were	  
made	  within	  30	  days	  to	  assess	  for	  treatment	  failure,	  defined	  as	  new	  admission,	  prescription	  of	  a	  new	  
antibiotic	  for	  persistence	  or	  relapse	  of	  symptoms	  or	  for	  drug	  side	  effects	  (eg	  rash,	  diarrhea)	  within	  
30	  days	  after	  discharge,	  and/or	  side	  effects.	  	  
Admissions	   for	   CAP	   in	   the	   same	   patient	   occurring	   greater	   than	   30	   days	   apart	   were	   analysed	   as	  
separate	  events.	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This	   study	   was	   approved	   by	   the	   Institutional	   Review	   Board	   of	   Department	   for	  Woman	   and	   Child	  
Health	  at	  the	  University	  of	  Padua.	  
	  
Determination	  of	  outcomes	  
Primary	  outcome	  
The	   following	   aspects	   of	   antibiotic	   prescriptions	   for	   CAP	  were	   assessed	   every	  month	   over	   the	   six	  
months	  before	  and	  the	  six	  months	  after	  CP	  implementation:	  -­‐ Prevalence	  of	  antimicrobial	  prescriptions	  by	  active	  agent;	  -­‐ Duration	  of	  therapy	  expressed	  in	  Days	  of	  therapy	  (DOT)	  and	  Length	  of	  Therapy	  (LOT)	  [20-­‐22],	  
DOT/LOT	  ratio,	  median	  DOTs	  of	  broad-­‐spectrum	  antibiotics	  (bsDOTs)	  and	  bsDOT/DOT	  ratio.	  -­‐ Dosage	  of	  the	  most	  frequently	  prescribed	  antibiotics,	  expressed	  in	  mg/kg/day;	  -­‐ Length	  of	  hospital	  stay	  (LOS)	  for	  inpatients.	  
	  
Secondary	  outcome	  
Thirty	   day	   treatment	   failures	   investigated	   through	   a	   phone	   call,	   defined	   as:	   changes	   in	   antibiotic	  
prescription	  for	  persistence	  or	  worsening	  of	  symptoms;	  treatment	  changes	  for	  antibiotic	  side	  effects	  





Results	  are	  summarized	  as	  frequencies	  and	  proportions	  for	  categorical	  variables	  and	  as	  median	  and	  
range	  for	  quantitative	  variables.	  
Comparisons	   of	   categorical	   and	   quantitative	   variables	  were	   conducted	  with	   chi-­‐square	   or	   Fisher’s	  
exact	   test	   and	  Wilcoxon	   rank	   sum	   test	   respectively,	   since	   the	   data	  were	   not	   normally	   distributed	  
(Shapiro-­‐Wilk	   test).	   Statistical	   significance	   was	   declared	   for	   p	   ≤0.05.	   Statistical	   analysis	   was	  
conducted	  with	  SAS	  9.2	  (SAS	  Institute,	  Inc.,	  Cary,	  NC)	  for	  Windows.	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Results	  
Over	   the	  6-­‐month	  pre-­‐intervention	  period,	  13,262	  children	  were	  evaluated	   in	   the	  PED	  and	  12,335	  
children	  were	  seen	  during	  the	  6-­‐month	  post-­‐intervention	  period.	  
During	   the	   pre-­‐intervention	   period,	   120	   patients	  were	   diagnosed	  with	   CAP,	   accounting	   for	   0.90%	  
(120/13,262)	   of	   total	   PED	   visits.	   In	   the	   post-­‐intervention	   period	   86/12,335	   (0.70%)	   children	  were	  
evaluated	  for	  CAP.	  Of	  these,	  70/120	  (58.3%)	  children	  and	  59/86	  (68.6%)	  met	  the	  inclusion	  criteria	  in	  




Fig	  1.	  Flowchart	  of	  children	  enrolled	  during	  the	  pre	  and	  post-­‐intervention	  period.	  
	  
	  
Characteristics	  of	  the	  studied	  population	  
Variables	   including	   sex,	   age,	   severity	   and	   time	   of	   disease	   were	   assessed	   in	   pre-­‐	   and	   post-­‐CP	  
populations.	  The	  two	  groups	  were	  similar	  with	  respect	  to	  sex	  (p=0.76):	  50.0%	  (35/70)	  females	  pre-­‐
intervention	  and	  54.2%	  (28/59)	  post-­‐intervention.	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Age	  was	  stratified	  into	  three	  age	  ranges:	  3	  months-­‐2	  years,	  2	  years-­‐5	  years	  and	  5	  years-­‐15	  years.	  In	  
both	  groups,	  the	  highest	  prevalence	  of	  CAP	  was	  reported	  in	  the	  2-­‐5	  years	  group	  with	  55.7%	  (39/70)	  
pre	   and	   61.0%	   (36/59)	   post-­‐intervention	   respectively	   (p=0.44).	   The	   same	   analysis	   was	   performed	  
also	  for	  excluded	  patients	  with	  similar	  results.	  
To	  describe	  prescription	  trends	  over	  time,	  both	  groups	  were	  divided	  in	  four	  sub-­‐periods	  of	  45	  days	  
each.	  	  
For	   both	   the	   inpatient	   and	   outpatient	   groups,	   there	   was	   no	   statistically	   significant	   difference	   in	  
frequency	   or	   proportion	   of	   patients	   diagnosed	   with	   Mycoplasma	   pneumoniae	   by	   serology.	  
Proportion	   of	   inpatients	   presenting	  with	   hypoxemia	   and	  with	   pleural	   effusion	  were	   similar	   in	   the	  








Included	  Patients	   70	   59	  
Included	  0utpatients	  
56	   (80.0%	   of	  
included	  patients)	  
41	   (69.5%	   of	  
included	  patients)	  
	  	   N	   %	   N	   %	  
Sex	  
m	   24	   42.9	   19	   46.3	  
0.73	  
f	   32	   57.1	   22	   53.7	  
Age	  
3	  mo	  -­‐	  2	  yr	   12	   21.4	   9	   22.0	  
0.10	  2	  yr	  -­‐	  5	  yr	   31	   55.4	   29	   70.7	  
5	  yr	  -­‐	  15	  yr	   13	   23.2	   3	   7.3	  
Period	  
15	  Oct	  -­‐	  30	  Nov	   0	   0	   6	   14.6	  
<0.0001	  
1	  Dec	  -­‐	  15	  Jan	   25	   44.6	   17	   41.5	  
16	  Jan	  -­‐	  28/29	  Feb	   14	   25.0	   18	   43.9	  
1	  Mar	  -­‐	  15	  Apr	   17	   30.4	   0	   0	  
Mycoplasma	  
Pneumoniae	  
IgM	  	  test	  	  
performed	   1	   1.8	   3	   7.3	  
0.31	  
not	  performed	   55	   98.2	   38	   92.7	  
Number	   of	   M.	   Pneumoniae	   IgM	  
positive	   test/number	   of	   test	  
performed	  
1	   100	   0	   0	   0.40	  









Included	  Patients	   70	   59	  
Included	  Inpatients	  
14	  (20.0%	  of	  included	  
patients)	  
18	  (30.5%	  of	  included	  
patients)	  
	  
N	   %	   N	   %	  
Sex	  
m	   11	   78.6	   8	   44.4	  
0.11	  
f	   3	   21.4	   10	   55.6	  
Age	  
3	  mo	  –	  2	  yr	   4	   28.6	   7	   38.9	  
0.87	  2	  yr	  –	  5	  yr	   8	   57.2	   7	   38.9	  
5	  yr	  –	  15	  yr	   2	   14.2	   4	   22.2	  
Period	  
15	  Oct	  –	  30	  Nov	   1	   7.1	   2	   11.1	  
0.02	  
1	  Dec	  –	  15	  Jan	   2	   14.2	   6	   33.3	  
16	  Jan	  –	  28/29	  Feb	   5	   35.7	   10	   55.6	  
1	  Mar	  –	  15	  Apr	   6	   43.0	   0	   0	  
Mycoplasma	  
Pneumoniae	  IgM	  	  
test	  
performed	   8	   57.1	   13	   72.2	  
0.47	  
not	  performed	   6	   42.9	   5	   27.8	  
Number	  of	  M.	  pneumoniae	  IgM	  positive	  
test/number	  of	  test	  performed	  
3	   37.5	   2	   15.4	   0.33	  
Hypoxia	   8	   57.1	   11	   72.2	   1	  
Pleural	  effusion	   4	   28.6	   3	   16.7	   0.67	  
Chest	  Drainage	   1	   7.1	   0	   0	   0.44	  
	  
Table	  2.	  Characteristics	  of	  inpatient	  population	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Antibiotic	  prescription	  in	  outpatients	  
	  
Changes	  in	  prevalence	  of	  antibiotic	  prescriptions	  for	  CAP	  	  
Before	   implementation	   50%	   of	   children	   (28/56)	   received	   exclusively	   amoxicillin,	   compared	   with	  
73.2%	  (30/41)	  after	  CP	  release;	  prescriptions	  for	  broad-­‐spectrum	  antibiotics	  also	  decreased.	  Due	  to	  
the	   high	   prevalence	   of	   combination	   therapy,	   further	   analysis	   on	   antibiotic	   prescriptions	   were	  
performed	  using	  Days	  of	  Therapy	  (DOTs)	  for	  each	  patient.	  The	  median	  DOT	  for	  the	  pre-­‐intervention	  
period	  was	  10	   (range,	  5-­‐26),	   the	  median	  DOT	   for	   the	  post-­‐intervention	  period	  was	  8	   (range,	  5-­‐20)	  
(p<0.0001).	  	  
The	  median	  DOT	  was	  calculated	  for	  every	  sub-­‐period	  of	  observation	  (Figs	  2a	  and	  2b).	  	  
DOTs	   analysis	   for	   each	  antimicrobial	   reflected	   the	  prescriptions	  prevalence.	   Statistically	   significant	  
increase	   in	  use	  of	   amoxicillin	   (54.5%	  pre-­‐CP	   vs.	   71.1%	  post-­‐CP,	   p	   <0.0001)	   and	  decrease	   in	  use	  of	  
macrolides	   (21.3%	   pre-­‐CP	   vs.	   6.4%	   post-­‐CP,	   p	   <0.0001)	   was	   observed.	   Cephalosporins	   and	  
amoxicillin-­‐clavulanate	  use	  decreased	  as	  well	  (9.7%	  and	  14.5%	  pre-­‐CP	  vs.	  8.5%	  and	  14.0%	  post-­‐CP),	  
but	  the	  difference	  was	  not	  statistically	  significant.	  
	  
Changes	  in	  prevalence	  of	  broad-­‐spectrum	  antibiotic	  prescriptions	  for	  CAP	  	  
In	  the	  pre-­‐intervention	  period	  the	  median	  bsDOT	  was	  10	  (range	  1-­‐25)	  and	   in	  the	  post-­‐intervention	  
period	  8	  (range	  4-­‐14),	  with	  a	  significant	  and	  stable	  difference	  in	  prescribing	  between	  pre-­‐	  and	  post-­‐
intervention	   groups	   reported	   for	   each	   sub-­‐period	   in	   the	   time	   series	   (Fig	   3).	   As	   a	   result	   pre-­‐
intervention	  bsDOT/DOT	  was	  0,45,	  while	  in	  post-­‐intervention	  it	  was	  0.29.	  
	  
Changes	  in	  duration	  of	  therapy	  	  
For	  treating	  mild	  CAP	  our	  clinical	  pathway	  recommends	  a	  7-­‐day	  antibiotic	  therapy.	  
Pre-­‐intervention	  median	  LOT	  was	  10	  (range	  3-­‐15),	  while	  post-­‐intervention	  median	  LOT	  was	  8	  (range	  
5-­‐10)	   (p<0.0001)	   according	   to	   the	   pathway,	   with	   a	   decreasing	   trend	   over	   all	   sub-­‐periods	   after	  
implementation.	  
DOT/LOT	   ratio	   indicates	   use	   of	   combination	   therapy	   and	   the	   length	   of	   therapy:	   pre-­‐intervention	  
DOT/LOT	   was	   1.16,	   post-­‐intervention	   1.07.	   Specifically,	   during	   the	   related	   sub-­‐periods,	   pre-­‐CP	  
DOT/LOT	  was	  included	  between	  1.25	  and	  1.08,	  post-­‐CP	  ratio,	  instead,	  ranged	  from	  1.19	  to	  1.04	  (Figs	  
2c	  and	  2d).	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Fig	   2a.	   Median	   DOT	   pre	   and	   post-­‐implementation	   for	   outpatients;	   2b.	   DOT	   over	   time	   for	   outpatients;	  













Fig	  3.	  bsDOT/DOT	  for	  outpatients.	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Changes	  in	  dosage	  for	  the	  most	  commonly	  prescribed	  antibiotic	  for	  CAP	  	  
The	  most	  commonly	  prescribed	  antibiotic	  for	  outpatients	  with	  CAP	  was	  amoxicillin.	  Pre-­‐intervention	  
median	   dosage	   corresponds	   to	   82.9mg/kg/day	   (range	   28.6-­‐102).	   Post-­‐intervention	  median	   dosage	  





Fig	  4.	  Median	  amoxicillin	  dosage	  over	  time.	  
	  
	  
Antibiotic	  prescription	  in	  inpatients	  
	  
Changes	  in	  prevalence	  of	  antibiotic	  prescriptions	  for	  CAP	  in	  inpatients	  	  
We	   observed	   an	   increase	   in	   narrow-­‐spectrum	   regimens	   prescribed	   in	   the	   post-­‐CP	   period:	   6/18	  
children	   (33.3%)	   after	   CP	   implementation	   received	   exclusively	   narrow-­‐spectrum	   antibiotics	   in	  
contrast	  with	  0%	  in	  the	  pre-­‐intervention	  period	  (p=0.02).	  Broad-­‐spectrum	  antibiotics	  also	  showed	  a	  
decreasing	  trend	  (14/14	  pre-­‐CP,	  12/18	  post-­‐CP).	  
Median	  DOT	  for	  the	  pre-­‐intervention	  period	  was	  18.5	  days	  (range	  11-­‐32),	  for	  the	  post-­‐intervention	  it	  
was	  10	  (range	  3-­‐26)	  (p=0.004)	  (Table	  3).	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We	  reported	  a	  statistically	  significant	  increase	  in	  use	  of	  ampicillin	  and	  amoxicillin	  and	  a	  concomitant	  
decrease	   in	   use	   of	   cephalosporins	   and	   macrolides.	   Furthermore,	   use	   of	   amoxicillin-­‐clavulanate,	  
ampicillin-­‐sulbactam,	  carbapenems	  and	  glycopeptides	  was	  abandoned.	  Clindamycin	  was	  prescribed	  
only	  in	  the	  post-­‐CP	  period.	  
	  
Table	  3.	  Total	  DOT	  for	  each	  type	  of	  antibiotic	  prescribed.	  
	  
Changes	  in	  prevalence	  of	  broad-­‐spectrum	  antibiotic	  prescriptions	  for	  CAP	  	  
Broad-­‐spectrum	   antibiotic	   use	   was	   assessed	   through	   median	   bsDOTs:	   pre-­‐intervention	   median	  
bsDOT	  was	   17	   (range	   11-­‐24)	   and	   it	   decreased	   to	   4.5	   (range	   1-­‐23)	   in	   the	   post-­‐intervention	   period	  
(p<0.0001).	  
Broad-­‐spectrum	  in	  relation	  to	  overall	  antibiotic	  use	  evaluated	  through	  bsDOT/DOT	  ratio	  decreased	  









14	   18	  
Total	  DOT	   295	   200	  
	  	   N	   %	  of	  DOT	   N	   %	  of	  DOT	  
Ampicillin	   0	   0	   15	   7.5	   <0.0001	  
Amoxicillin	   33	   11.2	   98	   49.0	   <0.0001	  
Cephalosporins	   89	   30.2	   43	   21.5	   0.03	  
Macrolides	   80	   27.1	   32	   16.0	   0.004	  
Amoxicillin-­‐
clavulanate	  
14	   4.7	   0	   0	   0.002	  
Ampicillin-­‐
sulbactam	  
15	   5.1	   0	   0	   0.001	  
Carbapenems	   29	   9.8	   0	   0	   <0.0001	  
Glycopeptide	   35	   11.9	   0	   0	   <0.0001	  
Clindamycin	   0	   0	   12	   6	   <0.0001	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Changes	  in	  duration	  of	  therapy	  and	  length	  of	  stay	  
Pre-­‐CP	  median	  LOT	  was	  11	  days	  (range	  5-­‐17),	  while	  post-­‐CP	  LOT	  was	  10	  days	  (range	  3-­‐15)	  (p=0.06).	  
Pre-­‐intervention	  ratio	  of	  DOT/LOT,	  which	  measures	  the	  quantity	  of	  antibiotics	  prescribed	  per	  day,,	  
was	  1.70,	  while	  post-­‐intervention	  DOT/LOT	  was	  1.26.	  
Median	  LOS	  in	  the	  pre-­‐CP	  period	  was	  5	  days	  (range	  3-­‐16)	  and	  in	  the	  post-­‐CP	  period,	  4	  days	  (range	  2-­‐
14)	  (p=0.23).	  
	  
Changes	  in	  dosage	  for	  the	  most	  commonly	  prescribed	  antibiotics	  for	  CAP	  	  
The	  CAP	  CP	  developed	   for	   this	   study	   recommends	  ampicillin	  dosage	  of	  200-­‐300	  mg/kg/day.	   In	   the	  
pre-­‐CP	  period,	  there	  were	  no	  ampicillin	  prescriptions.	  In	  the	  post-­‐intervention	  period,	  6/18	  (16.7%)	  
patients	  received	  ampicillin	  with	  median	  dosage	  of	  200	  mg/kg/day	  (range	  200-­‐307.7).	  
The	   recommended	   dosage	   of	   ceftriaxone	   in	   our	   CAP	   CP	   is	   50-­‐100	   mg/kg/day.	   Ceftriaxone	   was	  
prescribed	   in	   8/14	   (57.1%)	   pre-­‐CP	   patients	   and	   8/18	   (44.4%)	   post-­‐CP.	   The	  median	   dosage	  was	   75	  
mg/kg/day	  both	  pre-­‐intervention	  (range	  38.5-­‐100)	  and	  post-­‐intervention	  (range	  75-­‐100).	  
	  
Treatment	  failure	  in	  outpatients	  
As	  a	  balancing	  measure,	  we	  assessed	   treatment	   failure:	   44/56	   (78.5%)	   children	  were	  available	   for	  
CAP	  follow-­‐up	  in	  the	  baseline	  period,	  in	  comparison	  with	  37/41	  (90.3%)	  in	  post-­‐intervention	  period.	  	  	  
The	   two	   groups	   were	   compared	   for	   prevalence	   of	   prescriptions:	   amoxicillin	   and	   broad	   spectrum	  
antibiotic	   prescriptions	   did	   not	   show	   significant	   differences	   before	   and	   after	   CP	   implementation,	  
though	  trends	  for	  all	  antibiotics	  indicated	  improvement	  post-­‐intervention	  (Table	  4).	  	  	  
In	   the	  pre-­‐CP	  period,	   treatment	   failure	  occurred	   in	  2.3%	   (1/44)	  of	  cases,	  while	  11.8%	   (4/34)	   failed	  
treatment	   in	   the	  post-­‐CP	  period	   (p=0.29)	   (Fig	  5).	  All	   these	  cases	  consist	  of	  change	  of	  antibiotic	   for	  
persistence	  or	  worsening	  of	  symptoms.	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Fig	  5.	  Outpatients	  treatment	  failure	  flow-­‐chart.	  







Number	  of	  outpatients	  
available	  for	  follow-­‐up	  
44	   34	  
Number	  of	  
prescriptions	  	  
56	   39	  
Prescriptions/patients	  
ratio	  
1.3	   1.1	  
	  	   N	   %	   N	   %	  
Amoxicillin	   28	   50	   25	   64.1	   0.17	  
Cephalosporins	   9	   16.1	   4	   10.3	   0.42	  
Macrolides	   10	   17.8	   3	   7.7	   0.16	  
Amoxicillin-­‐clavulanate	   9	   16.1	   7	   17.9	   0.97	  
	  158	  
Treatment	  failure	  in	  inpatients	  
Twelve	  out	  of	  14	  (85.7%)	  parents	  were	  available	  for	  a	  follow-­‐up	  call	   in	  the	  pre-­‐intervention	  period	  
and	  13/18	   (72.2%)	   in	   the	  post-­‐intervention	  period	   (p=0.36).	   In	   the	  pre-­‐CP	  period	  83.3%	   (10/12)	  of	  
prescribed	   therapy	   was	   effective,	   with	   2/12	   cases	   of	   antibiotic	   change	   during	   hospitalization	   for	  
persistence	   or	   worsening	   of	   symptoms.	   There	   was	   no	   significant	   change	   in	   the	   post-­‐CP	   period,	  
where	  84.6%	   (11/13)	  of	  prescribed	   therapies	  was	  effective	  and	   for	  2/13	  patients’	   antibiotics	  were	  
changed	  for	  persistence	  of	  symptoms	  (Fig	  6;	  Table	  5).	  
	  
Table	  5.	  	  Antibiotics	  prescriptions	  for	  inpatients	  follow-­‐up	  	   	  
	  	   Pre-­‐intervention	  period	   Post-­‐intervention	  period	  
p	  value	  
Number	  of	  inpatients	  
available	  for	  follow-­‐up	  
12	   13	  
Number	  of	  prescriptions	   34	   25	  
Prescriptions/Patients	  
ratio	  
2.8	   1.9	  






Ampicillin	   0	   0	   3	   12	   0.07	  
Amoxicillin	   4	   11.8	   11	   44	   0.01	  
Cephalosporins	   13	   38.3	   7	   28	   0.41	  
Macrolides	   7	   20.6	   3	   12	   0.49	  
Amoxicillin-­‐clavulanate	   1	   2.9	   0	   0	   1	  
Ampicillin-­‐sulbactam	   3	   8.8	   0	   0	   0.25	  
Carbapenems	   2	   5.8	   0	   0	   0.50	  
Glycopeptide	   4	   11.8	   0	   0	   0.13	  
Clindamycin	   0	   0	   1	   4	   0.03	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Fig	  6.	  Inpatients	  treatment	  failure	  flow-­‐chart.	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Discussion	  	  
In	  accordance	  with	  the	  literature,	  the	  highest	  prevalence	  of	  CAP	  was	  observed	  in	  children	  between	  
2-­‐5	  years	  of	  age	  in	  our	  population	  [23].	  
Children	  treated	  as	  outpatients	  were	  all	  patients	  evaluated	  at	  the	  PED	  for	  mild	  CAP	  and	  discharged	  
home.	  The	  two	  groups,	  before	  and	  after	   implementation,	  both	  had	  a	  higher	  prevalence	  of	  females	  
and	  2-­‐5	  year	  olds.	  
Current	  recommendations,	  reflected	  in	  our	  CAP	  CP,	  indicate	  that	  children	  with	  a	  clinical	  diagnosis	  of	  
pneumonia	   should	   receive	   antibiotics,	   as	   bacterial	   and	   viral	   pneumonia	   cannot	   be	   reliably	  
distinguished	  from	  each	  other	  [8].	  Narrow-­‐spectrum	  monotherapy	  (amoxicillin)	  is	  the	  first	  option	  for	  
mild	  CAP	  in	  fully	  immunized	  children,	  as	  S.	  pneumoniae	  accounts	  for	  21-­‐44%	  of	  disease	  [24-­‐29].	  	  
Adding	  β-­‐lactamase	  inhibitors	  (amoxicillin-­‐clavulanate)	  is	  suggested	  in	  case	  of	  β-­‐lactamase	  producing	  
bacteria	   (H.	   influenzae	   type	   B	   and	   S.	   aureus),	   lack	   of	   immunization	   or	   children	   with	   amoxicillin	  
treatment	   in	   the	  previous	  30	  days	   [1,8].	  Use	  of	  macrolides	   is	  only	  appropriate	   if	   atypical	  bacterial	  
ethology	  is	  suspected,	  as	  the	  use	  of	  azithromycin	  has	  been	  associated	  with	  the	  selection	  of	  resistant	  
organisms	  because	  of	  its	  prolonged	  serum	  elimination	  half–life	  [1,8].	  	  
Our	   study	   showed	   relevant	   changes	   in	   physicians’	   prescribing	   behaviours	   for	   outpatients	  
immediately	  after	  CP	  implementation	  and	  after	  6	  months,	  in	  contrast	  to	  findings	  of	  delayed	  effects	  
of	  CPs	  in	  other	  settings	  where	  significant	  effects	  were	  achieved	  only	  during	  the	  second	  year	  of	  the	  
intervention	  [11].	  	  
We	   documented	   an	   increase	   in	   use	   of	   narrow-­‐spectrum	   antibiotics	   and	   concomitant	   decrease	   of	  
broad-­‐spectrum	   ones	   after	   intervention,	   as	   single	   DOT	   analysis	   for	   amoxicillin	   and	   macrolides	  
confirms,	  with	  also	  a	   significant	  decrease	   in	  overall	  median	  DOT	   from	  10	   to	  8.	  This	   trend	  of	   lower	  
bsDOTs	  continues	  throughout	  the	  post-­‐intervention	  period.	  
LOT	   evaluation	   showed	   a	   statistically	   significant	   decrease	   from	   10	   to	   8	   in	   the	   post-­‐CP	   period,	  
approaching	  7	  days	  of	  therapy	  which	  is	  the	  current	  recommendation	  by	  the	  IDSA	  [1].	  This	  indicates	  
that	  during	  the	  post-­‐intervention	  period	  more	  narrow-­‐spectrum	  regimens	  were	  prescribed	  for	  fewer	  
days.	  
In	   our	   population,	   macrolide	   over-­‐prescription	   in	   the	   pre-­‐CP	   period	   may	   have	   resulted	   from	   the	  
perception	   that	   two	   antimicrobials	   were	  more	   reliable,	   as	   only	   one	   patient	   was	   actually	   infected	  
with	  Mycoplasma	  pneumoniae	   in	  this	  period.	   Indeed,	  the	  pre	  and	  post	  populations	  were	  similar	   in	  
terms	  of	  number	  of	  tests	  performed	  to	  detect	  M.	  pneumoniae	  infection	  and	  positive	  tests	  (only	  one	  
in	  the	  pre-­‐CP	  period).	  All	  inpatients	  were	  admitted	  to	  the	  PACU	  for	  an	  episode	  of	  moderate	  CAP.	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No	   statistical	   difference	   was	   reported	   between	   the	   two	   groups	   before	   and	   after	   implementation	  
with	  regard	  to	  sex,	  age,	  symptoms	  onset	  time,	  M.	  pneumoniae	  IgM	  serology	  positivity	  and	  presence	  
of	  complications	  (hypoxia,	  pleural	  effusion,	  necrotizing	  pneumonia).	  	  
After	  CAP	  CP	   implementation,	  prescription	  of	  narrow-­‐spectrum	  regimens	   (ampicillin	  or	  amoxicillin)	  
among	  inpatients	  decreased	  significantly,	  with	  a	  concomitant	  significant	  decrease	  of	  broad-­‐spectrum	  
antibiotics.	   This	   is	   in	   line	   with	   most	   recent	   recommendations,	   which	   recommend	   high	   doses	   of	  
narrow-­‐spectrum	  β-­‐lactams	  as	  the	  first-­‐line	  parenteral	  therapy	  for	  moderate	  CAP	  if	  the	  child	  is	  fully	  
immunized	  or	   is	  not	  admitted	  for	  a	  previous	  amoxicillin	  treatment	  failure.	  Alternatively,	  parenteral	  
third	  generation	  cephalosporins	  are	  recommended	  [1]	  when	  these	  criteria	  are	  not	  med.	  
Median	  DOTs	   showed	  a	   substantial	  decrease	   from	  18.5	   to	  10	  days	   in	  pre-­‐	   versus	  post-­‐CP	  periods,	  
indicating	  a	  decrease	  in	  the	  prevalence	  of	  antibiotic	  prescriptions.	  We	  also	  saw	  a	  significant	  increase	  
in	  use	  of	  ampicillin	  and	  amoxicillin	  and	  decrease	  in	  cephalosporins	  and	  macrolides.	  This	  was	  in	  line	  
with	   the	   CAP	   CP	   developed	   for	   this	   study,	   which	   recommended	   parenteral	   third-­‐generation	  
cephalosporins	   in	   case	   of	   penicillin	   treatment	   failure,	   since	   ceftriaxone	   or	   cefotaxime	   are	   more	  
active	  in	  vitro	  against	  penicillin-­‐resistant	  strains	  [1].	  Indeed,	  wide-­‐spread	  cephalosporin	  use	  can	  lead	  
to	   an	   increase	   in	   multi-­‐drug	   resistant	   pathogens	   (e.g.	   third-­‐generation	   cephalosporin-­‐resistant	   E.	  
coli)	  [31,32].	  
Furthermore,	   use	   of	   broad-­‐spectrum	   antibiotics	   like	   amoxicillin-­‐clavulanate,	   ampicillin-­‐sulbactam,	  
carbapenems	   and	   glycopeptides	   were	   abandoned	   after	   CP	   implementation	   in	   our	   centre,	   while	  
clindamycin	   was	   prescribed	   in	   the	   post-­‐CP	   period	   only	   in	   case	   of	   complicated	   pneumonia	  
(parapneumonic	  effusion,	  necrotizing	  pneumonia).	  	  
Carbapenems	  are	  one	  of	  the	  β-­‐lactams	  with	  the	  broadest	  antibacterial	  spectrum	  currently	  available,	  
with	  a	  relatively	  low	  rate	  of	  adverse	  effects.	  They	  are	  recommended	  as	  “last-­‐line	  agents”	  for	  severe	  
infections	   or	   resistant	   bacteria,	   since	   carbapenems	   are	   not	   destroyed	   by	  most	  β-­‐lactamases	   [33].	  
From	   this	   study,	   it	   emerged	   that	   their	   empiric	   use	   was	   not	   exclusively	   for	   severe	   nosocomial	  
infections	  in	  critically	  ill	  patients,	  but	  was	  prescribed	  as	  drug	  of	  choice	  for	  moderate	  CAP	  during	  pre-­‐
intervention	  period,	  as	  also	  reported	  by	  other	  authors	  [34].	  The	  wide	  use	  of	  these	  lifesaving	  drugs	  is	  
problematic	  due	  to	  the	  emergence	  of	  carbapenem-­‐resistant	  bacteria	  which	  cause	  severe	  infections	  
[35-­‐40].	  
The	   dramatic	   change	   in	   antimicrobial	   choices	   is	   attributable	   to	   the	   shift	   in	   suggested	   first-­‐line	  
therapy	  for	  CAP	  and,	  since	  the	  starting	  therapy	  is	  established	  for	  both	  outpatients	  and	  inpatients	  by	  
the	  PED,	   improvements	   in	  PED	  prescriptions	  determine	   improvements	   in	  PACU	  prescriptions,	  even	  
because	  the	  two	  wards	  share	  the	  same	  medical	  staff.	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Indeed,	   starting	   with	   penicillin	   (amoxicillin/ampicillin)	   gives	   physicians	   the	   possibility	   to	   observe	  
children	   for	   48-­‐96	  hours	   and,	   in	   case	   of	   persistence	  of	   symptoms,	   to	   switch	   to	   a	   third-­‐generation	  
cephalosporin.	  On	  the	  other	  hand,	  physicians	  starting	  with	  ceftriaxone	  are	  more	  prone	  to	  change	  to	  
a	  broader	  spectrum	  antibiotic	  such	  as	  carbapenem.	  
Furthermore,	  the	  introduction	  of	  clindamycin	  recommendations	  for	  complicated	  moderate	  CAP	  gave	  
the	  opportunity	  to	  avoid	  glycopeptides,	  hence	  reducing	  their	  use.	  
DOT,	   LOT	   and	   DOT/LOT	   ratio	   analysis	   was	   performed	   to	   describe	   inpatient	   prescriptions.	   Our	  
intervention	  resulted	  in	  a	  statistically	  significant	  decrease	  in	  overall	  median	  DOT	  (narrow	  and	  broad-­‐
spectrum)	  from	  18.5	  to	  10,	  as	  well	  as	  bsDOT	  from	  17	  to	  4.5.	  LOT	  median	  did	  not	  significant	  decrease,	  
despite	  CAP	  guidelines	  recommending	  7	  days	  of	  therapy	  in	  case	  of	  uncomplicated	  CAP	  and	  14	  days	  if	  
complicated	  (parapneumonic	  effusion,	  necrotizing	  pneumonia).	  This	  suggests	  pediatricians	  are	  more	  
inclined	  to	  change	  their	  attitude	  towards	  the	  choice	  of	  antibiotic	  prescribed	  rather	  than	  the	  duration	  
of	  therapy.	  	  
The	   increased	  use	  of	   ampicillin/amoxicillin	  also	   resulted	   in	  a	  decrease	  of	   the	  median	   LOS	  after	  CP	  
implementation.	   Indeed,	   a	   rapid	   and	   uneventful	   improvement	   during	   the	   first	   24-­‐48	   hours	   after	  
ampicillin	   administration	   has	   a	   favourable	   impact	   on	   switch	   to	   oral	   antibiotic	   and	   early	   discharge	  
[41].	  
Changes	   in	   antibiotic	   dosage	   were	   analysed	   for	   the	   most	   prescribed	   antibiotics	   (ampicillin	   and	  
ceftriaxone)	  in	  inpatients.	  
The	  median	  dosage	  of	  ampicillin	  in	  the	  post-­‐implementation	  period	  was	  200	  mg/kg/day,	  in	  line	  with	  
recommend	  dose	  of	  200-­‐300	  mg/kg/day	  in	  the	  CAP	  CP	  developed	  for	  this	  study.	  This	  is	  an	  important	  
achievement	  for	  inpatients:	  before	  the	  CP	  implementation	  physicians	  didn’t	  even	  consider	  ampicillin	  
for	  moderate	  CAP	  treatment	  in	  our	  centre.	  
Alternatively,	  therapy	  can	  be	  provided	  with	  ceftriaxone	  in	  standard,	  non-­‐meningitis	  dosages	  which	  is	  
documented	   to	   be	   effective	   with	   CAP	   caused	   by	   strains	   previously	   considered	   resistant	   to	  
ceftriaxone	   [1,42].	  Ceftriaxone	  dosage	  was	   stable	  with	  a	  median	  value	  of	  75	  mg/kg/day	  both	  pre-­‐	  
and	  post-­‐CP	  implementation.	  	  
For	  both	  outpatient	  and	  inpatient	  populations,	  no	  differences	  in	  treatment	  failure	  were	  reported	  
despite	  a	  remarkable	  decrease	  in	  broad-­‐spectrum	  antibiotic	  prescription.	  During	  the	  post-­‐CP	  period,	  
an	  increase	  in	  treatment	  failure	  was	  reported	  in	  outpatients	  but	  it	  was	  not	  statistically	  significant.	  
This	  may	  be	  due	  to	  relatively	  low	  sample	  sizes	  and	  to	  the	  very	  low	  occurrence	  of	  treatment	  failure	  
overall,	  even	  in	  the	  pre-­‐CP	  period.	  Continuing	  surveillance	  is	  needed	  to	  confirm	  this	  trend.	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This	  study	  has	  strengths	  and	  limitations.	  It	   is	  the	  first	  study	  that	  evaluates	  the	  effectiveness	  of	  ASP	  
through	  CPs	  in	  an	  Italian	  hospital.	  This	  intervention	  was	  designed	  to	  be	  feasible	  and	  was	  developed	  
by	  a	  multidisciplinary	  team	  to	  guarantee	  a	  high	  quality	  and	  level	  of	  coordination,	  with	  cooperation	  
between	   the	   Infectious	   Diseases	   and	   PED	   teams.	   Furthermore,	   following	   CP	   presentation	   a	  
prominent	   educational	   campaign	   included	   lectures	   and	   distribution	   of	   handy	   pocket	   cards	   and	  
posters.	  
This	   is	   the	   first	   study	  with	   a	   phone	   call	   follow-­‐up	   to	   assess	   antimicrobial	   stewardship	   in	   the	   PED	  
context,	  allowing	  evaluation	  of	  antibiotic	  changes	  for	  persistence	  of	  symptoms	  or	  side	  effects.	  
Limitations	  include	  the	  retrospective	  nature	  of	  the	  analysis,	  its	  single-­‐centre	  setting,	  the	  short	  period	  
of	  observation	  and	  the	  inability	  to	  assess	  appropriateness	  of	  single	  antimicrobial	  prescriptions.	  	  
Thus,	  a	   longer	   term	   follow	  up	   study	  evaluating	   the	   longevity	  of	  observed	  changes	   in	  antimicrobial	  
prescription	   is	  warranted	   to	   analyse	   further	   improvements,	   as	  well	   as	   expanding	   to	   include	   other	  
Italian	  PED	  for	  validation	  of	  this	  tools.	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Conclusions	  
This	   study	   provides	   evidence	   that	   clinical	   pathway	   implementation	   in	   an	   Italian	   PED	   setting	   is	   an	  
effective	  tool	  for	  antimicrobial	  stewardship,	  appearing	  to	  be	  associated	  with	  the	  kind	  of	  treatment	  
children	  receive.	  
An	  evidence-­‐based	  CP	  supplemented	  by	  educational	  and	  explanatory	   lectures	  was	  associated	  with	  
significant	   changes	   in	   prescribing	   habits	   of	   physicians	   at	   our	   centre,	   decreasing	   the	   use	   of	   broad-­‐
spectrum	   antibiotics	   in	   favour	   of	   narrow-­‐spectrum,	   and	   reducing	   the	   length	   of	   therapy	   without	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ABSTRACT	  
Background.	  Antimicrobial	   resistance	  has	  become	  a	   global	   problem.	   Italian	  pediatric	   antimicrobial	  
prescription	  rates	  are	  among	  the	  highest	  in	  Europe	  (EU).	  As	  a	  first	  step	  for	  antimicrobial	  stewardship	  
(AS)	  implementation,	  clinical	  pathways	  (CP)	  outlining	  standard	  of	  care	  for	  acute	  otitis	  media	  (AOM),	  
and	   group	   A	   streptococcus	   (GAS)	   pharyngitis	   and	   community-­‐acquired	   pneumonia	   (CAP)	   were	  
developed	   and	   implemented	   in	   our	   pediatric	   emergency	   department	   (PED)	   in	   collaboration	   with	  
Children’s	  Hospital	  of	  Philadelphia.	  
Aims.	  The	  primary	  aim	  of	  this	  study	  was	  to	  assess	  changes	  in	  antibiotic	  prescription	  one	  year	  after	  
the	   CP	   implementation	   for	   AOM,	   GAS	   pharyngitis	   and	   CAP;	   secondary	   aim	   was	   to	   compare	  
treatment	  failure	  before	  and	  after	  CPs	  implementation.	  
Methods.	   CPs	   were	   implemented	   at	   the	   Department	   for	   Woman	   and	   Child	   Health	   of	   Padua	   on	  
October	  1st	  2015.	  The	  first	  before/after	  quasi-­‐experimental	  study	  has	  been	  conducted	  between	  the	  
Pre-­‐intervention	   period	   (from	   15/10/2014	   to	   15/04/2015),	   Post-­‐intervention	   period	   (from	  
15/10/2015	  to	  15/04/2016)	  and	  1-­‐Year	  post	  intervention	  period	  (from	  15/10/2016	  to	  15/04/2017).	  
ITS	  was	  used	  to	  determine	  the	  effect	  of	  the	   intervention,	  chi	  squared	  test	  to	  define	  the	  treatment	  
failure	  and	  Kruskal	  Wallis	  test	  to	  compare	  antibiotic	  dosages	  and	  durations.	  
Results.	  AOM:	  after	  CP	  implementation	  there	  was	  an	  increase	  in	  “wait	  and	  see”	  (21.7%	  vs.	  33.1%	  vs.	  
28.9%,	  p=0.08)	  and	  in	  the	  use	  of	  amoxicillin	  as	  first	   line	  therapy	  (25.1%	  vs.	  34.5%,	  p<0.001),	  with	  a	  
decrease	   from	   53.2%	   to	   32.4%	   (p<0.001)	   in	   overall	   prescription	   of	   broad-­‐spectrum	   antibiotics.	  
Amoxicillin	  prescriptions	  increased	  (32%	  Pre	  vs.	  51.6%	  Post	  and	  52.8%	  1-­‐Year	  Post,	  p<0,001)	  with	  a	  
decrease	   in	   overall	   prescription	   of	   broad-­‐spectrum	   antibiotics.	   Among	   fully	   immunized	   with	   no	  
complicated	  OMA,	  broad-­‐spectrum	  antibiotics	  were	  prescribed	  in	  only	  4.7%	  of	  cases	  (29.8%,	  Pre	  vs.	  
7.2%	  Post,	  p<0.001).	  Pharyngitis:	  During	  1-­‐year	  Post	  intervention	  period	  63.2%	  of	  patients	  received	  a	  
diagnosis	  	  Goup	  A	  Steptococcus	  pharyngitis	  	  (50.7%	  Pre	  vs	  45.4%	  Post),	  reflecting	  the	  increasing	  age	  
of	  the	  population	  examined	  (more	  patients	  aged	  3-­‐15	  years).	  Amoxicillin	  was	  the	  choice	  for	  93.2%	  of	  
patients	  (53.6%	  Pre	  and	  93.4%	  Post).	  CAP:	  prescriptions/patients	  rate	  has	  decreased	  to	  1.02	  (1.3	  Pre,	  
1.12	  Post)	  reflecting	  an	  increase	  use	  of	  monotherapy.	  82.5%	  of	  patients	  received	  amoxicillin	  (52.1%	  
Pre	  vs.	  69.9%	  Post,	  p<0.001)	  and	  macrolide	  prescriptions	  decreased	  to	  2.1%	  (19.7	  Pre	  vs.	  6.5%	  Post).	  
No	  statistically	  significant	  difference	  in	  treatment	  failure	  was	  seen	  for	  all	  the	  pathologies	  examined.	  
Conclusions.	   A	   reduction	   in	   broad-­‐spectrum	  antibiotic	   prescriptions	   for	  AOM.	  Gas	  pharyngitis	   and	  
CAP	   without	   compromising	   clinical	   outcomes	   indicates	   effectiveness	   of	   CPs	   in	   this	   setting.	  
Furthermore	  their	  effects	  after	  more	  than	  one	  year	  suggests	  CPs	  are	  useful	  and	  suitable	  tool.	  




Antibiotics	   are	   the	   most	   commonly	   prescribed	   drugs	   in	   the	   pediatric	   population,	   especially	   in	  
preschool	  age1.	  Moreover,	  it	  has	  been	  estimated	  that	  half	  of	  the	  prescriptions	  are	  unnecessary1–4.	  	  
Although	  resistance	  can	  occur	  naturally	  or	  can	  be	  acquired	  through	  gene	  transfer,	  antibiotic	  overuse	  
plays	   a	   key	   role	   in	   the	   selection	   of	   multi-­‐drug	   resistant	   organisms5.	   The	   emergence	   of	   such	  
pathogens	  and	  their	  rapid	  global	  spread	  has	  transformed	  resistance	  into	  an	  important	  global	  public	  
health6–9.	  
In	   response	   to	   this	   frightful	   situation,	   in	   2007	   IDSA	   emphasized	   the	   concept	   of	   an	   antimicrobial	  
stewardship	   program	   (ASP)	   as	   a	   key	   component	   of	   programs	   designed	   to	   reduce	   inappropriate	  
antimicrobial	   use,	   prevent	   resistance,	   enhance	   patients’	   safety	   and	   lower	   drug	   costs10.	   Despite	  
prospective	  pre-­‐authorization	  or	  audit	  and	  feedback	  represent	  the	  main	  ASP	  core	  strategies,	  Clinical	  
Pathways	   (CPs)	   are	   a	   reasonable	   first	   step	   for	   ASP	   implementation,	   especially	   in	   setting	   where	  
funding	  are	  limited10–14.	  
Although	  prudent	  antibiotic	  prescribing	  has	  been	  a	  high	  priority	  in	  the	  EU,	  focused,	  organized	  efforts	  
to	   improve	   prescribing	   are	   lacking.	   Italy	   is	   still	   one	   of	   the	   European	   countries	   with	   the	   highest	  
prescription	   rate,	   with	   an	   overuse	   of	   third	   generation	   cephalosporins	   and	   penicillin	   plus	   beta-­‐
lactamase	  inhibitors15.	  	  	  
Since	  CPs	  have	  proven	  a	  promising	  tool	  to	  reduce	  antibiotic	  prescription	  in	  the	  Pediatric	  Emergency	  
Department	   (PED)	   (Chapter	   IV	   and	   VI),	   we	   hypothesized	   the	   positive	   results	   on	   antimicrobial	  
prescriptions	  would	  remain	  stable	  also	  one	  year	  after	  CPs	  implementation.	  
The	   primary	   aim	   of	   this	   study	  was	   to	   assess	   changes	   in	   antibiotic	   prescriptions	   one	   year	   post	   CP	  
implementation	   for	   acute	   otitis	   media	   (AOM),	   Pharyngitis	   and	   Community-­‐acquired	   pneumonia	  
(CAP).	  	  
The	   secondary	   aim	   was	   to	   compare	   treatment	   failures	   pre,	   post	   and	   one	   year	   post	   CP	  
implementation.	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Material	  and	  methods	  
	  
Study	  design	  
On	  1	  October	  2015	  CPs	  for	  the	  management	  of	  AOM,	  Pharyngitis	  and	  CAP	  were	  implemented	  in	  the	  
PED	   of	   the	   Department	   for	   Woman	   and	   Child	   Health	   of	   Padua	   University	   Hospital.	   The	   CPs	  
summarize	  national	  and	  international	  guidelines	  for	  the	  diagnosis	  and	  treatment	  of	  the	  three	  clinical	  
conditions	  and	  have	  been	  developed	  by	   the	  Division	  of	  Pediatric	   Infectious	  Diseases	  and	  Pediatric	  
Emergency	  Department	  of	  Padua	  in	  collaboration	  with	  the	  Division	  of	  Pediatric	  Infectious	  Diseases	  of	  
the	  Children’s	  Hospital	  of	  Philadelphia.	  
This	   is	  a	  pre-­‐post	  quasi-­‐experimental	  study	  to	  assess	  changes	   in	  antibiotic	  prescribing	  during	  the	  6	  
months	   period	   prior	   to	   CP	   implementation	   (pre-­‐intervention:	   15	   October	   2014	   through	   15	   April	  
2015),	  the	  6	  months	  after	   intervention	  (post-­‐intervention:	  15	  October	  2015	  through	  15	  April	  2016)	  
and	  other	  6	  months	  after	  one	  year	  from	  the	  intervention	  (1-­‐year	  post-­‐intervention:	  15	  October	  2016	  
through	  15	  April	  2017).	  The	  same	  months	  have	  been	  analyzed	  in	  each	  period	  to	  control	  for	  effects	  of	  
seasonality	  (Figure	  1).	  
Three	   educational	   lectures	   were	   presented	   to	   physicians	   and	   residents	   in	   October	   2015	   and	   one	  
recall	   lecture	   was	   given	   in	   January	   2017.	   CPs	   were	   delivered	   as	   laminated	   pocket	   cards	   to	   all	  
physicians	  and	  CPs	  posters	  were	  also	  hung	  in	  the	  PED.	  
This	  study	  was	  approved	  by	  Institution	  Review	  Board	  of	  Department	  for	  Woman	  and	  Child	  Health	  at	  
the	  University	  of	  Padua.	  An	  informed	  consent	  form	  was	  sent	  to	  the	  families,	  and	  follow-­‐up	  data	  were	  












Figure	  1.	  Study	  design	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Study	  population	  
In	  the	  study	  were	  included	  all	  patients	  aged	  2	  months	  to	  15	  years	  with	  an	  International	  Classification	  
of	  Diseases,	  9th	  Revision,	  Clinical	  Modification	  (ICD-­‐9-­‐CM)	  code	  or	  descriptive	  diagnosis	  of	  AOM,	  GAS	  
pharyngitis	  and	  all	  patients	  aged	  3	  months	  to	  15	  years	  with	  a	  ICD-­‐9	  code	  or	  descriptive	  diagnosis	  of	  
CAP.	  
AOM	   exclusion	   criteria	   were:	   immunodeficiency	   or	   immunosuppressive	   therapy,	   tympanostomy	  
tubes	  at	   the	   time	  of	   the	  diagnosis,	  craniofacial	  abnormalities,	  cystic	   fibrosis,	  concomitant	  bacterial	  
infections	   involving	  other	  sites	  or	  systemic	  bacterial	   infection,	  diabetes,	  chronic	  otitis	  media,	  AOM	  
complicated	  by	  mastoiditis,	  AOM	  with	  ongoing	  antibiotic	  therapy	  at	  admission	  and	  admission	  to	  the	  
Pediatric	  Department.	  	  
Pharyngitis	   exclusion	   criteria	   were:	   immunodeficiency	   or	   immunosuppressive	   therapy,	   pharyngitis	  
with	   an	   ongoing	   antibiotic	   therapy	   at	   the	   time	   of	   admission,	   concomitant	   bacterial	   infections	  
involving	  other	  sites	  or	  systemic	  bacterial	  infection,	  previous	  tonsillectomy,	  chronic	  disease	  included	  
PFAPA	  and	  admission	  to	  the	  Pediatric	  Department.	  
CAP	   exclusion	   criteria	   were:	   cystic	   fibrosis	   or	   other	   chronic	   lung	   diseases	   (except	   asthma),	  
immunodeficiency	  or	  immunosuppressive	  therapy,	  pneumonia	  with	  an	  ongoing	  antibiotic	  therapy	  at	  
the	   time	   of	   admission,	   concomitant	   bacterial	   infectious	   involving	   other	   sites	   or	   systemic	   bacterial	  
infection,	  tracheostomy,	  risk	  factors	  for	  aspiration	  pneumonia,	  IV	  antibiotic	  therapy	  during	  previous	  
30	   days,	   hospital	   acquired	   pneumonia	   (<14	   day	   from	   previous	   admission)	   and	   admission	   to	   the	  
Pediatric	  Department.	  	  
	  
Data	  source	  
Antimicrobial	  use,	   clinical	   and	  demographic	  data	   for	   all	   patient	  were	  extracted	  manually	   from	   the	  
electronic	  medical	  records	  using	  REDCap®	  data	  collection	  forms	  designed	  for	  the	  three	  conditions.	  
Broad-­‐spectrum	   antimicrobials	   were	   defined	   as:	   beta-­‐lactam	   and	   beta-­‐lactamase	   inhibitor	  
combinations,	  second-­‐	  and	  third-­‐generation	  cephalosporins,	  fluoroquinolones,	  macrolides.	  
To	  ensure	  data	  privacy	  a	  survey	  number	  was	  assigned	  to	  each	  patient.	  No	  personally	  identifying	  data	  
were	  collected.	  
Admission	   occurring	   for	   the	   same	   patient	   greater	   than	   30	   days	   apart	   were	   analyzed	   as	   separate	  
events.	  	  
To	   evaluate	   the	   safety	   of	   the	   intervention,	  we	   collected	   data	   on	   treatment	   failure	  within	   30	   days	  
after	  discharge	  through	  a	  standardized	  telephone	  survey	  to	  the	  family.	  
	  




The	  following	  aspects	  of	  antibiotic	  prescriptions	  for	  AOM,	  GAS	  pharyngitis	  and	  CAP	  were	  assessed:	  1)	  
proportion	  of	   ‘wait	   and	   see’	   approach	   (AOM	  only);	  2)	  proportion	  of	  antimicrobial	  prescriptions	  by	  
specific	   disease	   and	   active	   agent;	   3)	   dosage	   of	   the	   most	   prescribed	   antibiotics,	   expressed	   in	  
mg/kg/day,	  4)	  duration	  of	  therapy,	  expressed	  in	  days	  of	  therapy	  (DOTs)	  and	  Length	  of	  Therapy	  (LOT),	  
DOT/LOT	  ratio	  (LOT	  and	  DOT/LOT	  ratio	  only	  for	  CAP).	  	  
A	  DOT	  represents	  any	  dose	  of	  antibiotic	  administered	  during	  a	  24	  hour-­‐period.	   Instead,	   the	  LOT	   is	  
the	   total	  number	  of	   treatment	  days,	   irrespective	  of	   the	  number	  of	  different	  antibiotics.	   	  DOT/LOT	  




Any	  of	  the	  following	  were	  considered	  treatment	  failure	  at	  30-­‐day	  follow-­‐up:	  1)	  change	  in	  antibiotics	  
prescription	   for	   persistence	   or	   worsening	   of	   symptoms;	   2)	   treatment	   change	   for	   antibiotics	   side	  
effects;	  3)	  new	  antibiotic	  prescription	  within	  30	  days	  from	  discharge	  for	  relapse	  of	  symptoms;	  4)	  in	  
case	  of	  AOM,	  new	  antibiotic	  prescription	  after	  ‘wait	  and	  see’.	  
	  
Data	  analysis	  
Data	  were	  analyzed	  using	  STATA®13.	  	  Results	  were	  summarized	  as	  frequencies	  and	  percentages	  for	  
categorical	  variables	  and	  as	  median,	  minimum	  and	  maximum	  for	  continuous	  variables.	  Comparison	  
of	  categorical	  variables	  in	  pre-­‐	  vs.	  post-­‐	  vs.	  1-­‐year	  post-­‐intervention	  period	  were	  conducted	  with	  chi	  
square	  test.	  Continuous	  variables	  were	  compared	  with	  Kruskal-­‐Wallis	   test.	   Interrupted	  Time	  Series	  
(ITS)	   were	   used	   to	   compare	   the	   prescription	   rate17.	   Each	   of	   the	   three	   periods	   were	   divided	   in	   6	  
different	  sub-­‐periods	  of	  1	  month	  each	  for	  AOM	  e	  GAS	  pharyngitis	  and	  in	  4	  different	  sub-­‐periods	  of	  
45	  days	  each	  for	  CAP.	  




Over	   the	   6-­‐month	   of	   1-­‐year	   post	   intervention	   period,	   13,082	   children	   attended	   the	   PED,	   in	  
comparison	  to	  13,262	  children	  in	  the	  pre	  and	  12,335	  children	  in	  the	  post	  intervention	  period.	  
	  
AOM	  population	  
During	   1-­‐year	   post	   intervention	   period	   370	   patients	   were	   discharged	   with	   a	   diagnosis	   of	   AOM,	  
accounting	   for	   2.8%	   (370/13,082)	   of	   total	   PED	   visits.	   The	   same	   proportion	   was	   observed	   in	   pre-­‐
intervention	  period	  (334/13,262,	  2.5%)	  and	   in	  post-­‐intervention	  period	  (332/12,335,	  2.7%)	  (p=0.3).	  
Three	  hundred	  and	  one	  children	  were	  included	  in	  the	  study	  for	  1-­‐year	  post	  intervention	  period,	  295	  
for	  pre-­‐intervention	  and	  278	   for	  post-­‐intervention	  period.	  The	   study	  population	  pre-­‐,	  post-­‐	   and	  1-­‐
year	  post	  intervention	  period	  is	  shown	  in	  table	  1.	  
	  
	  
Abbreviations:	  PED=Pediatric	  Emergency	  Department;	  AOM=Acute	  Otitis	  Media;	  n=the	  number	  of	  patient	  for	  each	  category	  
	  
Table	  1.	  Characteristics	  of	  Study	  population	  with	  AOM	  
	  
The	  three	  populations	  were	  similar	  with	  respect	  to	  sex	  and	  age,	  with	  an	  overall	  male	  predominance	  
and	  an	  increased	  incidence	  of	  AOM	  in	  children	  younger	  than	  5	  years.	  The	  percentage	  of	  complicated	  
AOM	  remains	  stable	  during	  the	  three	  different	  periods	  (pre	  15.6%	  (46/295),	  post	  21.9%	  (61/278),	  1-­‐
year	   post	   23.3%	   (70/301),	   p=0.05),	   as	  well	   as	   the	  percentage	  of	   children	   eligible	   for	  wait	   and	   see	  
approach	  (pre	  48.1%	  (142/295),	  post	  48.2%	  (134/278),	  1-­‐year	  post	  38.2%	  (115/301),	  p=0.21).	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Antimicrobial	  prescription	  rate	  for	  AOM	  
During	   1-­‐year	   post	   intervention	   period	   there	   was	   an	   increase	   of	   ‘wait	   and	   see’	   approach	   as	  
compared	  to	  pre-­‐CP	  period	  (pre	  21.7%	  (64/292),	  post	  33.1%	  (92/278),	  1-­‐year	  post	  28.9%,	  p=0.008)	  
and	  a	  decrease	  in	  antibiotic	  prescriptions,	  especially	  for	  broad	  spectrum	  ones	  (pre	  68.0%	  (157/231),	  
post	   48.4%	   (90/186),	   1-­‐year	   post	   47.2%	   (101/214),	   p<0.001)	   (Table	   2).	   This	   result	   is	   further	  
highlighted	   by	   the	   ITS	   analysis	   in	   figure	   2.	   The	   decrease	   in	   broad-­‐spectrum	   antibiotics	   was	   even	  
greater	  considering	  only	  those	  children	  for	  whom	  this	  class	  of	  antibiotics	  were	  strictly	  recommended	  
(not	   fully	   immunized,	  with	  complicated	  AOM	  and	  treated	  with	  amoxicillin	   in	   the	  previous	  30	  days)	  
(pre	  29.8%	  (88/295),	  post	  7.2%	  (20/278),	  1	  year	  post	  4.7%	  (14/301))	  (figure	  3).	  
Abbreviations:	  n=	  indicates	  the	  number	  of	  patient	  for	  each	  category;	  AOM=	  acute	  otitis	  media	  
Table	  2.	  Treatment	  option	  of	  Acute	  Otitis	  Media	  
Antibiotics	  dosage	  for	  AOM	  
Dosage	   comparison	   was	   conducted	   only	   for	   the	   most	   prescribed	   antibiotics:	   amoxicillin	   and	  
amoxicillin-­‐clavulanate.	  Kruskal-­‐Wallis	  test	  comparing	  overall	  pre,	  post	  and	  1-­‐year	  post	  intervention	  
found	  a	  significant	  increase	  in	  the	  median	  dose	  for	  both	  drugs	  (p<0.001).	  The	  trend	  analysis	  showed	  
the	  optimal	  dosage	  recommended	  by	  the	  AOM	  CP,	  reached	  within	  the	  post	  implementation	  period,	  






Abbreviations:	  AOM=Acute	  Otitis	  Media;	  Abx=antibiotics;	  CP=Clinical	  Pathway	  	  
Figure	  2.	  ITS	  analysis	  of	  broad-­‐spectrum	  antibiotic	  prescription	  for	  AOM	  	  
	  
	  
Abbreviations:	  AOM=Acute	  Otitis	  Media;	  Abx=antibiotics;	  CP=Clinical	  Pathway	  	  
Figure	  3.	  ITS	  analysis	  of	  broad-­‐spectrum	  antibiotic	  prescriptions	  for	  AOM	  in	  children	  fully	  immunized,	  with	  
uncomplicated	  AOM	  and	  who	  have	  not	  received	  amoxicillin	  within	  the	  previous	  30	  days	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Abbreviations:	  AOM=Acute	  Otitis	  Media;	  	  CP=Clinical	  Pathway	  	  
Figure	   4.	   Amoxicillin	   and	   Amoxicillin-­‐Clavulanate	   dosage	   for	   AOM	   and	   interquartile	   range	   changing	   over	  
time.	  
	  
Treatment	  duration	  for	  AOM	  
Treatment	  duration	  was	  analyzed	  stratifying	  the	  population	  by	  age	  (<2	  years	  old,	  ≥2	  years	  old)	  and	  
disease	  severity	  (complicated	  vs.	  uncomplicated),	  independently	  from	  the	  oral	  agent	  prescribed.	  
In	  children	  <2	  years	  old	  and	  in	  children	  ≥2	  years	  old	  not	  fully	  immunized	  or	  with	  complicated	  AOM,	  
median	   DOT	  met	   the	   recommended	   duration	   of	   10	   days	   and	   7	   days	   respectively.	   The	   difference	  
between	  median	  DOT	  in	  the	  three	  periods	  was	  statistically	  significant	  (p<0.001)	  (Figure	  5	  and	  Figure	  
6).	  	  
In	  children	  ≥2	  years	  old,	   fully	   immunized	  and	  with	  uncomplicated	  AOM,	  median	  DOT	  fails	  to	  reach	  
the	   recommended	  duration	  of	  5	  days	  despite	   in	   the	   last	   forth	  months	  of	  1-­‐year	  post	   intervention	  
period	   never	   exceeds	   the	   duration	   of	   6	   days.	   The	   difference	   between	   media	   DOT	   in	   the	   three	  
periods	  was	  statistically	  significant	  (p<0.001)	  (Figure	  7).	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Figure	  5.	  Duration	  of	  therapy	  in	  median	  DOT	  and	  interquartile	  range	  each	  month	  in	  pre-­‐,	  post-­‐	  and	  1	  year	  
post	  period	  for	  children	  <2	  years	  old	  with	  AOM.	  
	  
	  
Figure	  6.	  Duration	  of	  therapy	  in	  median	  DOT	  and	  interquartile	  range	  each	  month	  in	  pre-­‐,	  post-­‐	  and	  1	  year	  
post	  period	  for	  children	  ≥	  2	  years	  old	  not	  fully	  immunized	  or	  with	  complicated	  acute	  otitis	  media	  
	  
	  
Figure	  7.	  Duration	  of	  therapy	  in	  median	  DOT	  and	  interquartile	  range	  each	  month	  in	  pre-­‐,	  post-­‐	  and	  1	  year	  
post	  period	  for	  children	  ≥	  2	  years	  old	  fully	  immunized	  with	  uncomplicated	  acute	  otitis	  media	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Pharyngitis	  population	  
During	  1-­‐year	  post	  intervention-­‐period,	  417	  patients	  were	  evaluated	  for	  pharyngitis,	  accounting	  for	  
3.2%	  (417/13,082)	  of	  total	  PED	  visits.	  The	  same	  proportion	  was	  observed	  in	  pre-­‐intervention	  period	  
(388/13,262,	   2.9%)	   and	   in	   post-­‐intervention	   period	   (448/12,335,	   3.6%)	   (p=0.005).	   Three	   hundred	  
and	  twenty-­‐six	  children	  were	  included	  in	  the	  study	  for	  1-­‐year	  post,	  298	  for	  pre-­‐intervention	  and	  366	  
for	  post-­‐intervention	  period.	  The	  study	  population	  is	  shown	  in	  Table	  3.	  
	  
	  
Abbreviations:	  PED=Pediatric	  Emergency	  department;	  GAS	  pharyngitis=Group	  A	  Streptococcus	  Pharyngitis;	  n=the	  number	  of	  children	  for	  
each	  category	  
Table	  3.	  Characteristics	  of	  Study	  population	  with	  GAS	  pharyngitis	  
	  
The	  three	  populations	  were	  similar	  in	  terms	  of	  sex,	  with	  a	  slight	  male	  predominance.	  Although	  in	  all	  
three	  populations	  the	  incidence	  was	  higher	  among	  older	  children.	  In	  1-­‐year	  post	  intervention	  period	  
the	  percentage	  of	  children	  between	  3	  and	  15	  years	   increased	  compared	  to	  other	  analyzed	  periods	  
(pre	  63.8%	  (190/298),	  post	  60.1%	  (220/366),	  1-­‐year	  post	  73.3%	  (239/326),	  p<0.001).	  For	  this	  reason,	  
a	   higher	   number	   of	   GAS	   pharyngitis	  was	   diagnosed	   in	   1-­‐year	   post-­‐intervention	   period	   (pre	   50.7%	  
(151/298),	  post	  45.4%	  (166/366),	  1-­‐year	  post	  63.2%	  (206/326),	  p<0.001).	  
	  
Antimicrobial	  prescription	  rate	  for	  pharyngitis	  
During	  1-­‐year	  post	  intervention	  period	  there	  was	  an	  increase	  in	  amoxicillin	  prescription	  rate	  as	  was	  
observed	  in	  post-­‐implementation	  group	  in	  comparison	  to	  pre-­‐implementation	  (Pre	  53.6%	  (81/151),	  
Post	  93.4%	  (155/166),	  1-­‐year	  post	  93.2%	  (192/206),	  p<0.001)	  with	  a	  concomitant	  decrease	  in	  broad-­‐
spectrum	   antibiotic	   prescription,	   especially	   amoxicillin-­‐clavulanate	   prescription	   rate	   (Pre	   39.7%	  
(60/151),	  Post	  3%	   (5/166),	  1	  year	  post	  4.4%	   (9/206),	  p<0.001).	   Stratifying	  prescriptions	  by	  age	   (<3	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years	  old,	  3-­‐15	  years	  old),	  the	  majority	  were	  administered	  to	  children	  older	  than	  3	  years	  (pre	  74.2%	  
(112/151),	  post	  78.3%	  (130/166),	  1	  year	  post	  81.6%	  (168/206),	  p=0.25)	  (Table	  4).	  
Analyzing	  the	  GAS	  pharyngitis	  prescriptions	  trend	  for	  each	  month	   in	  time	  series,	  a	  remarkable	  and	  
stable	  reduction	  in	  broad-­‐spectrum	  antibiotic	  prescriptions	  was	  reported	  (figure	  8).	  
	  
Abbreviations:	  n=the	  number	  of	  patient	  for	  each	  category;	  GAS	  pharyngitis=Group	  A	  Streptococcal	  Pharyngitis	  




Abbreviations:	  GAS	  pharyngitis=Group	  A	  Streptococcus	  Pharyngitis;	  Abx=antibiotics;	  CP=Clinical	  Pathway	  
Figure	  8.	  ITS	  analysis	  of	  broad-­‐spectrum	  antibiotic	  prescription	  for	  GAS	  pharyngitis	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Antibiotic	  dosage	  and	  treatment	  duration	  for	  GAS	  pharyngitis	  
Changes	   in	   dosage	   over	   time	   were	   assessed	   only	   for	   amoxicillin,	   as	   amoxicillin-­‐clavulanate.	   Dose	  
remained	  stable	  during	  the	  three	  analyzed	  periods,	  in	  line	  with	  CP’s	  recommendations	  (Figure	  9).	  
In	  1-­‐year	  post	  intervention	  period,	  median	  DOT	  met	  the	  recommended	  10	  days	  for	  all	  the	  6	  months,	  
as	  was	  observed	  for	  post-­‐intervention	  period.	  Kruskal	  Wallis	  test	  comparing	  overall	  pre-­‐,	  post-­‐	  and	  1	  
year	  post-­‐intervention	  median	  DOT	  found	  a	  significant	  increase	  (p<0.001)	  (Figure	  10).	  
	  
	  
Abbreviations:	  GAS	  pharyngitis=Group	  A	  Streptococcus	  pharyngitis;	  CP=Clinical	  Pathway.	  




Abbreviations:	  GAS	  pharyngitis	  =	  Group	  A	  Streptococcus	  pharyngitis;	  CP	  =	  Clinical	  Pathway;	  DOT=	  Days	  of	  therapy.	  
	  
Figure	  10.	  Duration	  of	  therapy	  in	  median	  DOT	  and	  interquartile	  range	  each	  month	  in	  pre-­‐,	  post-­‐	  and	  1	  year	  
post	  period	  for	  children	  with	  GAS	  pharyngitis	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During	  1-­‐year	  post	   intervention	  period	   there	  was	  an	   increase	   in	   the	  number	  of	  patients	  evaluated	  
for	   CAP	   in	   comparison	   to	   other	   periods	   (Pre	   120/13,262,	   0.9%,	   Post	   86/12,335,	   0.7%,	   1-­‐year	   post	  
181/13,082,	   1.38%,	   p=0.03).	   Ninety-­‐five	   children	   were	   included	   in	   the	   study	   for	   1-­‐year	   post	  
intervention	   period,	   56	   for	   pre-­‐intervention	   and	   41	   for	   post-­‐intervention	   period.	   The	   study	  
population	  pre-­‐,	  post-­‐	  and	  1-­‐year	  post	  intervention	  period	  is	  shown	  in	  Table	  5.	  
The	  three	  populations	  were	  similar	  with	  respect	  to	  age,	  with	  an	  increased	  incidence	  among	  children	  




Abbreviations:	  PED=Pediatric	  Emergency	  department;	  CAP=community	  acquired	  pneumonia;	  n=the	  number	  of	  children	  for	  each	  category	  
Table	  5.	  Characteristics	  of	  Study	  population	  with	  CAP	  
	  
Antimicrobial	  prescription	  rate	  for	  CAP	  
During	   1-­‐year	   post-­‐intervention	   period	   97	   prescriptions	   were	   made	   by	   the	   PED	   physicians.	   The	  
prescriptions/patients	   ratio	   decreased	   compared	   to	   pre	   and	   post-­‐intervention	   period	  
(prescriptions/patients	   ratio:	   Pre	   1.3,	   Post	   1.12;	   1	   year	   post	   1.02	   prescriptions/patients	   ratio).	  
Considering	   the	   number	   of	   prescriptions	   for	   the	   different	   molecules,	   there	   was	   an	   increase	   of	  
amoxicillin	   prescriptions	   (Pre	   52.1%	   (37/71),	   Post	   69.6%	   (32/46),	   1	   year	   post	   82.5%	   (80/97),	  
p=0.0001)	   with	   a	   concomitant	   decrease	   in	   broad-­‐spectrum	   antibiotics	   prescription,	   especially	   for	  
macrolides	  (pre:	  19.7%	  (14/71),	  Post	  6.5%	  (3/46),	  1	  year	  post	  2.1%	  (2/97),	  p=0.003)	  (Table	  6).	  
	  
	  








Abbreviations:	  n=the	  number	  of	  patient	  for	  each	  category;	  CAP=community	  acquired	  pneumonia	  
Table	  6.	  Treatment	  option	  of	  CAP	  
	  
The	  reduction	  in	  broad-­‐spectrum	  antibiotic	  prescription	  rate	  is	  showed	  in	  figure	  11.	  
	  
Abbreviations:	  CAP=Community	  Acquired	  Pneumonia;	  Abx=antibiotics;	  CP=Clinical	  Pathway	  	  
Figure	  11.	  ITS	  analysis	  of	  broad-­‐spectrum	  antibiotic	  prescription	  for	  CAP	   	  
CP	  implementation 
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Antibiotics	  dosage	  for	  CAP	  
Amoxicillin	  dose	  increased	  in	  1-­‐year	  post	  intervention	  period;	  reaching	  the	  recommended	  dose	  (90	  
mg/kg/day).	   The	   difference	   between	   median	   dose	   in	   the	   three	   different	   periods	   was	   statistically	  
significant	  (p<0.001)	  (Figure	  12).	  
	  
	  
Abbreviations:	  CAP=Community	  Acquired	  Pneumonia;	  CP=Clinical	  Pathway	  
Figure	  12.	  Amoxicillin	  dosage	  for	  CAP	  and	  interquartile	  range	  changing	  over	  time.	  
	  
Treatment	  duration	  for	  CAP	  
Median	  DOT	  for	  CAP	  decreased	  from	  the	  10	  days	  of	  pre-­‐	   intervention	  period	  to	  the	  recommended	  
duration	   of	   7	   days.	   The	   difference	   between	   median	   DOT	   in	   the	   three	   periods	   was	   statistically	  
significant	  (p<0.001)	  (Figure	  13).	  Median	  LOT	  reflected	  median	  DOT	  and	  the	  difference	  between	  the	  
three	  periods	  was	  statistically	  significant	  (p<0.001)	  (Figure	  14).	  
DOT/LOT	   ratio	   decreased	   in	   1-­‐year	   post	   implementation	   period	   and	   reached	   the	   value	   of	   1	   in	  
comparison	  to	  1.2	  in	  pre-­‐intervention	  and	  1.1	  in	  post-­‐intervention	  period	  (figure	  15).	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Abbreviations:	  CAP=Community	  Acquired	  Pneumonia;	  CP=Clinical	  Pathway,	  DOT=days	  of	  therapy	  
Figure	  13.	  Duration	  of	  therapy	  in	  median	  DOT	  and	  interquartile	  range	  in	  pre-­‐,	  post-­‐	  and	  1	  year	  post	  period	  
for	  children	  with	  CAP	  
	  
Abbreviations:	  CAP=Community	  Acquired	  Pneumonia;	  CP=Clinical	  Pathway,	  LOT=length	  of	  therapy	  
Figure	  14.	  Duration	  of	  therapy	  in	  median	  LOT	  and	  interquartile	  range	  in	  pre-­‐,	  post-­‐	  and	  1	  year	  post	  period	  
for	  children	  with	  CAP	  
	  
Abbreviations:	  CAP=Community	  Acquired	  Pneumonia;	  CP=Clinical	  Pathway,	  DOT/LOT	  ratio	  Day	  of	  therapy/Length	  of	  therapy	  ratio	  
Figure	  15.	  DOT/LOT	  ratio	  in	  pre-­‐,	  post-­‐	  and	  1	  year	  post	  period	  for	  children	  with	  CAP	   	  
CP	  implementation 
1	  October	  2015 
CP	  implementation 
1	  October	  2015 
CP	  implementation 
1	  October	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Secondary	  aim	  
AOM	  treatment	  failure	  
In	   1-­‐year	   post	   intervention	  period	   207/301	   (68.8%)	   children	  were	   available	   for	  AOM	   follow-­‐up,	   in	  
comparison	   to	  214/295	   (72.5%)	  and	  206/278	   (74.1%)	   children	   in	  pre	  and	  post-­‐intervention	  period	  
respectively	  (Table	  7).	  	  
	  
Abbreviations:	  n	  =	  the	  number	  of	  patient	  for	  each	  category;	  AOM	  =	  	  Acute	  Otitis	  Media	  
Table	  7.	  Treatment	  and	  treatment	  failure	  during	  follow-­‐up	  of	  patients	  with	  AOM	  
	  
During	  1-­‐year	  post	  intervention	  period	  only	  14.5%	  (30/207)	  of	  patient	  presents	  a	  treatment	  failure,	  
in	  line	  with	  the	  previous	  periods	  (Pre	  12.1%	  (26/214),	  Post	  11.2%	  (23/206),	  p=0.31).	  The	  difference	  
between	   the	   treatment	   failure	   was	   not	   statistically	   significant	   both	   in	   the	   group	   treated	   with	  
antibiotics	  (p=0.26)	  and	  in	  the	  ‘wait	  and	  see’	  group	  (p=0.13).	  
	  
Pharyngitis	  treatment	  failure	  
Only	  patients	  with	  a	  diagnosis	  of	  GAS	  pharyngitis	  were	  followed-­‐up.	  In	  1-­‐year	  post	  implementation	  
period	  142/206	  (68.9%)	  children	  were	  contacted	  (Table	  8).	  	  
The	   difference	   between	   overall	   treatment	   failure	   rates	   in	   pre,	   post	   and	   1-­‐year	   post	   intervention	  




Abbreviations:	  n	  =	  the	  number	  of	  patient	  for	  each	  category;	  GAS	  pharyngitis	  =	  Group	  A	  Streptococcus	  Pharyngitis	  
Table	  8.	  Treatment	  and	  treatment	  failure	  during	  follow-­‐up	  of	  patients	  with	  GAS	  pharyngitis	  
	  
CAP	  treatment	  failure	  
CAP	   follow-­‐up	  was	   available	   for	   70/95	   (73.7%)	   children	   in	   the	   1-­‐year	   post	   intervention	   period,	   in	  
comparison	   to	   44/56	   (78.6%)	   and	   37/39	   (90.3%)	   children	   in	   pre-­‐	   and	   post-­‐intervention	   period	  
respectively	  (Table	  9).	  
During	  1-­‐year	  post	   intervention	  period	  only	  14.3%	  (10/70)	  of	  patient	  had	  a	  treatment	   failure,	  with	  
no	  significant	  change	  compared	  to	  the	  previous	  periods	  (Pre	  2.3%	  (1/44),	  Post	  10.8%	  (4/37),	  p=0.11).	  
All	   treatment	   failures	   were	   represented	   by	   the	   need	   to	   change	   antibiotics	   for	   the	   persistence	   of	  
symptoms.	  
	  
Abbreviations:	  n=the	  number	  of	  patient	  for	  each	  category;	  CAP=community	  acquired	  pneumonia	  




An	  antimicrobial	  stewardship	  program	  (ASP)	  based	  on	  CPs	  was	  implemented	  on	  October	  1st	  2015	  at	  
the	  PED	  of	  Padua.	  
Afterwards,	   data	  on	   antibiotic	   prescriptions,	   including	   timing	  of	   prescription,	   breadth	  of	   spectrum	  
prescribed,	  dose,	  duration	  of	   therapy	  and	  outcomes	  were	  assessed	   for	  AOM,	  GAS	  pharyngitis	   and	  
CAP.	  	  
As	  already	  reported	  by	  other	  authors,	  also	  in	  our	  case,	  CPs	  have	  been	  proven	  a	  useful	  tool	  to	  reduce	  
antibiotic	   prescriptions	   for	   common	   illnesses11–13,18–20.	   However,	   only	   few	   authors	   have	   reported	  
data	  on	  the	  sustainability	  of	  an	  ASP	  long	  after	  its	  implementation21.	  	  
Regarding	  AOM,	   the	   results	  obtained	  were	   in	   line	  with	   those	  obtained	   in	  post-­‐intervention	  period	  
with	   a	   reduction	   in	   antibiotic	   prescription	   rate	   and	   an	   increase	   in	   ‘wait	   and	   see’	   approach.	   This	  
strategy	  was	  encouraged	  since	  AOM	  could	  be	  caused	  by	  viruses	  or	  bacteria	  with	  a	  high	  spontaneous	  
eradication	   rate,	   such	   as	   Moraxella	   Catharralis	   and	   Haemophilus	   Influenzae	   (80%	   and	   50%	  
respectively).	  For	  this	  reason,	  this	  became	  the	  first	  option	  for	  all	  immunized	  children	  6	  months	  to	  2	  
years	  old	  with	  unilateral	  non-­‐severe	  illness	  and	  for	  those	  >2	  year	  old with	  bi–unilateral	  AOM22.	  	  
Streptococcus	   pneumoniae,	   responsible	   for	   at	   least	   50%	   of	   AOM	   episodes23,	   has	   a	   spontaneous	  
eradication	   rate	   around	   10%;	   for	   this	   reason	   it	   should	   be	   considered	   the	   first	   target	   of	   antibiotic	  
therapy.	   Currently,	   the	   polyvalent	   pneumococcal	   vaccine	   (PCV13)	   confers	   immunity	   to	  
approximately	  85%	  of	  serotypes	  responsible	  for	  most	   invasive	  pneumococcal	  diseases24.	  Data	  from	  
an	  Italian	  survey25	  showed	  that	  S.	  Pneumoniae	  amoxicillin	  resistance	  rate	  is	  still	  around	  11.3%	  with	  
only	  4.8%	  representing	  high	  resistance	  isolates.	  Since	  S.	  pneumoniae	  does	  not	  develop	  resistance	  to	  
beta-­‐lactams	  through	  β-­‐lactamase	  enzymes	  production	  but	  through	  the	  alteration	  of	  the	  cell	  wall’s	  
antimicrobial	   target	   (penicillin-­‐binding	   protein)26	   the	   addition	   of	   β-­‐lactamase	   inhibitors	   has	   no	  
rational	   support.	   For	   all	   of	   these	   reasons	   amoxicillin	   was	   the	   first	   recommended	   choice	   for	  
uncomplicated	   AOM	   in	   fully	   immunized	   children22,27–30.	   Penicillins	   with	   β-­‐	   lactamase	   inhibitors	  
(amoxicillin-­‐clavulanate)	  were	  suggested	  only	  for	  complicated	  AOM	  or	  when	  β-­‐lactamase	  producing	  
bacteria	   could	   be	  more	   likely,	   such	   as	   in	   cases	   of	   lack	   of	   immunization,	   children	   with	   amoxicillin	  
treatment	  in	  the	  previous	  30	  days	  or	  concurrent	  purulent	  conjunctivitis22,27,30.	  
The	   change	   in	   dosage	   obtained	   in	   the	   post	   implementation	   period	   was	   confirmed	   in	   1-­‐year	   post	  
implementation	  period	  both	  for	  amoxicillin	  and	  amoxicillin-­‐clavulanate.	  	  
Regarding	  treatment	  duration,	  the	  results	  obtained	  in	  1-­‐year	  post	  implementation	  were	  excellent	  for	  
children	  <	  2	  years	  old	  and	  for	  children	  ≥	  2	  years	  old	  with	  complicated	  AOM.	  In	  both	  cases	  treatment	  
duration	  met	  CP	  recommendations.	  On	  the	  contrary,	  treatment	  duration	  for	  children	  ≥	  2	  years	  old	  
with	   uncomplicated	   AOM	   was	   not	   so	   easy	   to	   reach.	   This	   confirm	   the	   physicians’	   discomfort	   in	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prescribing	   a	   AOM	   short-­‐course	   treatment	   already	   reported	   in	   post-­‐intervention	   period	   (Chapter	  
IV).	  
Compared	  to	  pre-­‐intervention	  period,	  in	  1-­‐year	  post	  intervention	  period	  there	  was	  a	  slightly	  increase	  
in	  treatment	  failure	  that	  resulted	  not	  statistically	  significant.	  This	  changing	  is	  almost	  entirely	  due	  to	  
the	   increase	   of	   treatment	   failure	   after	   ‘wait	   and	   see’	   approach.	   In	   fact,	   despite	   the	   remarkable	  
decrease	  of	  broad	  spectrum	  prescription	   rate,	   the	  proportion	  of	  patients	  who	  need	   to	  change	   the	  
antibiotic	  for	  persistence	  or	  worsening	  of	  symptoms	  was	  lower	  in	  1	  year	  post	  implementation	  period	  
than	  in	  pre-­‐intervention	  period.	  	  
Regarding	  pharyngitis,	   in	  1-­‐year	  post	   intervention	  period	   there	  was	  an	   increase	   in	  GAS	  pharyngitis	  
diagnosis	   compared	   to	   the	   two	   previous	   periods.	   This	   may	   be	   related	   to	   the	   increase	   in	   the	  
proportion	   of	   children	   between	   3	   and	   15	   years	   of	   age	   in	   the	   1-­‐year	   post-­‐intervention.	   Indeed,	   as	  
reported	  by	  literature,	  GAS	  pharyngitis	  is	  more	  common	  between	  school	  children31.	  	  
	  
Our	  CP	  follows	  the	  US	  and	  Italian	  guidelines	  which	  suggest	  calculating	  a	  McIsaac	  score	  using	  previous	  
clinical	  evaluation	  and	  through	  that	  score	  to	  recognize	  children	  eligible	  for	  RAD	  testing.	  Moreover,	  a	  
further	   stratification	  was	   proposed	   as	   suggested	   in	   the	   Emilia	   Romagna	   guidelines32.	   According	   to	  
CP,	   children	  presenting	  with	  pharyngitis	   and	  McIsaac	   score	  of	  3	  or	  4	   should	   receive	  a	  RAD	   test	   to	  
confirm	  GAS	  etiology.	  In	  case	  of	  McIsaac	  score	  of	  5,	  the	  physician	  could	  reasonably	  skip	  the	  RAD	  test	  
and	  directly	  prescribe	  antimicrobial	   therapy.	   In	  case	  of	  a	  McIsaac	  score	  below	  3	  suggestive	  of	  viral	  
pharyngitis	  antimicrobials	  should	  be	  avoided.	  	  
Amoxicillin	  was	  always	  the	   first	  antibiotic	   treatment	  choice,	  given	  the	  high	  susceptibility	  of	  GAS	  to	  
penicillin,	  while	  oral	   cephalosporins	  were	  accepted	  only	   in	  case	  of	  non-­‐severe	  beta-­‐lactam	  allergy,	  
both	   because	   of	   the	   higher	   cost	   compared	   to	   penicillin	   and	   the	   risk	   of	   selection	   of	   multi-­‐drug	  
resistant	   organism33.	   As	   for	   S.pneumoniae,	  macrolides	   are	   no	   longer	   indicated	   as	   first-­‐line	   due	   to	  
GAS	   high	   resistance	   rates33.	   Amoxicillin-­‐clavulanate	   was	   never	   considered	   suitable	   for	   acute	   GAS	  
pharyngitis	  because	  S.	  pyogenes	  does	  not	  produce	  beta-­‐lactamase	  and	  the	  use	  of	  clavulanate	  would	  
only	   increase	   related	   side	  effects.	  According	   to	  GAS	  pharyngitis	  CP,	   the	  most	  prescribed	  antibiotic	  
was	  amoxicillin.	  This	  result	  is	  in	  line	  with	  the	  one	  obtained	  in	  post-­‐intervention	  period.	  
The	  change	  in	  treatment	  duration	  and	  dose	  obtained	  in	  post	  intervention	  period	  was	  confirmed	  also	  
in	  1-­‐year	  post	  implementation	  period.	  
Despite	  the	  dramatic	  decrease	   in	  broad	  spectrum	  antibiotic	  use,	  no	  difference	   in	  treatment	  failure	  
was	  observed	  between	  1-­‐year	  post	  intervention	  period	  and	  pre-­‐intervention	  period.	  
Regarding	  CAP,	   the	  number	  of	  patients	  evaluated	   in	  PED	   for	   this	  pathology	  has	  doubled	   in	  1-­‐year	  
post	  intervention	  period	  in	  comparison	  to	  the	  other	  two	  periods.	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According	   to	   guidelines	   all	   children	   with	   a	   clear	   clinical	   diagnosis	   of	   pneumonia	   should	   receive	  
antibiotics	   as	   bacterial	   and	   viral	   pneumonia	   cannot	   be	   reliably	   distinguished	   from	   each	   other34.	  
Narrow-­‐spectrum	  regimen,	  defined	  as	  a	  prescription	  of	  amoxicillin	  in	  monotherapy,	  was	  encouraged	  
since	  S	  pneumoniae	  accounts	  for	  21-­‐44%	  of	  disease35–37.	  
Currently,	  the	  polyvalent	  pneumococcal	  vaccine	  (PCV13)	  confers	  immunity	  to	  approximately	  85%	  of	  
serotypes	   responsible	   for	   most	   invasive	   pneumococcal	   diseases24.	   Data	   from	   an	   Italian	   survey	  
showed	  that	  S.	  Pneumoniae	  amoxicillin	  resistance	  rate	  is	  still	  around	  to	  11.3%	  with	  only	  4.8%	  of	  high	  
resistant	   isolates25.	   Since	   S.	   pneumoniae	   does	   not	   develop	   resistance	   to	  β-­‐lactamases	   through	   β-­‐
lactamase	   enzymes	   production	   but	   through	   the	   alteration	   of	   the	   cell	   wall’s	   antimicrobial	   target	  
(penicillin-­‐binding	  protein)	  the	  addition	  of	  β-­‐lactamase	  inhibitors	  has	  no	  rational	  support26.	  
For	   this	   reason,	   amoxicillin	  monotherapy	  became	   the	   first	   option	   for	  mild	  CAP	   in	   fully	   immunized	  
children.	  Penicillins	  with	  β-­‐lactamase	  inhibitors	  (amoxicillin-­‐clavulanate)	  were	  suggested	  only	  when	  
β-­‐lactamase	  producing	  bacteria	   (H.	   influenzae	   type	  B	   (HiB),	  and	  S.	  aureus)	  could	  be	  more	   likely	  as:	  
lack	  of	   immunization,	  children	  with	  amoxicillin	   treatment	   in	   the	  previous	  30	  days34,38.	  Mycoplasma	  
pneumoniae	  is	  more	  frequent	  in	  school-­‐aged	  children	  and	  adults.	  According	  to	  CP,	  use	  of	  macrolides	  
is	  accepted	  only	   if	  atypical	  etiology	   is	   suspected.	  Their	   strict	   indications	  derives	   from	  the	  evidence	  
that	  Mycoplasma	   low-­‐tract	   respiratory	   infections	   (LTRI)	   have	   an	   high	   rate	   of	   spontaneous	   clinical	  
remission	  and	  the	  use	  of	  azithromycin	  has	  been	  associated	  with	  the	  selection	  of	  resistant	  organisms	  
because	  of	  its	  prolonged	  serum	  elimination	  half–life34.	  	  
	  The	  prescription/patient	   ratio	  decreased	  compared	   to	   the	  previous	  periods,	   reaching	  a	  value	  very	  
close	   to	  1.	   This	   value	   indicates	   that	   clinicians	  had	  preferred	  monotherapy,	   instead	  of	   combination	  
therapy.	  Furthermore,	  in	  1-­‐year	  post	  intervention	  period	  there	  was	  a	  dramatic	  increase	  in	  the	  choice	  
of	   amoxicillin	   as	   first	   line	   therapy.	   Broad-­‐spectrum	   prescription	   rate	   decreased,	   especially	   for	  
macrolides	  prescription	  with	  a	  ten-­‐fold	  reduction	  compared	  to	  pre	  intervention	  period.	  Indeed,	  use	  
of	  macrolides	  is	  acceptable	  only	  if	  atypical	  etiology	  is	  suspected.	  	  
In	  1-­‐year	  post	   intervention	  period,	  the	  amoxicillin	  dosage	  met	  the	  90	  mg/kg/day	  recommended	  by	  
the	  CP	  improving	  the	  result	  obtained	  in	  post	  implementation	  period.	  
Despite	  the	  fewer	  overall	  broad-­‐spectrum	  antibiotic	  prescriptions,	  the	  number	  of	  treatment	  failure	  
slightly	   increase	   without	   statistical	   significance.	   All	   treatment	   failure	   was	   due	   to	   persistence	   or	  
worsening	  of	  symptoms	  as	  happened	  in	  the	  two	  previous	  periods.	  	  





This	  study	  has	  strengths	  and	  limitation.	  	  
First	   of	   all,	   this	   is	   the	   first	   study	  which	   evaluated	   the	   sustainability	   of	   ASP	  with	   CPs.	   Second,	   this	  
study	  had	  a	  phone	  call	  follow-­‐up	  to	  collect	  information	  about	  treatment	  failure	  directly	  speaking	  to	  
the	  families.	  Third,	  all	  patients	  with	  ongoing	  therapy	  were	  excluded	  in	  order	  to	  avoid	  the	  influences	  
in	  treatment	  choices	  by	  other	  physicians.	  	  
The	  primary	  limitation	  of	  our	  study	  is	  the	  retrospective	  nature	  of	  the	  analysis.	  Furthermore,	  this	  was	  
a	  single	  center	  study,	  so	  further	  validation	  of	  this	  tool	  should	   include	  other	  Italian	  PEDs.	  Third,	  our	  
analysis	  of	  treatment	  failure	  was	  underestimated	  due	  to	  the	  high	  number	  of	  children	  lost	  to	  follow-­‐









This	   study	   confirms	   that	   CPs	   represent	   a	   reasonable	   first	   step	   of	   ASP	   implementation.	   Evidence-­‐
based	  CP	   supported	  by	   adequate	  provider	   education	  have	  been	  proven	  a	  promising,	   efficient	   and	  
sustainable	   tool	   that	   can	   effectively	   influence	   prescribing	   practices	   without	   compromising	   clinical	  
outcomes.	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Background.	   SSI	   is	   the	   second	  most	   common	   healthcare-­‐associated	   infection.	   It	   represents	   more	  
than	  16%	  in	  adults	  and	  17-­‐18%	  in	  children	  of	  all	  hospital-­‐acquired	  infections.	  While	  trends	  in	  surgical	  
prophylaxis	  among	  adult	  patients	  are	  widely	  available,	  only	  a	  few	  studies	  include	  pediatric	  data.	  
The	   aim	   of	   this	   study	   is	   to	   determine	   the	   effectiveness	   of	   an	   Antimicrobial	   Stewardship	   Program	  
based	  on	  a	  Clinical	  Pathway	   (CP)	   to	   improve	   the	  adherence	   to	  perioperative	  antibiotic	  prophylaxis	  
(PAP)	  guidelines	  [9].	  Secondary	  aim	  is	  to	  evaluate	  the	  effect	  CP	  implementation	  on	  SSIs.	  
	  
Materials	   and	  methods.	   This	   is	   a	   pre-­‐post	   quasi-­‐experimental	   study	   to	   assess	   the	   changes	   in	   PAP	  
appropriateness	   during	   a	   6-­‐month	   period	   preceding	   CP	   implementation	   (per-­‐intervention,	   from	   1	  
February	   2016	   to	   31	   July	   2016)	   and	   during	   the	   six	   months	   after	   CP	   implementation	   (post	  
intervention,	   from	   1	   February	   2017	   to	   31	   July	   2017).	   On	   31	   January	   2017	   the	   CP	   for	   PAP	   was	  
implemented.	  All	  patients	  aged	  between	  1	  months	  and	  15	  years	  subjected	  to	  one	  or	  more	  surgical	  
procedures	  were	  eligible	  to	  be	  included	  in	  our	  study.	  	  
Results.	  810	   children	  were	   included	   in	   the	   study,	   412	   in	   pre-­‐intervention	   period	   and	   385	   in	   post-­‐
intervention	  period.	  Two	  hundred	  and	  two	  (202/412,	  49.0%)	  and	  166/385	  (43.1%)	  patients	  received	  
a	  PAP	  during	  pre	  and	  post-­‐intervention	  period	  respectively	  (p=0.09).	  
The	  majority	  of	  patient	  receiving	  an	  antibiotic	  prophylaxis	  gad	  an	  indication	  for	  PAP	  in	  both	  periods	  
(170/202	   (84.6%)	   vs	   145/166	   (87.3%),	   p=0.38).	   In	   the	   post-­‐intervention	   period,	   there	   was	   an	  
increasing	  of	   correct	  PAP	  with	  90/202	   (44.6	  %)	   in	  pre	  and	  93	   (56.0	  %)	   in	  post	   intervention	  period	  
(p=0.03).	  Indeed,	  we	  found	  that	  the	  selection	  of	  the	  appropriate	  antibiotic	  for	  prophylaxis	  improved	  
in	  the	  post	  intervention	  period,	  both	  for	  monotherapy	  (111	  (81.0%)	  for	  pre	  vs	  114	  (91.9%)	  for	  post,	  
p=0.02)	   and	   combination	   therapy	   (31	   (47.7	   %)	   for	   pre	   vs	   29	   (69.0%)	   fro	   post,	   p=0.03)	   .	   Also	   the	  
duration	   of	   prophylaxis	   decreased	   during	   the	   post	   intervention	   period,	   with	   an	   increase	   of	   PAP	  
discontinuation	  from	  83/202	  (41.0	  %)	  in	  the	  pre-­‐intervention	  period	  to	  102	  (61.4%)	  (<0.001).	  Despite	  
the	   higher	   use	   of	   narrow-­‐spectrum	   antibiotic	   for	   fewer	   days,	   there	  was	   no	   increase	   in	   treatment	  
failures	  between	  the	  two	  analysed	  periods	  (16	  (3.9	  %)	  pre	  vs	  10	  (2.6%)	  post,	  p=0.3).	  
	  
Conclusions.	  CPs	  with	  a	  proper	  educational	  intervention	  can	  be	  a	  useful	  tool	  to	  improve	  the	  choice	  
of	  first-­‐line	  antibiotic	  and	  the	  duration	  of	  PAP	  in	  pediatric	  patients.	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Background	  
SSI	  is	  the	  second	  most	  common	  healthcare-­‐associated	  infection	  [1]	  and	  CDC	  showed	  that	  it	  
complicates	  approximately	  5%	  [2]	  of	  surgical	  operations	  each	  year.	  
It	  represents	  more	  than	  16%	  [3]	  in	  adults	  and	  17-­‐18%	  [4,5]	  in	  children	  of	  all	  hospital-­‐acquired	  
infections	  recorded	  in	  the	  National	  Healthcare	  Surveillance	  Safety	  Network	  of	  the	  Centres	  for	  
Disease	  Control	  and	  Prevention	  (CDC)	  and	  38%	  of	  nosocomial	  infections	  in	  surgical	  patients	  [2].	  
While	  trends	  in	  surgical	  prophylaxis	  among	  adult	  patients	  are	  widely	  available,	  only	  a	  few	  studies	  
include	  pediatric	  data	  [3,6-­‐8].	  	  	  
The	  aim	  of	  this	  study	  is	  to	  determine	  the	  effectiveness	  of	  an	  Antimicrobial	  Stewardship	  Program	  
based	  on	  a	  Clinical	  Pathway	  (CP)	  to	  improve	  the	  adherence	  to	  perioperative	  antibiotic	  prophylaxis	  
(PAP)	  guidelines	  [9].	  Secondary	  aim	  is	  to	  evaluate	  the	  effect	  CP	  implementation	  on	  SSIs.	  
	  
Materials	  and	  methods	  
Study	  design	  
This	  is	  a	  pre-­‐post	  quasi-­‐experimental	  study	  to	  assess	  the	  changes	  in	  PAP	  appropriateness	  during	  a	  6-­‐
month	  period	  preceding	  CP	  implementation	  (per-­‐intervention,	  from	  1	  February	  2016	  to	  31	  July	  
2016)	  and	  during	  the	  six	  months	  after	  CP	  implementation	  (post	  intervention,	  from	  1	  February	  2017	  
to	  31	  July	  2017)	  (figure	  1).	  
The	  study	  was	  set	  at	  the	  Surgical	  Paediatric	  Unit	  of	  the	  Department	  for	  Women	  and	  Children	  Health	  




Figure	  1.	  Study	  design	   	  
Pre-­‐interveno	  	  period	  
01/02/16	  -­‐31/07/16	  
Intervenon	  	  
31	  January	  2017	  




On	  31	  January	  2017	  the	  CP	  for	  PAP	  was	  implemented	  (figure	  2,3,4,5).	  	  
On	   the	   same	   day,	   an	   educational	   lecture	   was	   presented.	   This	   meeting	   provided	   a	   review	   of	   the	  
clinical	  guidelines	  for	  PAP	  and	  the	  potential	  benefits	  of	  a	  correct	  PAP,	  discussed	  the	  rationale	  for	  the	  
guideline	  recommendations	  and	  highlighted	  situations	  where	  local	  practice	  in	  the	  pediatric	  surgery	  
department	  diverged	  from	  guideline	  recommendations.	  
Following	   the	   lecture,	   a	  pocket	   card	  was	  delivered	   to	  all	   participants	   and,	  on	   the	   same	  day,	   to	  all	  
other	  physicians	  and	  residents	  who	  were	  unable	  to	  attend	  the	  seminar.	  	  
The	   clinical	   pathway	   was	   developed	   by	   a	   multidisciplinary	   group	   (paediatric	   infectious	   disease,	  
microbiology	   and	   paediatric	   surgery)	   based	   on	   international	   clinical	   guidelines	   [9]	   with	   the	  




All	   patients	   aged	   between	   1	  months	   and	   15	   years	   subjected	   to	   one	   or	  more	   surgical	   procedures	  
were	  eligible	  to	  be	  included	  in	  our	  study.	  	  
Exclusion	   criteria	   were:	   concomitant	   infections,	   ongoing	   antibiotic	   therapy,	   immunodeficiency,	  





All	  clinical,	  demographic,	  diagnostic	  and	  antimicrobial	  data	  were	  manually	  collected	  from	  electronic	  
(Galileo	  system)	  or	  paper	  medical	  records.	  We	  used	  a	  password-­‐protected	  REDCap®	  data	  collection	  
form	  and	  we	  stored	  them	  in	  the	  secure	  server	  at	  the	  University	  of	  Padua.	  Surgical	  procedures	  were	  
recorded	  using	  the	  international	  classification	  of	  disease,	  9th	  revision	  and	  clinical	  modification	  (ICD	  9	  
CM).	  
For	  every	  patient	  were	  recorded:	  	  
1)	  preoperative	  data	  including	  gender,	  age,	  weight	  ;	  
2)	  procedure	  data	  including	  type	  of	  procedure	  (divided	  for	  major	  categories,	  according	  to	  the	  ICD-­‐9-­‐
CM,	   wound	   class	   (Clean,	   Clean-­‐Contaminated,	   Contaminated),	   duration	   of	   surgical	   procedure,	  
urgency	  of	  procedure	  and	  length	  of	  hospital	  stay	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3)	   perioperative	   PAP	   data	   such	   as	   need	   for	   PAP,	   received	   PAP,	   indication	   for	   PAP	   among	   those	  
received	   PAP,	   correct	   PAP	   (both	   agent	   and	   duration),	   correct	   antimicrobial	   agent,	   correct	   time	   of	  
antibiotic	  discontinuing.	  
4)	  postprocedure	  data	  including	  date	  of	  medical	  evaluation	  for	  SSI.	  
 
PAP	   was	   defined	   appropriated	   only	   if	   the	   correct	   antimicrobial	   agent	   for	   the	   specific	   surgical	  
procedures	  performed	  had	  been	  discotniued	  within	  24	  h	  after	  completion	  of	  surgery,	  according	  to	  
Clinical	  practice	  guidelines	  for	  antimicrobial	  prophylaxis	  in	  surgery	  [9].	  
To	   evaluate	   the	   effectiveness	   and	   safety	   of	   the	   intervention,	   medical	   records	   follow-­‐up	   was	  
performed	  to	  assess	  for	  SSIs	  within	  3	  months	  after	  discharge.	  
Privacy	  was	  guaranteed	   in	  two	  ways:	  a	  unique,	  study-­‐specific	  survey	  number	  was	  assigned	  to	  each	  
patient	  and	  no	  personally	  identifying	  data	  were	  collected.	  
This	   study	  was	   approved	   by	   the	   Research	   Ethics	   Committee	   of	  Department	   for	  Woman	   and	  Child	  




The	  data	  was	  analyzed	  with	  SAS	  9.4	  program	  (SAS	  Institute	  Inc.,	  Cary,	  NC,	  USA)	  for	  Windows.	  
Patient’s	  demographic	  and	  clinical	  data	  was	  analysed	  in	  a	  descriptive	  way,	  reporting	  the	  number	  and	  
percentage	  of	  patients	  in	  every	  category	  for:	  qualitative	  variables,	  median,	  minimum	  and	  maximum	  
for	  quantitative	  variables	  considering	  that	  their	  distribution	  wasn’t	  Normal	  (Shapiro-­‐Wilks	  test).	  	  
Association	   between	   the	   two	   periods	   was	   performed	   with	   Chi-­‐square	   test	   or	   Fisher	   test	   for	  
qualitative	  variables,	  with	  Rank-­‐sum	  Wilcoxon	  test	  for	  quantitative	  variables.	  
Logistic	   regression	   analysis	   was	   performed	   to	   evaluate	   the	   efficacy	   of	   the	   intervention	   on	  
appropriate	   PAP	   overall,	   appropriate	   selection	   of	   PAP	   antibiotic	   agent	   and	   appropriate	  
administration	  time	  of	  PAP.	  
We	  conducted	  stratified	  analyses	  to	  assess	   if	   the	  effectiveness	  of	   intervention	  was	  affected	  by	  the	  
surgical	  characteristics	  such	  as	  type	  of	  procedure,	  urgent	  surgical	  procedure,	  length	  of	  hospital	  stay,	  
duration	  of	  hospital	  stay.	  
Statistical	  significance	  was	  p<0.05.	  
	  































Figure	  3	  Perioperative	  Antibiotic	  Prophylaxis	  CP	  (page	  2)	  









Figure	  5	  Perioperative	  Antibiotic	  Prophylaxis	  CP	  (page	  3)	  




During	  the	  study	  period,	  842	  children	  underwent	  surgery.	  Of	  430	  children	  in	  pre-­‐intervention	  period,	  
11	   were	   excluded	   because	   admitted	   to	   an	   intensive	   care	   ward	   (PICU/NICU)	   and	   seven	   had	   an	  
ongoing	   infectious	   process.	   For	   post-­‐intervention	   period	   population,	   13	   were	   excluded	   because	  
admitted	   in	   the	   PICU/NICU	   and	   13	   because	   receiving	   antibiotics	   for	   an	   infection.	   	   Indeed,	   797	  
children	   were	   included	   in	   the	   study,	   412	   in	   pre-­‐intervention	   period	   and	   385	   in	   post-­‐intervention	  
period.	  
The	  two	  populations	  were	  similar	  in	  terms	  of	  sex	  and	  age,	  with	  an	  overall	  female	  predominance.	  
No	   difference	   between	   the	   different	   wound	   classes	   was	   reported	   between	   the	   two	   study	  
populations:	  clean	  300	  (72.8%)	  in	  pre	  and	  299	  (78.1%)	  in	  post,	  clean	  contaminated	  64	  (15.5%)	  in	  pre	  
and	  52	  (13.6%)	  in	  post	  and	  contaminated	  49	  (11.9%)	  in	  pre	  and	  32	  (8.4%)	  in	  post.	  	  
No	  difference	  in	  the	  type	  of	  surgical	  procedures	  was	  shown	  in	  the	  pre	  and	  post-­‐intervention	  period.	  	  
Table	  1	  presents	  the	  baseline	  patient	  and	  procedure	  characteristics	  for	  patients	  enrolled	  in	  pre	  and	  
post	  intervention	  period.	  
	  
Table	  1.	  Patient	  and	  preoperative	  data	  pre	  and	  post	  intervention	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Two	  hundred	  and	  two	  (202/412,	  49.0%)	  and	  166/385	  (43.1%)	  patients	  received	  a	  PAP	  during	  pre	  and	  
post-­‐intervention	  period	  respectively	  (p=0.09).	  
The	  majority	  of	  patient	  receiving	  an	  antibiotic	  prophylaxis	  gad	  an	  indication	  for	  PAP	  in	  both	  periods	  
(170/202	  (84.6%)	  vs	  145/166	  (87.3%),	  p=0.38)	  (table	  2).	  
	  
	  
Table	  2.	  PAP	  comparison	  
In	  the	  post-­‐intervention	  period,	  there	  was	  an	  increasing	  of	  correct	  PAP	  with	  90/202	  (44.6	  %)	  in	  pre	  
and	  93	  (56.0	  %)	  in	  post	  intervention	  period	  (p=0.03)	  (table	  3).	  
In	   the	   post	   intervention	   period,	   there	   was	   an	   increase	   of	   cefazolin	   use	   (159	   (78.7%)	   pre	   vs	   146	  
(88.0%)	   post,	   p=0.0001)	   with	   a	   decrease	   of	   ampicillin/sulbactam	   (41	   (20.3%)	   pre	   vs	   9	   (5.4%),	  
p=0.003)	  as	  suggested	  by	  the	  CPs	  (table	  3).	   Indeed,	  we	  found	  that	  the	  selection	  of	  the	  appropriate	  
antibiotic	   for	   prophylaxis	   improved	   in	   the	   post	   intervention	   period,	   both	   for	   monotherapy	   (111	  
(81.0%)	  for	  pre	  vs	  114	  (91.9%)	  for	  post,	  p=0.02)	  and	  combination	  therapy	  (31	  (47.7	  %)	  for	  pre	  vs	  29	  
(69.0%)	  fro	  post,	  p=0.03)	  (table	  4).	  
	  
Table	  3	  Correct	  PAP	  and	  most	  prescribed	  antibiotics	  in	  pre	  and	  post	  intervention	  periods	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Also	  the	  duration	  of	  prophylaxis	  decreased	  during	  the	  post	  intervention	  period,	  with	  an	  increase	  of	  
PAP	   discontinuation	   from	   83/202	   (41.0	  %)	   in	   the	   pre-­‐intervention	   period	   to	   102	   (61.4%)	   (<0.001)	  
(table	  4).	  
The	   stratification	  of	   the	  population	  by	   type	  and	   characteristics	   of	   the	   surgical	   procedures	   showed	  
how	   CP	   was	   effective	   especially	   on	   emergent	   procedure	   and	   all	   surgical	   procedures	   involving	  
Head/neck	  and	  thorax	  (table	  5).	  
SSIs	  rate	  assessment	  showed	  no	  difference	  between	  the	  two	  analysed	  periods	  (16/412	  (3.9	  %)	  pre	  vs	  












Perioperative	  antibiotic	  prophylaxis	   is	  the	  most	  effective	  intervention	  to	  prevent	  SSIs	  [1].	  The	  most	  
recent	  guidelines	   [9]	  define	  procedures	   requiring	  PAP,	   recommending	  narrow	  spectrum	  antibiotics	  
as	  first	  choice	  for	  less	  than	  24	  hours	  for	  all	  procedures	  (with	  the	  exception	  of	  cardiac	  surgery).	  So	  far,	  
few	   studies	   developed	   an	   antimicrobial	   stewardship	   program	   in	   children	   to	   improve	   antibiotic	  
prescriptions	  on	  PAP.	  	  Three	  of	  these	  studies	  showed	  an	  improvement	  of	  antimicrobial	  prescriptions	  
after	   the	   implementation	   of	   perioperative	   guidelines	   [3,6,7]	   while	   Putnam	   et	   al.	   reported	   no	  
improvement	  despite	  multiple	  interventions	  [8].	  	  	  
Despite	  the	  availability	  of	  consensus	  guidelines	  designed	  to	  facilitate	  the	  appropriate	  use	  of	  PAP,	  a	  
significant	   variation	   in	   this	   practice	   for	   the	   most	   commonly	   performed	   operations	   in	   pediatric	  
surgery	  has	  been	  found	  [11].	  
On	   31	   January	   2017	   the	   CP	   (figure	   2,3,4,5)	   for	   PAP	   was	   implemented	   and	   on	   the	   same	   day,	   an	  
educational	   lecture	   was	   presented.	   Following	   the	   lecture,	   a	   pocket	   card	   was	   delivered	   to	   all	  
participants.	  Step	  by	  step	  the	  CP	  details	  all	  the	  actions	  needed	  for	  administering	  a	  proper	  PAP.	  The	  
first	  step	  to	  take	  into	  account	  for	  antibiotic	  administration	  is	  the	  surgical	  procedure;	  depending	  on	  
the	   type,	   the	   site	   and	   the	   risk	   of	   developing	   surgical	   site	   infection	   based	   on	   CDC	   wound	  
classification,	  an	  antibiotic	  will	  or	  will	  not	  be	  given	  to	  the	  patient.	  
The	  second	  step	  suggested	  is	  to	  collect	  medical	  history,	  looking	  for	  any	  infection	  or	  colonization	  by	  
MRSA	  or	  other	  Multi-­‐drug	  Resistant	  Organism	  (MDRO).	  The	  therapy	  in	  this	  case	  will	  be	  targeted	  for	  
the	   resistant	   organisms	   isolated	   [9,11].	   If	   the	   medical	   history	   is	   negative	   for	   MDRO,	   an	   empiric	  
antibiotic	   regimen	   should	   be	   administered	   according	   the	   type	   of	   surgical	   procedure.	   Dose	   and	  
prophylaxis	  duration	  must	  follow	  the	  indications	  detail	  the	  CP.	  	  
The	   drug	   of	   choice	   for	   all	   surgical	   interventions	   is	   a	   first	   generation	   cephalosporin	   alone.	   The	  
association	  with	  metronidazole	  is	  recommended	  for	  surgical	  procedure	  with	  high	  risk	  for	  anaerobic	  
bacteria	   contamination.	   Other	   molecules	   as	   clindamycin,	   gentamicin	   and	   ciprofloxacin	   must	   be	  
reserved	  for	  patient	  with	  proven	  allergy	  to	  beta-­‐lactams	  antibiotic.	  
Antibiotic	  first	  dose	  should	  be	  administered	  within	  30-­‐60	  minutes	  before	  incision	  with	  the	  exception	  
of	   vancomycin	   and	   ciprofloxacin.	   Due	   to	   the	   longer	   half-­‐life	   they	   should	   be	   administered	   120	  
minutes	   before	   the	   incision.	   An	   intraoperative	   re-­‐dosing	   should	   be	   performed	   if	   the	   operative	  
procedure	  extends	  beyond	  two	  half-­‐lives	  of	  antibiotic	  and	  it	  should	  be	  considered	  in	  the	  setting	  of	  
excessive	  blood	  loss	  (>25	  mL/kg).	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Further	  doses	  of	  antibiotics	  should	  be	  administered	  no	  longer	  than	  24	  hours	  after	  the	  end	  of	  surgical	  
procedure.	   Another	   important	   aspect	   of	   this	   CP	   is	   that	   the	   antibiotic	   prophylaxis	   should	   not	   be	  
continued	  because	  of	  the	  presence	  of	  a	  wound	  drain	  or	  prosthetic	  implant	  [12].	  
As	  reported	  by	  the	  studies	  mentioned	  above	  [3,6,7],	  in	  our	  Centre	  the	  compliance	  to	  PAP	  guideline	  
improved	   after	   CP	   implementation.	   Correct	   PAP	   significantly	   increased	   from	   44.6	   %	   in	   pre	  
intervention	   period	   to	   56.0	   %,	   with	   a	   change	   in	   both	   antibiotic	   first	   choice	   and	   duration	   of	  
prophylaxis.	  	  
The	   choice	   of	   correct	  monotherapy	  was	   81	  %	   in	   pre-­‐intervention	   period	   reaching	   91.9%	   after	   CP	  
dissemination.	  Cefazolin,	  the	  most	  prescribed	  antibiotic	  in	  both	  periods,	  definitely	  became	  the	  first	  
choice	   in	   post	   intervention	   period	   with	   a	   concomitant	   decrease	   of	   ampicillin/sulbactam.	   	   	   This	  
change	  affected	  especially	  head/neck	  and	  thorax	  procedures.	  For	  both	  ampicillin/sulbactam	  was	  the	  
drug	  of	  choice	  before	  the	  intervention.	  Indeed,	  PAP	  CP	  suggests	  cefazolin	  as	  the	  first-­‐line	  antibiotic	  
for	   all	   the	  procedures	   due	   to	   its	   activity	   against	  S.	   aureus	   (MSSA)	   and	  Gram-­‐negative	   bacteria,	   its	  
narrow-­‐spectrum	  and	  the	   low	  cost.	   	  Ampicillin/sulbactam	  should	  be	  considered	  only	  an	  alternative	  
for	  its	  broader	  spectrum	  [9].	  	  	  
Moreover,	   the	   use	   of	   correct	   combination	   therapy	   increased.	   Also,	   in	   this	   case,	   an	   important	  
contribution	   was	   given	   by	   the	   reduction	   of	   ampicillin/sulbactam	   prescriptions	   especially	   in	  
association	   with	   metronidazole.	   Indeed,	   this	   combination	   should	   be	   avoided	   due	   to	   their	  
overlapping	   spectrum	   of	   activity	   against	   anaerobic	   bacteria.	   In	   the	   post	   intervention	   period,	   the	  
combination	   of	   choice	   was	   cefazolin	   and	   metronidazole,	   sometimes	   combined	   with	   an	  
aminoglycoside	   (gentamicin).	   	   The	   use	   of	   an	   aminoglycoside	   for	   surgical	   prophylaxis	   still	   presents	  
room	  for	  improvement.	  	  St.	  Peter	  at	  al,	  in	  a	  prospective	  randomized	  trial,	  showed	  how	  a	  once	  daily	  
dosing	   with	   the	   2-­‐drug	   regimen	   (ceftriaxone	   plus	   metronidazole)	   offers	   a	   more	   efficient,	   cost-­‐
effective	   antibiotic	   management	   in	   children	   with	   perforated	   appendicitis	   without	   compromising	  
infection	  control	  when	  compared	  to	  a	  traditional	  3-­‐drug	  regimen	  (which	  includes	  gentamicin)	  [13].	  
Also	  the	  number	  of	  patients	  with	  a	  PAP	  stopped	  in	  24	  hours	   increase	  from	  83/202	  (41.0	  %)	   in	  pre-­‐
intervention	  period	  to	  102	  (61.4%)	  during	  post	  intervention	  period.	  
The	   kind	   of	   procedures	   which	   have	   benefitted	   most	   from	   the	   intervention	   were	   emergent	  
procedures.	  Usually,	   patients	  who	  undergo	   emergent	   surgical	   evaluation	   are	   a	   severely	   ill	   and	   for	  
this	   reason	   surgeons	   are	  more	  prone	   to	  exceed	   the	  24	  hours.	   	   Indeed,	   this	   represents	  one	  of	   the	  
most	   difficult	   points	   of	   implementation	   for	   an	   antimicrobial	   stewardship	   program.	  Many	   are	   the	  
barriers	   identified	   in	   stopping	   PAP.	   The	   complexity	   and	   duration	   of	   surgical	   procedure,	   diagnostic	  
uncertainty,	  inexperienced	  clinicians,	  extend	  in-­‐hospital	  stay,	  patient	  preferences	  or	  the	  fear	  of	  SSIs	  
are	   the	   most	   common	   [3,10].	   The	   persistence	   of	   urinary	   catheter	   represents	   another	   point	   of	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discussion.	   Though	   all	   the	   guidelines	   recommend	   stopping	   PAP	   despite	   the	   presence	   of	   a	   urinary	  
catheter,	   many	   surgeons	   are	   still	   reluctant.	   This	   could	   be	   the	   reason	   why	   we	   have	   not	   seen,	   for	  
urologic	   procedures,	   the	   same	   improvement	   we	   seen	   for	   others.	   	   However,	  many	   of	   the	   current	  
guidelines	   and	   specialty-­‐specific	   recommendations	  used	   for	   the	  pediatric	  population	  are	  based	  on	  
old	  adult	  clinical	  data.	   It	   is	  possible	   that	  physicians	  may	  not	   find	   those	  guidelines	   relevant	   to	   their	  
pediatric	  patients.	  Finally,	  confusion	  may	  exist	  when	  indication	  from	  adult	  guidelines	  are	  not	  in	  line	  
with	  pediatric	  observational	  studies	  (eg	  inguinal	  hernia	  repair)	  [10].	  	  
For	  a	  further	  improvement	  in	  PAP	  compliance	  rate	  some	  authors	  [3]	  suggested	  to	  enforce	  guidelines’	  
effect	   with	   and	   periodic	   audit	   by	   a	   surgeon	   trained	   in	   antimicrobial	   stewardship.	   This	   physician	  
would	  monitor	   the	   choice,	   time	   and	  dose	   of	   PAP	   administration	   and	  would	   ensure	   the	   guidelines	  
adherence.	  
Moreover,	   Prado	   et	   al	   [14]	   demonstrated	   how	   hospital	   pharmacist	   could	   have	   a	   key	   role	  
participating	   in	  education	  activities	  as	  part	  of	  the	  discussion	  groups	  and	   in	  managerial	  actions	  that	  
optimized	   the	   process	   of	   ordering,	   dispensing,	   administering,	   and	   documenting	   the	   perioperative	  
antibiotic	  prophylaxis.	  
Despite	   the	   higher	   use	   of	   narrow-­‐spectrum	   antibiotic	   for	   fewer	   days,	   there	   was	   no	   increase	   in	  
treatment	  failures	  between	  the	  two	  analysed	  periods.	  
This	   study	   has	   strengths	   and	   limitations.	   This	   is	   the	   first	   study	   that	   evaluates	   the	   effectiveness	   of	  
antimicrobial	   stewardship	   through	   clinical	   pathways	   in	   an	   Italian	   hospital.	   This	   intervention	   was	  
designed	  to	  be	  feasible,	  generalizable	  and	  was	  developed	  by	  a	  multidisciplinary	  team	  to	  guarantee	  
the	  best	  quality	  and	  a	  high	  level	  of	  coordination	  of	  interventions.	  
The	  primary	  limitation	  of	  our	  study	  is	  the	  retrospective	  nature	  of	  the	  analysis.	  	  
Another	   limit	   was	   the	   analysis	   of	   treatment	   failure.	   We	   collected	   SSIs	   trough	   electronic	   medical	  





CPs	  with	  a	  proper	  educational	   intervention	  can	  be	  a	  useful	   tool	   to	   improve	   the	  choice	  of	   first-­‐line	  
antibiotic	  and	  the	  duration	  of	  PAP	  in	  pediatric	  patients.	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